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Abstract
Abstract
This study investigates the evolution of fluoroquinolone resistance in Burkholderia 
cepacia and assesses fitness of clinical isolates of the B. cepacia complex. B. cepacia 
was chosen as a clinically relevant model of antibiotic resistance because these 
bacteria cause chronic infections in cystic fibrosis patients, are highly resistant to 
killing by many antimicrobials and consequently require long term antibiotic 
treatment.
Fluoroquinolones are a widely used class of antimicrobials, increasingly used in 
medical and veterinary practice. A method was optimised and used to determine the 
rate of mutation occurring in topoisomerase genes that confer resistance to 
fluoroquinolones. The fitness cost associated with fluoroquinolone resistance 
mutations was assessed as a measure of the stability of resistance in the bacterial 
population. Clinical isolates were assessed for hypermutability using mutation to 
fluoroquinolone resistance as a selective tool.
In Gram-negative bacteria resistance to fluoroquinolones occurs via three major 
mechanisms; drug efflux, reduced permeability and target alteration. The spectrum of 
fluoroquinolone resistance mutations occurring in vitro, the rate at which they arise, 
and the fitness costs of characterised topoisomerase mutations was investigated, using 
models relevant to transmission of the Burkholderia cepacia complex. Previous 
studies have shown that single point mutations in DNA gyrase, conferring resistance, 
have no or low cost. Only double mutations in gyrA and parC  conferred a fitness cost. 
Second step mutations occur at a faster rate than first step mutations. Mutation in 
gyrA, therefore, may predispose the genome to mutation in topoisomerase genes.
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Chapter 1 General Introduction
1.0 General Introduction
1.1 Antibiotic Resistance
1.1.1 Significance of antibiotic resistance
The number of infections caused by antibiotic resistant bacteria has been increasing 
worldwide, resulting in decreased efficacy of antimicrobial therapy. This problem has 
been exacerbated by the limited number of new antibiotics developed. The increase in the 
frequency of antibiotic resistance can be attributed to a number of factors, including the 
increase in immunocompromised patients and invasive procedures, the overuse and 
misuse of antibiotics in healthcare and animal husbandry (Witte, Klare, & Werner 1999) 
and breaches in infection control. This results in raised healthcare costs and increased 
patient mortality. For example, in the intensive care setting the widespread use of 
antibiotics for treatment of immunocompromised patients has allowed the selection of 
drug resistant bacteria e.g. Acinetobacter baumannii (Wroblewska et al. 2006).
The primary aim of in vitro susceptibility testing of clinical isolates is to assess the 
susceptibility to an antibiotic in order to guide therapy. A pathogen is classed as resistant 
if the Minimal Inhibitory Concentration (MIC) is greater than the defined breakpoint; the 
discriminatory antibiotic concentration used to define isolates as susceptible, intermediate 
and resistant. In most infections the in vitro susceptibility values correlate with the 
effectiveness of therapy. However in some situations such as infection of the cystic 
fibrosis (CF) lung by Pseudomonas aeruginosa the correlation is poor. The results of 
susceptibility testing, therefore, should be treated with caution.
The community and nosocomial spread of antibiotic resistance in numerous bacterial 
pathogens is causing concern. These include methicillin resistant Staphylococcus aureus
16
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(Fluit et al. 2001), vancomycin-resistant Enterococci (VRE) (Courvalin 2006; Kolar et al. 
2006), extended spectrum P-lactamase producing Enterobacteriacae (ESBLs) (Bedenic & 
Zagar 1998; Gangoue-Pieboji et al. 2005) and non-fermentative Gram-negative bacilli, 
including P. aeruginosa, A. baumannii and Stenotrophomonas maltophilia (McGowan, Jr. 
2006). A number of European and worldwide studies and surveillance programmes 
monitor the frequency of infections caused by antibiotic resistant pathogens. Examples of 
these are the SENTRY antimicrobial resistance surveillance programme (Fluit et al. 2001) 
and the European Network for Antimicrobial Resistance and Epidemiology (ENARE) 
(Voss et al. 1994).
1.1.2 Mechanisms of Antibiotic Resistance
Clinically meaningful levels of resistance arise via a number of mechanisms that enable 
bacteria to survive the effects of antimicrobial agents. These include the alteration of 
antibiotic targets (e.g. penicillin binding proteins or DNA gyrase), production of enzymes 
that inactivate the antibiotic (e.g. p-lactamases and aminoglycoside modifying agents), 
reduction of permeability and active efflux to reduce the antibiotic concentration in the 
bacterial cell and bypass of the metabolic pathway (e.g. resistance to trimethoprim and 
sulphonamides; Neu 1989; Dever & Dermody 1991).
1.1.2.1 Alteration of Target
Resistance to a number of antibiotic classes including P-lactams, glycopeptides, 
fluoroquinolones, aminoglycosides, rifampicin and fusidic acid occurs due to alteration of 
target molecules. These alterations occur via nucleotide mutations which result in a 
modification of the protein structure of the target so that the antibiotic can no longer bind 
and exert an effect, resulting in decreased susceptibility. For example, resistance to
17
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rifampicin occurs due to mutation within the rpoB gene that alters the p-subunit of RNA 
polymerase. Rifampicin, therefore, cannot bind to the ribosome and large increases in 
resistance occur. Fluoroquinolone resistance is another example of target alteration 
conferring resistance. The primary mechanisms of resistance to fluoroquinolones are 
target alteration mediated by point mutations in DNA gyrase (encoded by the genes gyrA 
and gyrB) and topoisomerase IV (encoded by the genes parC  and parE). These enzymes 
are essential for DNA replication as they alleviate topological stresses associated with 
progression of the replication fork (Drlica & Zhou 1997). These mutations occur in the 
conserved quinolone resistance determining regions (QRDR) of these genes.
1.1.2.2 Modification of Antibiotic
Antibiotics can be inactivated so that they can no longer have an effect on their target by 
hydrolysis of the antibiotic or addition of chemical groups (e.g. an acetyl group is added to 
chloramphenicol by acetyltransferase). These mechanisms are generally specific for a 
single drug or drug class.
P-lactamases achieve hydrolytic cleavage of the P-lactam ring of cephalosporins and 
penicillins by binding via the serine present at the active site of the enzyme. This was the 
first reported example of an antibiotic resistance mechanism (Abraham & Chain 1940).
p-lactamases that render bacteria resistant to first, second and third generation 
cephalosporins, aztreonam and penicillins by hydrolysis are known as extended spectrum 
p-lactamases and were first described in 1983 (Knothe et al. 1983). These enzymes are 
produced by single or double mutations within the sulfhydryl variable (SHV) encoding 
gene.
18
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A further example of antibiotic modification is the inactivation of macrolides, which exert 
an antimicrobial effect by interfering with protein synthesis. Macrolide esterases that 
cleave the ester bond of the lactone ring and inactivate the antibiotic were first described 
in Escherichia coli in 1984 (Barthelemy et al. 1984). Although not a common resistance 
mechanism, this results in very large increases in MIC. Another example is fosfomycin, an 
epoxide antibiotic that alters a gene essential for the production of N-acetylmuramic acid, 
can also be deactivated by epoxidases.
Modification by group transfer is a common way by which bacteria inactivate antibiotics. 
These enzymes modify antibiotics by addition of a chemical group e.g. phosphate and 
acetyl groups. This alters the antibiotic structure, impairing binding, thereby inactivating 
the antibiotic. For example, aminoglycoside modifying enzymes include 
acetyltransferases, phoshotransferases and nucleotidyl transferases (Mingeot-Leclercq, 
Glupczynski, & Tulkens 1999). These enzymes alter the structure of the antibiotic so that 
it can no longer bind to the ribosome. One or more enzymes may be expressed and the 
resistance conferred and spectrum of activity can vary.
A further enzymatic mechanism, other than hydrolysis and group transfer, is oxidation of 
antibiotics, although this is a rare mechanism among pathogens. An example of this is the 
oxidation of tetracycline by TetX. This gene was initially found in a plasmid in 
Bacteroides and can confer tetracycline resistance to E. coli (Speer & Salyers 1988; Speer 
& Salyers 1989).
19
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1.1.2.3 Reduction in Permeability
The cell wall of Gram-positive bacteria is more permeable to antibiotics than the Gram- 
negative cell wall. This is because the Gram-positive cell wall is a structure made of 
peptidoglycan attached to teichoic acid and lipoteichoic acid and this alone does not 
restrict the entry of antibiotics by diffusion. However the cell wall of Gram-negative 
bacteria is comprised of a thinner layer of peptidoglycan but additionally contains an outer 
membrane and the periplasmic space. The outer membrane lipopolysaccharides and 
phospholipids prevent penetration of antibiotics. The degree of impermeability varies 
between species.
Most antibiotics need to pass through outer membrane porins as they are hydrophilic in 
nature. Spontaneous mutations that prevent expression of porins can occur during therapy 
and some resistance in Gram-negative bacteria is attributable to altered expression of these 
porins. Imipenem resistant P. aeruginosa, for example, are deficient in the OprD porin, 
which facilitates uptake of imipenem and amino acids, preventing penetration of the cell 
(Wang & Mi 2006). Furthermore reduction in the permeability of the outer membrane of 
Burkholderia cepacia can confer high level resistance to chloramphenicol (Bums et al. 
1989).
The cytoplasmic membrane does not restrict the entry of lipophilic agents such as 
fluoroquinolones, chloramphenicol, trimethoprim and rifampicin but does restrict 
hydrophilic antibiotics such as erythromycin, clindamycin, sulfonamides and 
aminoglycosides. The ingress of hydrophobic antibiotics is dependent on the active uptake 
via transport proteins and resistance can be caused by alterations in their action. For
20
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example aminoglycoside resistance can be conferred by inactivation of the pumps that 
require proton motive force (PMF) (Mingeot-Leclercq, Glupczynski, & Tulkens 1999).
1.1.2.4 Efflux
Efflux pumps are proteins that are involved in the extrusion of toxic substances from 
within the cell and are found in Gram-positive and Gram-negative bacteria (Van 
Bambeke, Balzi, & Tulkens 2000). Efflux is dependent on the proton motive force (PMF) 
or the hydrolysis of ATP. Efflux systems that have a role in antibiotic resistance have been 
described in many pathogenic bacteria including P. aeruginosa, Campylobacter jejuni, 
Streptococcus pneumoniae, Salmonella typhi, S. aureus and E. coli (Lin, Michel, & Zhang 
2002; Poole 2000).
Genes encoding efflux pumps, that extrude toxic compounds from the cell, have been 
found in all sequenced bacterial genomes and confer antibiotic resistance in many 
pathogenic bacteria. Efflux pumps can be categorised into five superfamilies. These are 
the major facilitation family (MFS), small multidrug resistance family (SMR; Paulsen et 
al. 1996b, resistance nodulation cell division family (RND; Saier et al 1994) and 
multidrug and toxic compound extrusion family (MATE; Li & Nikaido 2004). The MFS 
and SMR are more common in Gram-positive organisms while most efflux pumps in 
Gram-negative bacteria are of the RND type. Antibiotic efflux pumps use the proton 
motive force to generate ATP to export antibiotics out of the cell and are members of the 
resistance nodulation cell division, major facilitation and multi drug and toxic compound 
extrusion superfamilies (Pao, Paulsen, & Saier, Jr. 1998; Paulsen, Brown, & Skurray 
1996; Poole 2000).
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P. aeruginosa and E. coli contain two of the most well studied efflux pump systems; the 
MexAB-OprM system of P. aeruginosa (Li, Nikaido, & Poole 1995) and the AcrB system 
of E. coli (Ma et al. 1995). Increased expression of these pumps can occur by mutation in 
structural genes, regulatory genes or horizontal acquisition of plasmids or transposons.
1.1.2.5 Metabolic Bypass
Some antibiotics target enzymes in metabolic pathways. Resistance to antibiotics can be 
mediated by use of alternative metabolic pathways that the antibiotic can not inhibit. 
Resistance to sulphonamide and trimethoprim antibiotics occurs via metabolic bypass by 
production of altered dihydropteroate synthetase and dihydrofolate reductase, respectively 
(Then 1982).
1.1.3 Genetic Basis of Antibiotic Resistance
The genetic mechanisms whereby bacteria become resistant to antibacterial agents develop 
by three ways: acquisition of resistance genes via plasmids and other transposable 
elements (Guiney, Jr. 1984; Lacey 1984; Maiden 1998; Ochman, Lawrence, & Groisman 
2000; Shapiro 1997), recombination of foreign DNA into the genome (Campbell 1962) 
and spontaneous mutational events in chromosomal genes (Davies 1994).
In the absence of a selective pressure mutations in the chromosome are stochastic in that 
the rates of beneficial mutations do not occur at higher frequencies than those that are 
neutral or disadvantageous. However there has been some controversial evidence to 
suggest that mutations can be directed to enhance growth (Cairns, Overbaugh, & Miller 
1988). This is discussed later (section 1.2.3 and 1.2.8). For bacterial cells there is a finite
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probability that a mutation will occur conferring the resistant phenotype, and unless a
revertant mutation occurs, all the progeny of such a cell will also be resistant.
Spontaneously occuring mutations occur in the range of 10'6 to 10'8 mutations/ cell 
division (Drake 1991). Resistance to streptomycin, rifampicin, fusidic acid, 
fluoroquinolones and oxazolidinones occurs via mutation.
1.1.3.1 Transformation
Transformation is the uptake of naked DNA and is dependent on bacteria being 
competent, a state in which they are able take up extraneous DNA. This ability was first 
demonstrated in S. pneumoniae by Fred Griffiths in 1928 (Griffiths 1928). In 1944 Avery, 
McCarty and Macleod showed that DNA was the vehicle for transformation (Avery, 
MacLeod, & McCarty 1944). Some bacteria are naturally competent e.g. Streptococcus 
pneumoniae, Bacillus subtilis, Neisseria gonorrhoeae and Haemophilus influenzae and 
others can be induced to take up DNA by calcium chloride or heat shock treatment
(Johnsborg, Eldholm & Havarstein 2007).
1.1.3.2 Conjugation
Conjugation is a process by which DNA is transferred from the donor cell to the recipient 
cell via the conjugation apparatus when cell surfaces are in contact. Conjugative transfer 
of plasmids or transposons is responsible for the majority of bacterial gene transfer in the 
environment and therefore the horizontal transfer of genes conferring antibiotic resistance. 
However this process is not restricted to resistance genes. These processes have a wide 
host range and allow the transfer of resistance genes across bacterial genera to remote 
taxa. The same resistance gene has been found in varied bacterial species sampled from
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the gastrointestinal tract and from the environment. For example, alleles of TetM have 
been found in a variety of Gram-positive and Gram-negative bacterial species (Roberts, 
Chung, & Roe 1996; Salyers et al. 1995).
Conjugative transposons are DNA segments of 18 to 150 k.b.p. that are integrated in the 
chromosome. These elements can excise to form non-replicating circular intermediates, 
which can integrate into the recipient genome.
The importance o f these mechanisms is emphasised by the fact that between 10% and 
16% of the E. coli chromosomal genome is foreign DNA arising from horizontal transfer 
(Lawrence & Ochman 1997).
1.1.3.3 Transduction
During transduction DNA is transferred from a donor bacterium to a recipient through the 
lifecycle of bacteriophages and this occurs in many pathogenic bacteria (Davison 1999). 
This genetic transfer can occur in two ways. In the first, known as generalised 
transduction, any portion of donor DNA can replace bacteriophage genetic material. 
However the second, known as specialised transduction, involves replacement of 
bacteriophage genes by a specific region of the host chromosome adjacent to the phage 
attachment site. The transducing bacteriophages in both generalised and specialised 
transduction are likely to be defective and cannot cause infection as essential genes have 
been replaced. Not all bacteria are transducible and not all bacteriophages can transduce. 
Bacteriophages may encode virulence factors, including shiga toxin in E. coli (Waldor & 
Mekalanos 1996). Transduction of imipenem, cefotaxime and kanamycin resistance
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determinants has been described in nosocomial isolates of P. aeruginosa (Blahova, 
Kralikova & Krcery 1992).
1.1.3.4 Stability of Acquired Elements
Many strains found in the environment carry resistance genes even if these strains are not 
exposed to antibiotics (Andersen & Sandaa 1994; Gotz et al. 1996). A plasmid will be 
maintained in a bacterial population if it contains genes that confer an added advantage in 
addition to the resistance genes, e.g. genes that promote colonisation. Antibiotic genes can 
also be propagated by integrons and transposons. Integrons are promoterless genes that 
can be carried on conjugative plasmids and transposons, containing an integrase gene and 
a cassette integration site into which gene cassettes can insert (Stokes et al. 1997). A gene 
cassette usually contains a promoterless gene with a recombination site known as the 59 
base element. Presence of integrons has been shown to be associated with increased 
probability of the multidrug resistant phenotype in the Enterobacteriaceae (Leverstein-van 
Hall et al. 2003). Transposons are mobile genetic elements found on plasmids or 
integrated into the chromosome. These genes are composed of an attachment site, an 
integrase and a promoter (Maiden 1998). Transposons frequently contain heavy metal 
resistance genes in addition to antibiotic resistance genes and therefore increase the 
likelihood of the antibiotic resistance genes being maintained in the population. 
Acquisition of multiple antibiotic resistance determinants, including aminoglycoside 
modifying enzymes, in strains of Acinetobacter calcoaceticus during a nosocomial 
outbreak has been attributed to transposon transfer (Devaud, Kayser & Bachi 1982).
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1.1.3.5 Persister Cells
Within bacterial populations a small number of cells can survive exposure to antibiotic 
concentrations that kill the majority of the cells. Survivors are known as persister cells and 
were first described in Staphylococcus spp. exposed to penicillin by Bigger in 1944 
(Bigger 1944). At this time Bigger proposed that these cells were dormant and it has since 
been confirmed that these cells, when exposed to antibiotics, have limited growth with 
downregulation of biosynthetic pathways (Balaban et al. 2004). Although the majority of 
cells are not persisters their presence may allow the survival of a population following 
antibiotic exposure and are likely to have a role in recalcitrant bacterial infections. 
Surprisingly, unlike resistant mutants, this resistance is nonheritable and cultures grown 
from persister cells have the same antibiotic susceptibility as the non-persister parent cells. 
Persistence genes, such as the high persistence mutant gene (hip), have been identified that 
result in an increased proportion of persisters (Moyed & Bertrand 1983; Moyed & 
Broderick 1986). Biofilms favour formation of persister cells where the proportion of
9 5persister cells has been reported to be 10' (Spoering & Lewis 2001), as opposed to 10’ - 
10'6 in planktonic cultures (Moyed & Bertrand 1983). As well as S. aureus persister cells 
have been identified in P. aeruginosa, E. coli and Candida albicans biofilms (Brooun, 
Liu, & Lewis 2000; Spoering & Lewis 2001; Lafleur, Kumamoto & Lewis 2006).
1.1.4 Use of Antibiotics and Antimicrobial Resistance
Few studies have investigated the effect of reduction in antibiotic use in humans, and 
subsequent levels of resistance in bacterial populations. Reduction in antibiotic use results 
in an observed decrease in the frequency of penicillin resistance in pneumococci (Nowak
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1994). However resistance in the population does not disappear and some resistant 
organisms will persist. If  the selective pressure of the antibiotic is restored then these 
resistant strains can take over the previously susceptible population. This has been 
demonstrated by Gerding and colleagues during their study of the return to use of 
gentamicin in a hospital and observed the rapid increase gentamicin resistant isolates 
(Gerding ^  al. 1991).
Reduction in macrolide use within an outpatient population in Finland during the 1990s 
resulted in a decline in erythromycin resistance in Group A streptococci isolated from 
throat swabs and pus samples (Seppala et al. 1997). However a series of studies that 
evaluated the effect of antimicrobial use on penicillin resistant S. pneumoniae carriage in 
children demonstrated that carriage of penicillin resistant isolates increased despite 
reduction in antibiotic use for respiratory tract infection (Arason et al. 2002; Arason et al. 
2006). A similar pattern of increased resistance despite reduced antibiotic use has been 
observed in Sweden (Hogberg et al. 2006).
An increase of 16% in fluoroquinolone use in Spain between 1997 and 2001, due to the 
introduction of levofloxacin and moxifloxacin, did not result in the expected 
corresponding increase in ciprofloxacin resistance in S. pneumoniae (Garcia-Rey, Martin- 
Herrero, & Baquero 2006). No significant association between fluoroquinolone use in 
hospitals and fluoroquinolone resistance in P. aeruginosa and S. aureus has been 
demonstrated (MacDougall et al. 2005).
Austin et al attempted to quantify the relationship between antibiotic use and frequency of 
resistance using epidemiological models. Their findings suggested that significant
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reduction in antibiotic use is required to cause a significant decline in resistance. This 
decline in resistance is likely to occur at a lower rate than the initial emergence of the 
resistance (Austin, Kristinsson, & Anderson 1999).
1.2 Mutation Rates
1.2.1 Mutation and Mutagens
A mutant organism is defined as a bacterium that varies in a characteristic from its 
parental strain and that can pass on this new characteristic to its progeny. For this variation 
to be inherited, a change, or a mutation, must occur in the genome of the organism. 
Variation in bacteria can also be by the acquisition or loss of genetic elements, such as 
plasmids and transposons but bacterial genotypes are generally stable. Selection may lead 
to predominance of the new variant characteristic. Of all the genes present in a genome 
only a subset will be expressed in any given set of conditions. These expressed genes will 
represent the phenotype of the organism as this confers the detectable characteristics of the 
organism. Therefore the phenotype of an organism may be very variable.
Mutations occur without any transitional state and arise continuously at low frequencies 
even in favourable growth conditions. Induction of mutation may be due to cellular 
function, interaction with the environment or exposure to a mutagenic agent (mutagen). 
Many spontaneous mutations occur following errors during replication and repair. Cellular 
repair systems remove most of the erroneous bases but a small proportion will remain 
without being corrected. Many mutagens are encountered by bacteria and mutagenic 
activity often occurs by production of reactive oxygen species (OH radicals, superoxide 
anions and hydrogen peroxide) that result in damage to DNA (table 1.1).
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Mutagenic Agent Method
Ionizing Radiation Causes breakage of the phosphate-deoxyribose of DNA. Single or 
double stranded breaks produced.
Ultraviolet Light Formation of thymine dimers. Cause DNA distortion. Mostly base 
substitutions.
Deaminating agents 
e.g. nitrous acid
Modify bases. DNA polymerase will not recognise base causing 
erroneously pairing and mutation.
Base analogues 
e.g. 5-bromouracil 
and 2-aminopurine
Integrated into DNA by polymerase. Different pairing capacities 
with bases depending on the tautomeric form.
Alkylating Agents
e.g. ethylmethane
sulphonate
Covalently bind alkyl residues to bases, causing random pairing.
Intercalating agents 
e.g. ethidium bromide, 
acrid ine orange
Flat molecules intercalate between bases. Causes frameshift 
mutations.
Cross linking agents 
e.g. mitomycin C
Covalent binding of bases on opposite strands of DNA helix. Stop 
unwinding of helix and block DNA synthesis
Table 1.1 Modes of action of mutagens (Griffiths et al. 2000)
The consequences of single point mutations depend on the nature and location of the base 
substitution within the codon. These mutations can cause alterations in the amino acid 
residue encoded (missense mutation) or may leave the amino acid unchanged (silent 
mutation). There are two types of base pair substitution; transitions (purine to purine or 
pyrimidine to pyrimidine) or transversions (purine to pyrimidine or pyrimidine to purine). 
Deletions and inversions may also occur and can have a greater effect. These mutations 
can change the phenotype of the cell by causing changes in the reading frame, and these 
are termed frameshift mutations.
An antibiotic resistant mutant may occur due to mutation in a resistance conferring gene 
of a susceptible strain. The initial isolate is referred to the ‘wild type’ or susceptible 
parent. The term ‘wild type’ is arbitrary and should be used to describe the first observed 
state of the gene in question, in this case susceptibility to an antibiotic. Subculture of this
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‘wild type’ may allow mutations to arise causing deviation from the initial state. Therefore 
efforts should be made to maintain the genotype of the characterised reference strains.
1.2.2 Mutation Rate versus Mutation Frequency
A mutation rate is an estimation of the probability of a point mutation occurring at each 
cell division and corresponds to the probability of a mutation occurring in the lifetime of a 
bacterial cell. A mutation frequency is simply the proportion of mutant bacteria in a 
culture. These two terms are often wrongly used interchangeably, causing confusion. 
Mutation frequency gives no indication of when the mutation occurred in the lifetime of 
the cell; if a mutation occurred early in the lifetime of the cell then a large number of 
mutant clones will be present, resulting in a high mutation frequency. This is known as a 
'Jackpot Culture' and is a rare event. This phenomenon was first described in 1943 by 
Luria and Delbriick during their classic set of experiments on bacterial mutation (Luria & 
Delbriick 1943).
1.2.3 The Fluctuation Test of Luria and Delbriick
Luria and Delbriick demonstrated that bacteriophage resistant mutant colonies of E. coli 
arise from a sensitive culture if T1 bacteriophage was present in excess (Luria & Delbriick 
1943). The E. coli culture was grown up in either nutrient broth (containing 0.5% NaCl) or 
asparagin-glucose synthetic medium. Their initial inocula contained between 50 and 500 
bacteria. Resistance was detected by lack of clearing of the culture. Resistant colonies 
appeared from sensitive cultures, in which there was clearing within a couple of hours. 
These bacteria were resistant to bacteriophage T1 but sensitive to other viruses active on
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that strain of E. coli. They showed that reversion to sensitivity must be a rare event as 
when the bacteriophage was mixed with resistant bacteria no increase in the titre of the 
bacteriophage occurred. In a growing culture the proportion of resistant bacteria will then 
increase with time. If the presence of the phage was needed to trigger the change to 
resistance then the distribution of mutant colonies should demonstrate a Poisson 
distribution. However the high variance in the mutant numbers led Luria and Delbriick to 
hypothesize that resistant mutants were present in the culture before bacteriophage 
exposure and that the mutation arose independently (Luria & Delbriick 1943). At the time 
this settled the issue of whether such resistant bacteria arise via random mutation or 
directed mutation from a selective pressure as it proved that mutations occur randomly 
during non selective growth. If mutations are random, the mutational events that are 
occurring are random in the sense that they do not occur at a higher rate if they are 
advantageous and that natural selection occurrs. If mutations are directed this would mean 
that the mutation rate conferring an advantage to a cell would be higher. For both of the 
hypotheses the resistance is inherited. If mutations are random, i.e. are not directed, then 
mutations will be clustered within a small subset of the population. If mutations are 
directed, the mutants will be more evenly spread throughout the whole population. 
However there has since been much debate over whether mutations can be directed 
towards being advantageous to the cell (see section 1.2.8).
Luria and Delbriick assumed that, for a bacterium, there was a small fixed chance that a 
resistance conferring mutation could occur per unit of time, if the bacteria are ‘in an 
identical state’. The numbers of mutated cells in a culture depend on how early the 
mutation occurred during growth of the bacterial population. If mutation occurs early in 
the culture, the number o f mutated cells will be higher than if it occurs later. This makes
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mutation frequencies inaccurate as it does not reflect the stochastic nature of mutant 
accumulation. Mutation rates, on the other hand, are more accurate and reproducible.
1.2.4 Determination of Mutation Rate
Broadly, there are two methods for determination of mutation rate. These are the mutation 
accumulation method and fluctuation analysis (Rosche & Foster 2000). The mutant 
accumulation method can be very accurate but is involved and time consuming. This is 
because the culture needs to be sampled at a series of time points. In this method cultures 
are grown exponentially until probability dictates that a mutant will be present. If we 
assume that the growth rate of wild type bacteria and mutant bacteria is the same then the 
proportion of mutants will increase linearly with time. Furthermore if the number of 
mutants and the total number of bacterial cells is known, at various time points, then the 
mutation rate (ju) is the gradient of the line of number of mutants against generation 
number. Terms are defined in Table 1.2.
Term Definition
m Number of mutations per culture
P Mutation rate
r Observed number of mutants
r Median number of mutants
C Number of cultures
Po Proportion of cultures without mutants
No Initial Number of Cells
f Mutant frequency
n Number of generations
Table 1.2 Definition of Terms
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For this method, a very large total cell number is needed with a long time period between 
Nj (number of cells at first time point) and N2 (number of cells at second time point) 
Serial dilutions would make this easier to perform but this introduces sampling errors. If 
available, continuous culture would be an alternative but this would allow selection of 
waves of bacteria, each better suited than the generation before, to take over the culture. 
Moreover Billington et al have shown that single point mutations can impose a significant 
fitness deficit which undermines one of the basic premises of the mutant accumulation 
method (Billington, McHugh, & Gillespie 1999). For these reasons a fluctuation analysis 
method is more commonly used. The introduction of this technique was a pivotal event in 
mutational research.
1.2.5 Fluctuation Analysis
A fluctuation analysis involves estimating the mutation rate from the distribution of 
mutants in a number of parallel cultures. This method was pioneered by Luria and 
Delbriick (Luria & Delbriick 1943). Briefly an initial inoculum of cells (of known culture 
volume) from a growing culture is added to a broth, which is then incubated at appropriate 
conditions in the absence of selective pressure. The cultures are then centrifuged to 
concentrate the cells. Screening for antibiotic resistant cells is performed by plating the 
cell deposit onto solid media containing a concentration of antibiotic, usually at 2 - 4 times 
that of the MIC. This will kill all sensitive cells and only the resistant mutants will remain. 
A plate count is performed on a proportion of the culture, as a measure of the number of 
cells in the cell deposit. A series of log dilutions of the cell deposit are performed and 
inoculated on agar not containing the test antibiotic. The number of colony forming units 
per mL of the deposit can then be determined. Luria and Delbriick then suggested two
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methods for estimating the overall mutation rate for the population: the po  method which 
is based on the proportion of cultures in which no mutants are observed and the method of 
the mean which relies on the determination of the mean number of mutants. Both methods 
assume a Poisson distribution with a mean and variance equal to the product of the 
probability of a mutation and the number of bacteria i.e. the ratio of variance of the mean 
is one. All of the methods described (Table 1.3) utilise the fluctuation analysis and use an 
estimate of the probable number of mutations that are the responsible for the distribution 
of mutations (m). This m is the number of mutations, not mutants, and will be controlled 
by the amount of growth and the mutation rate (ju) itself. The estimated value of m can be 
divided by the total number of cells to give the mutation rate. There are a number of 
different methods available for the estimation of mutation rate. Different methods are 
appropriate depending on the predicted number of mutations per culture (m).
Method Value of m (number of 
mutations per culture)
References
Po Method 0.3 < m < 2.3 Luria & Delbriick 1943
Method of the Mean None Luria & Delbriick 1943
Lea and Coulson 
Method of the Median
1.5 < m <  15 Lea & Coulson 1949
Drake Formula m >30 Drake 1991
MSS Maximum 
Likelihood Method
AH Sarkar, Ma, & Sandri 
1992
Koch's Quartiles 
Method
2 < m < 14 (See Koch et al 
for values outside range)
Koch 1982
Jones Mediator 
Method
Unknown
Works when 1.5 < m > 10
Jones et al. 1994
Table 1.3 Mutation rate estimation methods which are appropriate for different numbers
of mutations per culture
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1.2.5.1 The po method
The po can be used for selection of mutants on either liquid or solid media. This is the 
simplest method to calculate and was originally described by Luria and Delbriick (Luria and 
Delbriick, 1943). It is most suitable when the number of mutational events in a culture is 
low. This was initially apparent as few cultures (if any) exhibited resistant colonies. The 
proportion of cultures without mutants (po) is the zero term of the Poisson distribution given 
by equation 1.
Po -  Eq [1]
This method should only be used if the proportion of cultures without mutants is between 
0.1 and 0.7 i.e. the number of mutations per culture (m) is between 0.3 and 2.3. The formula 
can be rearranged to give the number of mutations (Equation 2).
m= -In po Eq [2]
As cultures are scored as positive or negative there is no need to enumerate the number of 
colonies (Foster, 2004).
The precision of m (number of mutations per culture) varies depending on the value of p 0. 
Compared with other methods the po method requires more cultures for the same level of 
precision. The method is not affected if the mutant growth rate is slower than that of the 
wildtype. However this is only true if each clone of mutants gives rise to a colony, post 
selection. If the clone does not give rise to a colony then that mutant will contribute to the 
proportion of cultures without mutants. Conditions need to be chosen so that the
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proportion of resistant colonies is not too large or too small. When the proportion of 
mutants detected is known then the actual value of m can be calculated. When this method 
is chosen the investigator should design the experiments so that 10-70 % of the cultures 
have no mutants and the number of mutations is between 0.3 and 2.3. This can be 
achieved by limiting the volume of the culture or by plating only a proportion of the 
culture.
1.2.5.2 Lea and Coulsons Method of the Median
Median methods should not be used if more than half the plates are devoid of mutants. 
Such methods are of most use when all or most of the cultures give rise to visible mutant 
colonies. Numbers of mutations per culture (m) is determined by equation 3.
r/m-ln(m) - 1.24 = 0 [3]
1.2.6 Parameters
For each mutation rate experiment there are three main parameters which need to be 
considered (Rosche & Foster 2000). The first of these is that the expected number of 
mutations (not mutants!) per culture (m) should not be less than 0.3. The number of 
mutations depends on the mutation rate itself and the amount of growth. The value of m 
can be varied by plating different volumes of culture but this can introduce errors. The 
method chosen will depend on the expected value of m.
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The second parameter is the number of parallel cultures chosen to represent the bacterial 
population. For all methods the precision of m is a function of 1 / V c and increases as C 
increases. Therefore if more cultures are tested then precision is increased. For the po 
method a precision level of 20 % is considered necessary to estimate the number of 
mutations per culture (Rosche & Foster 2000).
The final parameter is the size of the initial inoculum (No). As this inoculum should not 
contain any pre-existing mutants or generate too many mutants, the initial inoculum 
should be small. This inoculum, however, needs to be large enough to represent the 
bacterial population. For example Luria and Delbriick used an initial inoculum of between 
50 and 500 bacteria. The smaller the initial inoculum, the longer the incubation period that 
is required. This is especially important when working with slow growing cultures e.g. 
Mycobacterium tuberculosis. There are other complications involved in growing small 
numbers of organisms. For example many organisms monitor the density of cells via 
‘quorum sensing’ and only switch on virulence genes after a certain cell density of 
bacteria are present (Parsek & Greenberg 2000). They do this by the production and 
detection of moieties such as N-acyl-L-homoserine lactones (AHLs). In M. tuberculosis 
resuscitation promoting factors, originally identified in Micrococcus luteus (Mukamolova 
et al. 1998; Mukamolova et al. 2002), have been identified that promote recovery from a 
non replicating phase and increase cell growth. Therefore it may be necessary to stimulate 
the growth of small numbers of cells by stimulatory proteins. In each parallel culture the 
final cell number (Nt) should be the same. No should always be negligible compared to Nt 
(a ratio of at least <1/1000 is desirable). However a culture started from a small number of 
cells will take longer to grow. In addition a small inoculum may produce a reduction in 
viability resulting in greater variation in the final number of cells. Variations in Nt can be
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eliminated be using a large initial inoculum. Rosche and Foster have found that in their 
experiments a good rule of thumb is to use an initial inoculum of total cells of mNtl 104 
(Rosche & Foster 2000). This represents a compromise between the above factors.
In order to observe a mutation, it is necessary to have a large enough volume of cells, 
therefore the volume of the broth used will depend on the mutation frequency. If the 
frequency is high then a small broth culture can be used. However if the rate is low then 
large cultures should be used. To avoid inclusion of pre-existing mutants in the initial 
inoculum counterselectable markers or fluorescence-activated cell sorting methods can be 
used (Rossman, Goncharova, & Nadas 1995). The initial inoculum of cells should contain 
cells that are in the same phase of the growth cycle.
All of the above parameters should be kept constant between experiments.
1.2.7 Assumptions of Fluctuation Analysis
There are a number of assumptions that are made in order to perform a fluctuation 
analysis. These assumptions are summarised (Table 1.4).
The probability of a mutation occurring is constant per cell lifetime
The probability of this mutation occurring does not vary between growth phases
There is no cell death
Revertants occur at a negligible rate
Mutation occurs only during cell division and results in only one mutant
Growth rates of mutants and non mutants are the same
Initial cell numbers are negligible compared to final cell numbers,
All mutants are detected and no mutants occur after selection is imposed.
Table 1.4 Assumptions of mutation rate estimation
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It should be remembered that all of the available methods only provide a way of 
estimating mutation rates. Each method relies on a set of pragmatic assumptions that are 
made in order to make estimations possible and therefore each mutation rate is only an 
estimate and can not represent exactly what is happening in vivo.
1.2.8 Directed Mutation Controversy
Strategies that are used to estimate mutation rates assume that mutagenesis is spontaneous 
and random in the sense that it is not directed. Mutations in the chromosome are therefore 
stochastic in that the rates of beneficial mutations do not occur at higher frequencies than 
those that are neutral or disadvantageous.
Luria and Delbriick’s experiments provided evidence that mutations do not occur in a 
directed manner (Luria and Delbriick 1943). However this has since been an area of 
controversy. Experiments have been performed that provide evidence on both sides, 
although the evidence suggests that directed mutation is unlikely. In 1952 Lederberg and 
Lederberg used replica plating from non selective media to selective media as way to 
indirectly select mutants (Lederberg & Lederberg 1952). They noted that the location of 
mutants on the replica plate corresponded to the location on the master plate. Therefore 
these mutants must have been present prior to the selection. This provided further 
evidence for random mutation. However in 1988, it was observed mutations from Lac" to 
Lac+ in E. coli occur more frequently if lactose is present than if there is no lactose present 
(Cairns, Overbaugh, & Miller 1988). Subsequently it was pointed out that the low 
variance to mean ratio noted by Cairns, Overbaugh and Miller may have been due to 
deviations from the underlying assumptions (Lenski, Slatkin, & Ayala 1989). For example 
resistant mutants that grow on selective media may exhibit slower growth on non selective
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media. This will result in fewer progeny cells and would decrease the variance to mean 
ratio. This may become a problem if mutations are directed. However this can be 
overcome. If mutations occur after plating then the rate of mutation will reflect not only 
the mutations occur during growth in the aliquots but also those appearing on the solid 
media. This risk can be reduced by counting the number of mutants soon after plating and 
post plating mutations can be considered negligible.
Hendrickson et al have proposed a mechanism by which apparent directed mutation can 
be explained by natural selection (Hendrickson et al. 2002). During growth limitation 
bacterial cells are selected that contain an amplification of a mutant lac gene that enables 
the cells to utilise the available lactose. This selection increases the probability of a 
reversion occuring to lac +. This appears to direct mutation to allow bacterial growth.
1.2.9 Deviations from the Assumptions
Mutation rates may be higher during the growth phases where there is a faster rate of 
replication i.e. in the exponential phase. Resistant mutants may have a lower growth rate 
than the wild types due to a physiological fitness costs (Andersson & Levin 1999; 
Billington, McHugh, & Gillespie 1999; Gillespie & McHugh 1997). The net effect of this 
is to increase the variance of distribution. It is also possible that not all mutations are 
detected. For example mutations that occur late in the culture may not give rise to visible 
colonies and these mutants will not be included in the estimation. This phenomenon is 
known as phenotypic lag. It is also conceivable that mutations may occur after selection 
has been imposed i.e. mutants may arise on the antibiotic containing solid media.
40
Chapter 1 General Introduction
Reversions to the sensitive phenotype are assumed to be negligible. In the absence of 
selective pressure reversion mutations can and do occur, however. For example reversion 
to linezolid susceptibility in clinical isolates of S. aureus has been shown to occur (Meka 
et al. 2004). Reversion to wildtype may occur by mutation, loss of a gene or by a 
compensatory mutation in a resistance gene (Bjorkman et al. 2000).
There are a number of other factors that complicate calculation of mutation rates. For 
example mutation rates are not constant in a population of cells. They can vary depending 
on antibiotic concentration (Kohler, 1997), availability of the carbon source (Hughes & 
Anderson 1997) and whether the bacterium is under stress or not (Shapiro 1997). Under 
stress the mutation rate is likely to be higher (O'Sullivan, McHugh, & Gillespie 2005). 
Additionally the presence of cells prone to mutation (containing mutations in repair genes) 
(LeClerc et al. 1998) and so will exhibit an increased mutation rate of the whole 
population. Such mutator phenotypes can be beneficial to bacteria as variation may 
provide an advantage in changing conditions. However once the bacterium has adapted to 
the selective pressure then cells with high mutation rates may lose their advantage as some 
important function that is not needed for immediate survival may be lost (Giraud et al 
2001). Classical evolutionary theory would consider bacterial cells with the highest rates 
of replication as the fittest organisms. However a slow replication rate may still increase 
fitness as in the presence of a selective pressure, e.g. an antibiotic, a mutation may confer 
enough of a benefit to the slower replicator so that it can displace the fast replicator 
(Burch & Chao 2000). This has been confirmed using ‘digital organisms’ where at high 
mutation rates, faster replicating organisms were outcompeted by organisms with the 
lower replication rate with a selective advantage (Wilke et al. 2001). Some antibiotics can 
also increase the frequency of mutations in the genome (Mamber et al. 1993). For
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example fluoroquinolones have been shown to induce the SOS response in E. coli and 
Salmonella (Mamber et al. 1993). During the SOS response, which is controlled by 
products of lexA and RecA, the expression of polymerases is upregulated but these have a 
higher error rate as gaps, which are opposite thymidine dimers, are filled in by replication 
and not recombination. This increases the mutation rate (Gillespie et al 2005).
Sarkar et al attempted to improve the Luria and Delbriick model by considering the effect 
of nonsynchronous division and the effect of cell death (Sarkar 1991). It was proposed that 
mutants have a lower mutation frequency than wildtype cells. This may be due to a 
reduction in fitness or a reversion to the susceptible phenotype. It was suggested that this 
could be addressed by plating only a proportion of the final culture and calculating 
moments of the distribution. However Sarkar failed to consider the concept of phenotypic 
lag, which caused discrepancies between calculated mutation rates and in vivo rates. 
Phenotypic lag, describes the observation that mutations that occur late in the culture may 
not give rise to colonies. Armitage et al (Armitage 1952) identified the existence of 
phenotypic delay for the mutation described by Luria and Delbriick. Most methods do not 
take this factor into account, but Armitage et al subsequently introduced this extra 
parameter into the Lea and Coulson model (Armitage 1953). The results of this approach 
indicate that the outcome of fluctuation analysis tests may depend on the size of the 
original inoculum, however Armitage did not address this. A possible explanation is that a 
small proportion of cells in the inoculum may result in progeny that have a different 
mutation rate than the average cell. Therefore smaller inocula may not contain such cells. 
Phenotypic lag will increase the variance of the final distribution and will affect the lower 
end of the distribution more than the upper end. This alters the shape of the distribution as 
mutants that arise near the end of the culture period will not be expressed and will
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therefore be underestimated in the culture. Koch has suggested estimating the duration of 
the lag in generations (n) and calculating the values of m using values of r in quartiles that 
are lowered to 2n of the values which are observed (Koch 1982). The value of m is then 
multiplied by 2n-l to give the final estimated number of mutations.
It is assumed that all mutants are detected. However Ma et al (Ma & Sandri 1992) and 
Jones et al (Jones et al. 1994) have altered their fluctuation analysis method to allow for 
only an aliquot of the culture volume to be plated. Crane et al have proposed a modified 
fluctuation assay for estimation of mutation rates where small increases in mutation rate 
are expected (Crane, Thomas, & Jones 1996). In their method a proportion of large broth 
is examined as opposed to the original method of using a small culture. This allows the 
detection of small increases in mutation rate using small numbers of cultures.
1.2.10 Detection of Resistant Mutants
For all mutation rate estimation methods a number of parallel cultures are inoculated with 
a small number of wildtype bacteria i.e. no resistant mutants will be present in the initial 
inoculum. The culture is incubated and the number of cells in the culture at Nt is calculated 
by plating out the culture onto non selective media. To determine the number of resistant 
mutants the aliquots are cultured onto solid selective media containing the antibiotic. 
Antibiotic resistance of mutants is used as a selective marker for estimation of mutation 
rate but there may be other markers that could be used (see section 6.5). Using an 
antibiotic as a tool is distinct from the examination of the effect of antibiotics on the 
mutation rate.
43
Chapter 1 General Introduction
No satisfactory solution of the Luria and Delbriick distribution has been found that 
effectively describes the distribution numerically. Therefore extensive attempts have been 
made to improve the accuracy of the estimates (Asteris & Sarkar 1996; Kepler & Oprea
2001). It is important to note that mutation rates estimated via different methods cannot be 
compared.
1.2.11 Hypermutability
Within populations of pathogenic bacteria, some bacterial clones have a higher 
spontaneous mutation rate than the majority of the population. These variants exhibit the 
mutator phenotype and are therefore known as ‘mutators’ and owe their high mutation 
rates to defects in proof reading and repair mechanisms. These defects are likely to be in a 
methyl directed mismatch repair system that is encoded by mutH , mutL, mutS, dam and 
uvrD and defects causing an increase in mutation rate are commonly due to loss of activity 
in mutS (LeClerc, Li, & Payne 1996; Matic et al. 1997; Miller 1996; Sniegowski, Gerrish, 
& Lenski 1997). Mutation rates may be between 10 -  10,000 fold higher than the non 
mutator wildtype but this depends on the nature of the mutator allele. Mutator bacteria 
exist in populations of pathogenic bacteria and have been described in E. coli, (LeClerc, 
Li, & Payne 1996; Matic et al. 1997) Salmonella spp. and P. aeruginosa (Oliver et al. 
2000; Oliver et al. 2004).
1.2.12 High Mutation Rate leads to Adaptation
As stress is ever present for bacteria in the environment an organism that can adapt to 
changes is more likely to survive. Therefore it can be beneficial for the bacterial
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population to be heterogenous, increasing the probability that a subset of cells will 
survive. This ‘bet-hedging’ may be a useful strategy in uncertain environments and may 
promote survival. However few mutations are beneficial, most are deleterious. Therefore 
the mutation rate that has evolved represents a compromise between allowing adaptation 
and avoiding excessive deleterious mutations. Bacteria that have a higher spontaneous 
mutation rate than the majority of the population are more likely to gain resistance via 
mutation in chromosomal genes.
Mutation rates may be higher for individual mutants within a bacterial population as a 
whole. Genotypes with lower mutation rates than the mutator may also exist in the 
population but these mutation rates are still higher than rates in the wild-type (Giraud et 
al. 2001). During colonisation of the mouse gastrointestinal tract by E. coli a higher 
mutation rate was observed. This could prove advantageous as initial adaptation to a new 
environment may occur more readily. However deleterious mutations that occur after 
colonisation may accumulate and become problematic (Giraud et al. 2001).
1.2.13 Mutator Phenotypes Select for Antibiotic Resistance
Homology in DNA sequence is required to allow recombination to occur between 
bacteria. This prerequisite acts as a barrier to exchange between species. However it has 
been shown that recombination can occur between E. coli and S. typhimurium in mutants 
defective in the mismatch repair genes mutL, mutS and mutH  (Rayssiguier, Thaler, & 
Radman 1989). Therefore mutators that are defective in their methyl-directed mismatch 
repair genes display both a hypermutable phenotype and are more likely to transfer genetic 
elements across species barriers. This may result in increased selection and spread of
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antibiotic resistance genes. These mutators are also more likely to accumulate 
compensatory mutations which may reduce the physiological cost of the target site 
modifications that decrease susceptibility (Andersson, Bjorkman, & Hughes 1998; 
Bjorkman et al. 2000). These bacteria therefore represent a challenge for reducing rates of 
antimicrobial resistance.
1.2.14 Fitness of Mutators
It is possible that mutators may have an increased growth rate due to reduced use of cell 
resources on repair of damaged DNA. However there is very limited evidence for this 
increased fitness (Sniegowski et al. 2000). Through the use of competition assays between 
the mutator and non-mutator phenotypes Chao and Cox demonstrated that mutators have a 
small but measurable decrease in growth rate (Chao & Cox 1983). Progeny will also have 
defects in repair mechanisms and may accumulate further costly mutations. However 
mutators can be at an advantage due to increased rate of mutations that confer some 
advantage to the cell. There may be a selective pressure for mutators that increase the 
frequency of the phenotype in the population as the long term fate of the mutator allele is 
linked to the mutations that occur as a result. If beneficial mutations occur the mutator 
phenotype may ‘hitch-hike’ on the back of the beneficial mutation that provides a 
selective advantage (Chao & Cox 1983). For this to occur the beneficial mutations must 
occur in the mutator population before they occur in the wild type population. As the 
numbers of mutators is lower than non-mutators then the mutation rate must be increased 
to the point that allows for this. Relative numbers of mutators are unlikely to exceed 1 O' 
compared to the rest of the population. Therefore the mutation rate must be at least 1000 
fold than the wild-type for the mutators to be maintained in the general population (de
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Visser, 2002). Certain loci in the genome may have an increased mutation rate while 
housekeeping genes may be expected to have a lower rate (Moxon et al. 1994). This 
allows the exploitation of adaptability but minimises the detrimental effects of 
accumulation of costly mutations.
1.2.15 Stability of Mutators
If a mutator allele is eventually fixed in a population then it is possible that all cells in the 
population will have increased mutation rates. It is unlikely that reversion to fully 
functional repair genes will occur. Horizontal acquisition of functional genes is more 
likely (Brown et al. 2001). It has been shown that the mutator phenotype is retained in E. 
coli following 11500 generations of growth (Sniegowski, Gerrish, & Lenski 1997). 
Therefore it is unlikely that mutators will be lost from the population.
1.3 Fitness
1.3.1 Importance of fitness
Fitness is a complex characteristic that encompases the ability of a genotype to reproduce 
within a host, be transmitted and survive in defined environments.
When bacteria are exposed to antibiotics a mutation conferring resistance to that antibiotic 
is likely to give the bacterium an advantage in the presence of the antibiotic. However it is 
accepted dogma that a resistant organism pays a physiological price for resistance, 
particularly resistance mediated by chromosomal mutations (Levin, Perrot, & Walker 
2000). It is believed that following rational use of antibiotics, antimicrobials are removed
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from the environment and in the absence of a selective pressure, resistant mutants will be 
out-competed by their susceptible counterparts and will be lost from the population. 
Although studies have shown that acquisition of antibiotic resistance can incur a 
biological cost (Andersson & Levin 1999; Gillespie & McHugh 1997) there is evidence 
that some mutations conferring resistance may result in low or no fitness deficit (Gillespie 
2001; Gillespie, Voelker, & Dickens 2002; Kugelberg et al. 2005). Thus, quantification of 
fitness costs is important when determining the stability of antibiotic resistance in a 
population.
1.3.2 Fitness and Antibiotic Resistance
The major factors that influence the frequency of antibiotic resistance in a population of 
bacteria are the extent of antibiotic exposure, the cost of resistance and the extent that the 
bacteria can compensate for this cost. Within a population of bacteria different genotypes 
must compete with each other to fill a niche. Therefore, the incidence of resistance can be 
reduced by the rational use of antibiotics as resistant bacteria can be selected against in the 
absence of antibiotics due to a fitness cost. However, resistance will not disappear from 
the population, if  mutations conferring resistance have a low fitness cost, or no cost, then 
these mutants may remain at high levels in the bacterial population if antibiotic use is 
withdrawn or may return to high frequencies if antibiotic pressure is reintroduced.
1.3.3 Measuring Fitness
In vitro models of fitness have been used in order to investigate the evolution of antibiotic 
resistance and to assess the physiological price associated with acquisition of resistance. 
The growth rate of bacteria in liquid culture medium is a commonly used model for 
evaluating fitness (Bennett, Dao, & Lenski 1990; Kugelberg et al. 2005; Lenski et al.
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1998; Lenski, Simpson, & Nguyen 1994; Nguyen et al. 1989). Relative fitness of a 
resistant mutant compared to the susceptible parent is often determined by assay of 
competition between isogenic antibiotic susceptible and antibiotic resistant bacteria in 
culture or in animal models. Fitness costs have been measured in a number of ways. 
Growth rate in culture media is a good model for evaluating fitness, as are paired 
competition experiments (Billington, McHugh, & Gillespie 1999; Davies et al. 2000; 
Gillespie et al. 2002; Komp et al. 2005). In liquid culture relative fitness is defined by the 
difference in number of generations that have occurred between the susceptible parent and 
the mutant. These methods minimise observed variation and allow fitness costs to be 
calculated in terms of generations.
The models selected should aim to reflect growth and environmental survival conditions 
of the bacterial species of interest, and can be confounded by variations in measurements 
in experimental procedures. No one method in isolation is likely to be sufficient to 
describe in vivo fitness and multiple models are required. The models selected will depend 
on the organism and its mode of transmission. Fitness deficits will vary depending on the 
resistance mutation, the organism and the model used to quantify the cost. For example 
Sanchez et al assessed the fitness costs associated with overproduction of multidrug efflux 
pumps in P. aeruginosa using survival in water, maintenance on dry surfaces, biofilm 
formation, nematode killing, production of pyocyanin and pyoverdin and quantification of 
proteases (Sanchez et al. 2002). Mutants were shown to have fitness costs in terms of 
resistance to dessication, survival in water, loss of quorum sensing response and loss of 
virulence in the nematode killing model. However the nalB mutant exhibited greater 
biofilm formation than the wild type (Sanchez et al. 2002).
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Most studies investigating fitness costs use in vitro models while few have used animal or 
human in vivo models. These in vivo studies commonly use competitive colonisation to 
measure fitness (Johnson et al. 2005). Fitness of fluoroquinolone resistant C. jejuni, was 
assessed via colonisation and persistence in chickens in the absence of antibiotic selective 
pressure (Luo et al. 2005). It is unrealistic to assume that in vitro assays, using biological 
rich media, will accurately reflect the fitness costs experienced by the pathogen during 
infection. Fitness deficits may be affected by growth conditions (Durso, Smith, & Hutkins 
2004; Remold & Lenski 2001). Therefore use of minimal media may be more appropriate 
if in vivo models are not possible. Competitive colonisation of human skin by 
Staphylococcus epidermidis has been used to measure fitness costs associated with 
fluoroquinolone and fusidic acid resistance (Gustafsson, Cars, & Andersson 2003).
1.3.4 Cost of Fitness
1.3.4.1 Chromosomal Mutations
Antibiotic targets that are altered by chromosomal mutations to confer resistance include 
DNA gyrase, RNA polymerase, the cell wall or the ribosome and these alterations can 
cause a reduction in fitness (Andersson & Levin 1999; Gillespie & McHugh 1997; Levin, 
Perrot, & Walker 2000). Mutations in rpsL confer streptomycin resistance in Salmonella 
typhimurium due to changes in the ribosomal protein S I2. These mutants have been 
shown to be less fit than the wild type due to a decrease in peptide elongation rate, 
resulting in decreased protein synthesis and growth rate (Bjorkman, Hughes, & Andersson 
1998). Chromosomal mutations in RNA polymerase (rpoB) that confer resistance to 
rifampicin are associated with a fitness cost in S. aureus and M. tuberculosis (Billington, 
McHugh, & Gillespie 1999; Moorman & Mandell 1981; Wichelhaus et al. 2002). The
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extent of this fitness cost depends on the nature of the resistance mutation (Billington, 
McHugh, & Gillespie 1999).
In 1953, Barnett and colleagues showed that resistance to isoniazid in M. tuberculosis 
ameliorated disease in a guinea pig model (Barnett, Busby, & Mitchison 1953). Molecular 
tools have since shown that point mutations in katG confer isoniazid resistance. Functional 
katG, integrated to the genome, restored virulence to wild type levels (Wilson, de Lisle, & 
Collins 1995). In the mouse model, resistant strains of M. tuberculosis vary in virulence 
(Ordway et al. 1995), however the degree of drug resistance was not correlated with a 
reduction in virulence.
A number of mutations, conferring antibiotic resistance, which do not incur measurable 
fitness costs have been described. These include mutations in topoisomerase genes 
conferring fluoroquinolone resistance in S. pneumoniae (Gillespie, Voelker, & Dickens
2002), vancomycin resistance in Enterococci (Ramadhan & Hegedus 2005) and ribosomal 
mutations conferring aminoglycoside and spectinomycin resistance in Borrelia 
burgdorferi (Criswell et al. 2006).
1.3.4.2 Plasmids
The carriage of plasmids has been shown to reduce the fitness of bacteria (Lee & Edlin 
1985; Nguyen et al. 1989; Wames & Stephenson 1986). Insertion of a plasmid reduced 
fitness of the strain compared to the plasmid free strain. However, this fitness deficit was 
reduced following 500 generations (Nguyen et al. 1989). Restoration of fitness may be 
due to loss of plasmid containing bacteria from the population as plasmid free bacteria 
outgrow them (Lenski & Bouma 1987). This would suggest that following rational
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antibiotic use the frequency of resistant bacteria may decline, reducing the spread of 
antibiotic resistance. Subsequently, it has been demonstrated that, with time, chromosomal 
changes occur that increase the fitness of the plasmid carrying bacteria (Lenski, Simpson, 
& Nguyen 1994). Over many generations of association the effects of fitness can be 
decreased extensively by compensatory mutations which restore reproductive potential 
(Bouma & Lenski 1988; Modi et al. 1991).
1.3.4.3 Other Genetic Elements
In S. aureus methicillin resistance occurs due to acquisition of the Staphylococcal 
Chromosomal Cassette (SCCMec) element and this incurs a fitness cost. Fitness cost was 
measured via transformation of SCCMec into the susceptible parent strain. Growth rates 
were determined in paired competition assays. The generation time of S. aureus 
containing SCCMec was 29 +/- 0.1 min compared to 40 +/- 0.1 min to the parent strain 
(Ender et al. 2004). Lee et al measured fitness costs of type I and type IV SCCmec 
elements in glucose limited continuous culture. A fitness cost was measured for type I as 
measured by growth rate and cell yield but no similar cost was found for type IV (Lee et 
al. 2007).
The bla sm e-i P-lactamase is only found in carbapenem resistant Serratia marcescens 
strains and has not been identified on mobile genetic elements. However its mode of 
horizontal transfer is unknown. Using growth competition assays a fitness cost was 
associated with presence of this element and this may limit dissemination of the p- 
lactamase among S. marcescens isolates (Marciano, Karkouti & Palzkill 2007).
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1.3.4.4 Compensatory Mutations
A deleterious mutation may be lost from the population, revert to susceptibility or be 
compensated for by another mutation. In bacteria which are less fit, selection of mutations 
which compensate for this deficit may occur and restore reproductive potential. These 
mutations occur at another site and ameliorate the cost incurred by the initial resistance 
mutation without the loss of the resistance. These mutations can accumulate and restore 
fitness, stabilising the population of resistant bacteria. The compensated strain may then 
outcompete the wildtype strain. These mutations have been observed in a number of 
bacterial species. For example, compensation of fluoroquinolone resistance in S. aureus 
occurs by decreased expression of topoisomerase IV (Ince & Hooper 2003). It has also 
been demonstrated that the fitness cost of mutations in rpsL, conferring streptomycin 
resistance in E. coli, can be compensated to a restored rate of protein synthesis following 
adaptation (Schrag, Perrot, & Levin 1997). Similarly, adaptation experiments in M. 
tuberculosis have demonstrated that rifampicin resistant rpoB mutants lose the fitness 
deficit following serial passage (Billington, McHugh, & Gillespie 1999).
Most compensatory mutations that restore fitness are not revertants to susceptibility. This 
may be because the mutation rate for other mutations is higher due to multiple targets 
(Levin, Perrot, & Walker 2000).
Isoniazid resistant M. tuberculosis with mutation in katG, resulting in loss of a functional 
catalase, accumulates compensatory mutations that result in increased expression of the 
ahpC promoter. The ahpC gene encodes an alkyl hydroperoxidase reductase and it has 
been proposed that these mutations increase the expression of this enzyme which protects
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M. tuberculosis from oxidative stress and compensates for the loss of catalase (Sherman et 
a l  1996).
There is evidence to suggest that antibiotic resistance may reduce the ability of an 
organism to be transmitted and cause disease in another host. Drug resistant strains of M. 
tuberculosis have been shown to cause fewer secondary cases of tuberculosis than 
susceptible strains (Burgos et al. 2003). Some drug resistant strains have been shown to be 
as likely to occur in clusters, as compared to the wildtype and others less likely (van 
Soolingen et al. 1999).
1.3.5 Fitness Landscapes
Fitness or adaptive landscapes can be used to visualise relationships between genotypes 
and replication rates (Wright 1932). The fitness of all mutants can be compared via 
construction of a topographical map with fitness on the ordinate and genomes/phenotypes 
on the abscissa. A single large peak indicates that a single genotype has optimum fitness 
and that any deviations result in a decrease in fitness. Multiple peaks indicate that a 
number of possible genotypes may have similar fitness values.
1.3.6 Mullers Ratchet
In a culture a deleterious mutation is more likely to occur than a favourable mutation. 
Therefore, over numerous generations, an irreversible decline in fitness will be observed 
and the fittest individuals can be lost from the population. This has been referred to as 
‘Muller’s ratchet’ (Muller 1964) and occurs in RNA virus populations; the effect is 
exacerbated in asexual populations where populations are small and mutation rates are
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high. However Andersson and Hughes showed that Muller’s ratchet also operates in S. 
typhimurium (Andersson & Hughes 1996).
1.4 Bacterial Biofilms
1.4.1 Definition
Bacteria may exist in sessile or planktonic states. It is accepted that planktonic cells are 
necessary for replication and colonisation of new habitats and adherent cells are important 
for perseverance. Classic planktonic laboratory culture experiments have elucidated many 
aspects of bacterial physiology and molecular biology. Although planktonic cells are 
convenient to study, it is now commonly recognized that bacteria grow as biofilms both 
within the human body and in natural environments (Costerton et al. 1987). Bacterial 
biofilms have been isolated from 3.2 billion year old deep sea hydrothermal rocks and 
therefore represent an ancient mode of existence (Rasmussen 2000). Purely planktonic 
populations of bacteria are likely to be rare. In order to guide treatment of infections 
caused by biofilms, bacteria should be studied as biofilms because planktonic and biofilm 
cells are inherently different. The definition of a microbial biofilm has evolved over the 
last twenty years and may now be regarded as a complex community of interdependent 
microbial cells enclosed within a self produced extracellular polymer matrix that are 
associated with a biotic or abiotic surface or interface that express a distinct phenotype.
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1.4.2 Biofilms in Human Disease
Although it is accepted that biofilms are common in natural environments the significance 
of biofilms in infectious diseases is not yet clear. However, it is estimated that 65% of 
infections in the developed world are caused by biofilm forming organisms (Potera 1999). 
Many chronic bacterial infections, including otitis media (Fergie et al. 2004), endocarditis 
(Hyde, Darouiche, & Costerton 1998), dental caries (Marsh 1995), peridontitis (Darveau, 
Tanner, & Page 1997), biliary tree infection (Leung, Sung, & Costerton 1989) and lung 
infection in cystic fibrosis patients (Singh et al. 2000) owe their persistence, in part, to the 
formation of biofilms and the intrinsic resistance of these biofilms cells to antimicrobial 
killing and to the immune response of the host (Costerton, Stewart, & Greenberg 1999). 
Many nosocomial infections are associated with colonisation of indwelling medical 
devices include those relating to urinary catheters (Morris, Stickler, & McLean 1999), 
central venous catheters (Passerini et al. 1992), orthopaedic devices and prosthetic heart 
valves.
1.4.3 Biofilm Development
Biofilm development is a complex process and five stages have been suggested (Stoodley 
et al. 2002), see figure 1.1.
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Figure 1.1 Stages of Biofilm Development (obtained from Stoodley et al. 2002). Stage 1 
involves reversible initial attachment to a surface. Stage 2 involves irreversible binding via 
exopolysaccharide (EPS) production. Stages 3 and 4 represent differentiation of an initial 
biofilm to a mature biofilm. During stage 5, dispersion of single planktonic cells from the 
biofilm occurs.
Mature biofilms consist of 3D mushroom and pillar structures separated by water channels 
and the shape of these structures is affected by nutrient status (Stoodley et al. 1999). This 
allows the transport of oxygen and nutrients and the removal of metabolic waste products. 
Flow within these channels has been documented (Stoodley, Debeer, & Lewandowski 
1994).
1.4.4 Adhesion
Bacteria initially adhere to the surface in a reversible, then irreversible manner to form a 
structured community. Adhesion triggers changes in gene expression. For example 
attachment of P. aeruginosa cells during the initial stages of biofilm formation stimulates 
production of alginate from the algC promoter (Davies, Chakrabarty, & Geesey 1993;
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Hoyle, Williams, & Costerton 1993). Alginate is a biofilm matrix polymer that plays an 
important role in pathogenicity in P. aeruginosa lung infection in cystic fibrosis (CF) 
patients.
On abiotic surfaces reversible attachment is mediated by electrostatic, hydrophobic and 
van der Waals interactions but on tissue surfaces, specific binding of lectins and adhesins 
occurs (Dunne, Jr. 2002). High shear environments can promote biofilm formation. It is 
hypothesized that this represents a survival strategy as planktonic cells will be removed 
(Donlan & Costerton 2002).
1.4.5 Quorum Sensing
Quorum sensing is the regulation of cell density dependent expression of genes and allows 
coordination of virulence factor expression by the release of small molecules. Motility, 
production of antibiotics, exchange of DNA, and biofilm production have been shown to 
be controlled by quorum sensing systems. Quorum sensing was first described over 25 
years ago in the light producing marine bacteria Vibrio fischeri and Vibrio harveyi 
(Nealson & Hastings 1979). The luxCDABE luciferase operon encodes the enzymes 
responsible for light production. Emission of light was dependent on the accumulation of 
signalling molecules and only occurred at high population densities (Nealson & Hastings 
1979). The quorum sensing circuits identified in Gram-negative bacteria contain 
homologues of the luxl and luxR genes. The lux I  gene encodes the autoinducer 
homoserine lactone signalling molecules (AHLs). These are small diffusible molecules 
that accumulate with increases in cell population until a threshold is reached. The luxR 
gene binds autoinducers and can then activate expression of target genes (Hanzelka &
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Greenberg 1995). Quorum sensing has been described in a number of Gram-negative 
pathogens including P. aeruginosa (Passador et al. 1993), which contains two systems, 
lasRI and rhlRl (Latifi et al. 1995). The quorum sensing systems of P. aeruginosa activate 
the expression of a number of virulence factors including; elastase, encoded by lasB\ 
exotoxin A, encoded by toxA; alkaline phosphatase, encoded by aprA; siderophores and is 
involved in biofilm formation (Parsek & Greenberg 2000; Pearson, Pesci, & Iglewski 
1997; Whiteley, Lee, & Greenberg 1999).
1.4.6 P. aeruginosa grows as a biofilm in the CF lung
There are three separate lines of evidence to support the observation that P. aeruginosa 
grows as a biofilm in the lungs of CF patients (Lam et al. 1980; Singh et al. 2000). Cells 
isolated from CF sputum form microcolonies surrounded by a matrix that are visible using 
electron microscopy (Lam et al. 1980). Furthermore the ratio of quorum sensing acyl 
homoserine lactones expressed supports the role of the biofilm phenotype in infection of 
CF patients (Singh et al. 2000). This is because biofilm cells of P. aeruginosa produce 
more butryl (C4) acyl homoserine lactone than oxyodecanoyl (C l2) acyl homoserine 
lactone, while planktonic cells produce more of the C12 signal (Singh et al. 2000) and this 
is also observed in the CF lung. B. cepacia grow as biofilms in vitro (Al Bakri, Gilbert, & 
Allison 2004; Conway, Venu, & Speert 2002; Tomlin et al. 2005; Tomlin, Clark, & Ceri 
2004; Tomlin, Coll, & Ceri 2001) and therefore it is likely that growth within the lung is 
as the biofilm phenotype.
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1.4.7 Biofilm Resistance to Antimicrobial Killing
Biofilms growing in association with epithelial cells in the lungs of CF patients can cause 
persistent infections that are difficult to eradicate, partially because biofilms are highly 
resistant to killing to bactericidal antibiotics. Various mechanisms have been proposed to 
account for the increased resistance to antimicrobials and it is likely that multiple 
mechanisms act synergistically. However the reasons for increased tolerance to 
antimicrobials remain unclear. The cells that persist exhibit increased resistance to 
antibiotics (Stewart & Costerton 2001) have been shown to be up to 1000 fold more 
resistant than planktonic cells (Ceri et al. 1999). Accepted resistance mechanisms such as 
mutation in antibiotic target genes, modification enzymes and efflux pumps (Walsh 2000) 
are unlikely to be responsible as cells sacrificed from biofilms regain their susceptibility 
(Anwar et al. 1989). This implies that genetic events have not occurred. However 
derepression of a chromosomal P-lactamase in P. aeruginosa has been shown to occur 
over time (Bagge et al. 2004), suggesting although conventional mechanisms alone do not 
explain resistance, they may contribute to persistence.
There are three resistance mechanisms that have been proposed for cells growing in a 
biofilm. These are reduced penetration of the antibiotic, development of an altered 
environment and formation of a protected, resistant phenotype (Mah & O'Toole 2001). 
The first mechanism is more likely to be due to the deactivation of the antibiotic in the 
biofilm or by binding of positively charged antibiotics, e.g. aminoglycosides, to the 
negatively charged matrix (Kumon et al. 1994; Shigeta et al. 1997) than reduced 
penetration. It has been shown that some antibiotics readily penetrate biofilms, in 
particular the fluoroquinolones (Anderl, Franklin, & Stewart 2000; Ishida et al. 1998;
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Stewart 1996; Vrany, Stewart, & Suci 1997) and that reduced transport has only a minor 
effect on biofilm antibiotic resistance. In addition the biofilm matrix readily allows 
antibiotic sized molecules to pass through (Stewart 1998). The second hypothesis relies on 
the development of an altered environment and nutrient gradients within the biofilm. 
Antibiotic action could be antagonised by accumulation of acidic waste products or 
reduced in zones of depleted oxygen levels, inhibiting action of antibiotics such as the 
aminoglycosides which have less activity in anaerobic conditions. Conditions within the 
biofilm, such as nutrient limitation may cause the bacterial cells to enter a non-growing 
state and so antibiotics that target the bacterial cell wall are likely to have reduced 
efficacy. This hypothesis has been supported by visualisation of P. aeruginosa biofilms, 
which has shown that the majority of the biofilm consists of metabolically inactive cells 
with metabolically active cells being only at the biofilm/liquid interface (Xu, McFeters, & 
Stewart 2000). Planktonic cells in the stationary phase are more tolerant to antibiotics than 
biofilm cells (Spoering & Lewis 2001). This is most likely due to slow growth and the 
presence of microbial persister cells. Antibiotic exposure kills the majority of the biofilm 
and planktonic cells, leaving a proportion that are protected by being in the biofilm state, 
as the concentration of antibiotic declines persister cells grow and repopulate the biofilm.
There may be a genetic basis for biofilm recalcitrance to antimicrobials. Whiteley et al 
used microarrays to compare gene expression in planktonic and biofilm cells of P. 
aeruginosa. Approximately 1% of all genes were differentially expressed in the biofilm 
(Whiteley et al. 2001). Exposure of the biofilm to tobramycin resulted in differential 
expression of 20 genes, several of which are known to have a role in increased 
aminoglycoside resistance. Thus it is likely that during biofilm growth alteration in gene 
expression induces resistance to many antibiotic classes. The P. aeruginosa nvdB gene is
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required for synthesis of periplasmic glucans which may prevent tobramycin from 
exerting an effect via sequestration of the antibiotic. P. aeruginosa containing a mutant 
ndvB gene, resulting in less glucan production has been identified that can form biofilms 
but does not develop high level antibiotic resistance (Mah et al. 2003).
1.4.8 Genetic Diversity in Biofilms
Biofilm communities consist of distinct subpopulations. The diversity of biofilms 
increases the range of environmental conditions that the bacteria can survive. This is 
known as the ‘insurance hypothesis’ (Boles, Thoendel, & Singh 2004). Boles et al 
demonstrated that heritable variation in colony morphology, swimming capacity, biofilm 
formation, detachment, metabolism and hydrogen peroxide resistance occurs during 
biofilm growth of P. aeruginosa. A proportion of biofilm bacteria overproduced 
pyomelanin, which has a protective function against radiation and oxidants (Nosanchuk & 
Casadevall 2003). This variation is likely to be dependent on RecA, which can produce 
genetic change in the chromosome by recombination and can induce error prone DNA 
polymerases (Little & Mount 1982). Inactivation of RecA reduced colony variation.
Bacteria are continuously exposed to changing environmental conditions. Biofilms serve 
to buffer bacteria from these changes by offering protection from antimicrobial killing and 
the host immune system. These protected communities of cells select for genetic diversity. 
Increased diversity will not necessarily result in altered fitness of any one subpopulation 
as fitness will depend on the prevailing conditions. The existence of these subpopulations 
may enable a proportion of the population to survive environmental change.
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1.5 Fluoroquinolone Antibiotics
1.5.1 Fluoroquinolones
The fluoroquinolone (FQ) class of antibiotics contains synthetic broad spectrum 
antibacterial compounds that have been widely used to treat human infections, especially 
respiratory and urinary tract bacterial infections (Hooper 1998). FQs are a widely 
prescribed class of antibiotic, and this use continues to increase. Between 2003 and 2005, 
dispensed prescriptions of ciprofloxacin, the most widely used FQ, rose by 10% 
(www.publications.doh.gov/uk/prescriptionstatistics/index). The FQs are also commonly 
used for veterinary treatment and in animal husbandry (Chiu et al. 2002; Nelson et al. 
2007).
FQ compounds contain a 4-quinolone ring in their structure and exert bactericidal activity 
by inhibition of DNA synthesis, through action on DNA gyrase (topoisomerase II) and 
topoisomerase IV (Drlica & Zhou 1997; Drlica & Hooper 2003). The topoisomerases are 
essential in resolving topological problems encountered by the cell and allow DNA to be 
packaged within cells. Most bacteria have two types of topoisomerases, type I and II. Type 
II enzymes mediate alterations in topology by introducing double stranded DNA breaks 
and allow subsequent re-joining. The type I enzymes cause single stranded breaks only. 
There is little conservation in amino acid sequence between these two types of 
topoisomerase. These enzymes are not present in human cells which are therefore not 
affected by FQs. In Gram-negative bacteria the primary target is gyrase and in Gram- 
positive bacteria it is topoisomerase IV (Drlica & Zhou 1997).
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1.5.2 History of the Fluoroquinolones
The quinolones have been classified into four generations on the basis of their activity. 
An antibacterial compound derived from a preparation of the antimalarial agent 
chloroquine was used to develop the first quinolone, nalidixic acid, which was synthesized 
in 1962. The use of this compound was limited due to low plasma levels, limited oral 
absorbance, high toxicity and a narrow spectrum of activity (Goss, Deitz, & Cook 1964). 
Resistance develops quickly to nalidixic acid. However there are now many derivatives of 
this compound, see figure 1.2. Following the addition of a fluorine atom at the carbon 6 
position to produce the agent flumequine the resulting second generation compounds had 
increased activity. Additional of a piperazinyl side chain at position 7 improved activity 
against Gram-negative bacteria. The resulting compound, pipemidic acid had activity 
against Pseudomonas and can penetrate cells more efficiently. The second generation 
compound, ciprofloxacin has a fluorine atom added at the C-6 position, an N 1 cyclopropyl 
group, a piperazinyl ring at the C-7 position and a nitrogen atom at the C-8 position. The 
introduction of ciprofloxacin increased the therapeutic value of the FQs and there are now 
many derivatives of this compound. The combination of a fluorine atom at position 6 with 
a piperazine ring at position 7 to produce norfloxacin formed a cornerstone for the 
development of recent FQs. The majority of subsequent compounds contain a 4-oxo-l, 8- 
naphthyridin-3-carboxylic acid moiety. Compounds containing this structure are known as 
4-quinolones due to the exocyclic oxygen at position 4. Two types of ring structures exist; 
a naphthyridone nucleus, containing a nitrogen atom at position 1 and 8 or a quinolone 
nucleus, containing only one nitrogen atom at position 1. Third generation compounds 
include clinafloxacin, moxofloxacin, gatifloxacin, levofloxacin and sparfloxacin. 
Trovafloxacin is a fourth generation compound and has increased streptococcal and
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anaerobe coverage. Most licensed quinolones contain a quinolone nucleus while 
gemifloxacin, trovafloxacin, enofloxacin and sufloxacin contain a naphthyridone nucleus. 
Modification of the nucleus effects pharmokinetics, activity, drug interactions and adverse 
reactions. Subsequent compounds have a broader spectrum of activity are easily absorbed 
orally and can be used to treat systemic infections (Appelbaum & Hunter 2000).
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Figure 1.2 Development of 4th generation fluoroquinolones
66
Chapter 1 General Introduction
The recent third and fourth generation FQ compounds have greater activity against Gram- 
positive cocci, anaerobes and atypical pathogens than the preceding compounds. 
Sitafloxacin and clinafloxacin, in particular, have improved activity against anaerobic 
bacteria (Tanlan 2001). However these compounds are not as active as ciprofloxacin 
against Gram-negative non fermenters. FQs can be administered orally once or twice daily 
and therefore are an attractive choice for treatment of infections in the hospital and the 
community. New FQs continue to be developed and moxifloxacin and gatifloxacin, two of 
the most recent, are used for treatment of respiratory tract infection, as they have activity 
against Gram-positive cocci, in particular S. pneumoniae (Tanlan 2001).
1.5.3 Mechanism of Action
FQs act by forming complexes with DNA gyrase and DNA, which consequently block 
cell growth. DNA gyrase passes a region of DNA through another and in doing so traps a 
quinolone/DNA/drug reaction intermediate. This blocks replication and produces double 
stranded breaks that are lethal to bacteria (Drlica 2003). DNA gyrase produces negative 
supercoils so that initiation proteins can bind to the origin of replication. It also relaxes 
positive supercoils that occur as the replication fork progresses. DNA gyrase is essential 
for the cell to efficiently process DNA. FQs bind to the DNA/gyrase complex and stabilise 
the strand breaks in the DNA. DNA gyrase relieves topological stresses encountered 
during DNA replication and supercoils DNA so that the genetic material can be packed 
into the bacterial cell by twisting DNA in the opposite direction to the normal turn of the 
molecule. DNA gyrase was discovered and characterised in 1976 (Gellert et al. 1976) and 
is a type II DNA topoisomerase that is composed of two A and two B subunits gyrA and 
gyrB respectively (Wang 1985). The A subunit is responsible for breakage and rejoining
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of DNA while the B subunit is the site of ATP hydrolysis (Gellert et al. 1976). The Tyr- 
122 residue in the N terminal of GyrA is considered the active site of the quinolone 
resistance determining region. The protein can also catenate and decatenate covalently 
closed circular DNA (Drlica & Zhou 1997).
The primary function of topoisomerase IV is to decatenate daughter chromosomes 
following DNA replication. Topoisomerase IV, which is involved in chromosomal 
segregation shares significant homology with DNA gyrase and consists of 2 ParC and 2 
ParE subunits, encoded by parC  and parE  which are homologous to gyrA and gyrB 
respectively. In E. coli the gyrA gene shares 60 % amino acid similarity with parC  while 
gyrB has 62 % similarity with parC  (Huang 1996; Kato et al. 1990; Peng & Marians
1993). Most bacteria contain genes encoding DNA gyrase and topoisomerase IV. 
However some bacteria e.g. Treponema pallidum lack genes encoding topoisomerase IV 
(Fraser et al. 1998).
1.5.4 Induction of the SOS Response
The SOS response is a post replication DNA repair system that is induced by DNA 
damage. The SOS response increases the dissemination of antibiotic genes. Beaber et al 
demonstrated that in E. coli induction of this response increases transfer of the Vibrio 
cholerae derived intregating conjugative factor SXT conferring resistance to 
chloramphenicol, sulphamethoxazole, trimethoprim and streptomycin and that this was 
also induced by exposure to ciprofloxacin (Beaber, Hochhut, & Waldor 2004).
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Microarray technology has demonstrated that SOS genes are induced during exposure to 
fluoroquinolones in E. coli, H. influenzae and S. typhimurium (Piddock, Walters, & Diver 
1990; Shaw et al. 2003; Ysem et al. 1990). Piddock et al have also used 2D gel 
electrophoresis to investigate the response of S. enterica exposed to fluoroquinolone at 0.5 
and 2 x MIC. Exposure to FQs increased expression of the efflux pump AcrAB/TolC 
(Coldham et al. 2006).
1.5.5 Resistance Mechanisms
There has been a large increase in fluoroquinolone resistance since these drugs were 
introduced in the late 1980s due to extensive use in many organisms including S. 
pneumonie, S. typhimurium and C. jejuni (Aguiar et al. 1992; Chen et al 1999; Hakanen 
et al 1999; Kresken & Wiedemann 1988; Linares, de la Campa & Palla 1999; Tanaka et 
al. 2000) and this now restricts their use.
1.5.5.1 Target Alteration
Alteration in target genes and alterations that affect access of the drugs to targets e.g. 
increased expression of efflux pumps in Gram-negative bacteria, are the primary 
mechanisms of resistance to fluoroquinolones (Hooper 2003; Ruiz 2003). Bacteria become 
increasingly resistant to fluoroquinolones by accumulation of mutations in topoisomerase 
genes. This reduces the affinity of the drug for the targets and decreases susceptibility. 
These mutations occur in a stepwise manner, increasing the level of resistance with each 
successive mutation (Chen & Lo 2003; Hooper 2003). The result of this gradual increase 
in resistance may cause isolates that contain resistance mutations but are classed as
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susceptible to be missed by resistance surveillance studies. Mutations in the quinolone 
resistance determining regions (QRDR) within topoisomerase II (GyrA and GyrB) and 
topoisomerase IV (ParC and ParE) confer resistance to FQs (Everett et al. 1996). In E. coli 
the primary target of FQs is DNA gyrase (Gellert et a l 1977). Additional mutations in 
gyrA and parC  are required for high level fluoroquinolone resistance in E. coli, A. 
baumannii, P. aeruginosa and S. maltophilia (Mouneimne et al. 1999; Valdezate et al. 
2002; Vila et al. 1995). Mutations in parE  and gyrB, conferring a decrease in 
susceptibility, occur less commonly (Akasaka et al. 2001; Lee et al. 2005; Oh et al. 2003). 
Double mutations in topoisomerase II genes are associated with higher level resistance 
than individual mutations. The primary target of fluoroquinolones in S. aureus and other 
Gram-positive bacteria is topoisomerase IV (Drlica 2003; Ferrero et al. 1994; Ferrero, 
Cameron, & Crouzet 1995; Gellert et al. 1976; Gellert et al. 1977).
1.5.5.1.1 GyrA
Of the gyrA mutations that cause fluoroquinolone resistance in vitro in Gram-negative 
bacteria those that occur at codons 83 and 87 occur most frequently (Dessus-Babus et al. 
1998; Mouneimne et al. 1999). Codon 83 and 87, found within the QRDR, encode amino 
acids which form an a helical domain in the DNA gyrase protein. These codons encode 
the DNA binding region of gyrase and therefore fluoroquinolones are less able to form a 
complex with the DNA and gyrase, when mutated. Double mutants containing two gyrA 
mutations have been described in E. coli (McDonald et al. 2001). There is a 10 fold 
reduction in affinity of the gyrase/DNA complex for ciprofloxacin in isolates which 
contain Ser83Ala Asp87Asn double mutation within gyrA (Barnard & Maxwell 2001). 
Other mutations between codon 67-106 can also confer resistance. Resistance mutations in
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gyrA have been found outside the QRDR, such as Ala51Val but are less common 
(Yoshida et a l 1990). Alteration at codon 106 has been reported in E. coli and P. 
aeruginosa (Hallett & Maxwell 1991; Lee et al. 2005; Ruiz 2003). Mutations in gyrA are 
found more frequently than those in gyrB (Zhou et a l 2000). This can be explained by the 
larger MIC increases that result following gyrA mutation (Hooper 2003).
Mutations in gyrA have been detected by single strand conformation polymorphism 
(SSCP) analysis in a number of organisms (Takenouchi, Sakagawa, & Sugawara 1999; 
Vila et a l 1995). This technique utilises the altered migration in a nondenaturing 
polyacrylamide gel of isolates with changes in DNA conformation by nucleotide 
substitution to detect mutations (McHugh, 2000).
1.5.5.1.2 GyrB
Alterations in gyrA are reported more often than alterations in gyrB, this may be because 
gyrB mutations confer lower levels of resistance than gyrA. In E. coli common mutations 
are Asp426Val and Lys447Glu (Drlica & Malik 2003). Both result in decreased 
susceptibility to nalidixic acid but differ in extent of resistance conferred to FQ containing 
a piperazinyl moiety at position 7 (e.g. ciprofloxacin, norfloxacin). This may be due to 
electrostatic interactions between gyrB and drugs either containing or not containing the 
positively charged piperazinyl moiety (Yoshida et al. 1991). In P. aeruginosa substitution 
of Ser467 and Glu469 have been documented in norfloxacin resistant mutants selected in 
vitro (Kugelberg et al 2005).
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1.5.5.13 ParC
Mutations in parC  and parE  in isolation do not confer resistance but contribute to further 
elevations in MIC when gyrA and gyrB mutations are also present (Ruiz 2003).
Common mutations are Ser80Phe/Tyr and Glu84Lys/Leu E. coli (Drlica 2003). ParC has a 
secondary role in fluoroquinolone resistance and mutations in parC  or parE  only cause 
resistance in E. coli in the presence of mutant gyrA. ParC mutations have been found in 
high level resistance in combination with mutations in gyrA in many Gram-negative 
bacteria including E. coli (Vila et al. 1996), P. aeruginosa (Kugelberg et al. 2005; Lee et 
al. 2005), S. enterica (Eaves et al. 2004), Klebsiella pneumoniae (Brisse et al. 1999), 
Klebsiella oxytoca (Brisse et al. 1999) and Enterobacter aerogenes (Brisse et al. 1999).
1.5.5.1.4 ParE
Mutations in parE  have been found less commonly in clinical resistant isolates and 
mutants selected in vitro than mutations selected in the other topoisomerase genes but 
have not been evaluated as extensively as other mutations. Most mutations that have been 
reported are in Gram-positive bacteria. Few cases of parE  mutations have been described 
in Gram-negative bacteria but include Ala425Val in P. aeruginosa (Kugelberg et al. 2005) 
and Leu445His in E. coli (Breines et al. 1997).
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1.5.5.2 Efflux
Efflux is a major mechanism of fluoroquinolone resistance. Efflux mediated 
fluoroquinolone resistance confers resistance to other classes of antimicrobial with 
different structures e.g. chloramphenicol (Poole 2000).
1.5.5.3 Multiple Antimicrobial Resistance Phenotype (MAR)
Mutations in genes other than topoisomerase genes can have a role in the development of 
FQ resistance (Kern et al. 2000). For example mutations in regulatory genes can result in 
expression of the Multiple Antimicrobial Resistance Phenotype (MAR). This involves 
expression of porins and efflux pumps to confer chromosomally encoded low level cross 
resistance to FQs and other classes of antibiotics. These include p-lactams, tetracyclines, 
chloramphenicol (George & Levy 1983), agents causing oxidative stress (Ariza et al.
1994), disinfectants (McMurry, Oethinger, & Levy 1998; Moken, McMurry, & Levy
1997) and organic solvents (Asako et al. 1997). Mutation in mar A increases expression of 
micF, which decreases expression of the OmpF porin and decreases permeability of the 
cell (Cohen, McMurry, & Levy 1988). The Mar operon has been identified in E. coli 
(Hachler, Cohen, & Levy 1991), Klebsiella, Citrobacter, Hafnia, Enterobacter (Cohen, 
Yan, & Levy 1993) and S. enterica (Randall & Woodward 2001).
Mutations in acrR, the repressor gene of the AcrAB multidrug efflux pump, also have a 
role in fluoroquinolone resistance in E. coli (Wang et al. 2001). If the acrAB is inactivated 
in E. coli strains that also contain topoisomerase mutations then all strains become 
susceptible (Oethinger et al. 2000).
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1.5.5.4 Plasmid Mediated Resistance
The major mechanisms of FQ resistance are target alteration and overexpression of efflux 
pumps however plasmid mediated low level quinolone resistance has been described and 
was first documented in K. pneumoniae (Martinez-Martinez, Pascual, & Jacoby 1998). 
This gene, qnr, encoding a member of the pentapeptide repeat family, prevents 
fluoroquinolones from inhibiting DNA gyrase by binding to GyrA and GyrB before 
formation of the gyrase/DNA/quinolone complex. This has been hypothesised to reduce 
binding of gyrase to DNA thereby reducing the number of targets available to the 
fluoroquinolone molecules (Tran, Jacoby, & Hooper 2005). The mechanism by which this 
occurs is not known. The Qnr protein has similarity to gyrase protecting proteins, which 
protect gyrase from self produced microcin B17 (Garrido et al. 1988). Microcins are small 
inhibitory molecules that target DNA gyrase (Lomovskaya, Kawai, & Matin 1996). 
Before 2003 the qnr gene was thought to be a rare and had been found in one E. coli 
isolate, four K. pneumoniae isolates and one Klebsiella spp. isolate despite screening of 
350 isolates of Gram-negative bacteria in the United States (Jacoby, Chow, & Waites 
2003; Wang et al. 2003). However the qnr gene has been found in 78 unrelated strains of 
E. coli in a Shanghai hospital and subsequently in further K. pneumoniae strains in the 
United States (Wang et al. 2003; Wang et al. 2004). It has been postulated that these 
strains are now spreading across the United States (Wang et al. 2004). Plasmid mediated 
resistance may complement topoisomerase mutations and efflux mediated resistance by 
increasing the level at which resistance mutations can be selected. Other plasmid mediated 
quinolone resistance genes, qnrB and qnrS, have also been found in K. pneumoniae and 
Shigella flexneri respectively (Hata et al. 2005; Jacoby et al. 2006).
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1.5.5.5 Inactivation
Degradation of quinolones by the brown rot fungus Gloeophyllum striatum, has been 
described (Wetzstein, Schmeer, & Karl 1997). In 2006 the first evidence for FQ 
inactivation by bacterial enzymes was presented. Robicsek et al unexpectedly found that a 
variant of a previously reported plasmid mediated aminoglycoside modifying enzyme 
could also modify ciprofloxacin and norfloxacin by N-acetylation of the amino nitrogen 
on the piperazinyl substituent. This conferred a small increase in resistance. Other FQ 
antibiotics were not affected (Robicsek et al. 2006).
1.6 The Burkholderia cepacia complex
1.6.1 Taxonomy of Burkholderia
The genus Burkholderia consists of non spore-forming, motile, aerobic, Gram-negative 
bacilli that are pathogens of animals, plants and humans. In 1992 Pseudomonas cepacia 
and six other pseudomonads (.Pseudomonas pseudomallei, Pseudomonas mallei, 
Pseudomonas solanacearum, Pseudomonas gladioli, Pseudomonas picketti and 
Pseudomonas caryophylli) were transferred to the new genus of Burkholderia in the (3- 
subdivision of the phylum Proteobacteria (Yabuuchi et al. 1992).
Following increased scientific interest, the genus Burkholderia now contains at least 40 
species. The taxonomy of this group of organisms is shown in figure 1.3.
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Figure 1.3 Phylogenetic tree of Burkholderia species. Based on 16S rRNA gene 
sequences. Scale bar represents dissimilarity. Species names in quotation marks have not 
been validated (Vandamme, Go van & LiPuma 2007).
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1.6.2 The Burkholderia cepacia complex (Bcc)
The Burkholderia cepacia complex (Bcc) consists of at least 10 species (previously 
known as genomovars) that were originally thought to be a single species. However 
different groups of bacteria within this complex are genotypically heterogenous but are 
hard to differentiate on the basis of their phenotypic properties. In 1997, Vandamme et al 
proposed that these strains comprised five distinct genomovars (Coenye et al. 2001; 
Vandamme et al. 1997) that can be identified using genotypic and phenotypic methods 
(Vandamme et al. 1997). The complex now consists of 10 species; B. cepacia (genomovar 
I; Vandamme et al. 1997; Yabuuchi et al. 1992), B. multivorans (genomovar II; 
Vandamme et al. 1997), B. cenocepacia (genomovar III; Vandamme et al. 2003), B. 
stabilis (genomovar IV; Vandamme et al. 2000), B. vietnamensis (genomovar V; Gillis et 
al. 1995; Vandamme et al. 1997), B. dolosa (genomovar VI; Vermis et al. 2004), B. 
ambifaria (genomovar VII; Coenye et al. 2001), B. anthinia (genomovar VIII; Vandamme 
et al. 2002), B. pyrrocinia (genomovar IX; Vandamme et al. 2002) and B. ubonensis 
(genomovars X; Yabuuchi et al 2000). Genomovar I contains the type strain (the species 
chosen as the one that best represents the complex) and retains the name B. cepacia.
B. cepacia (formerly Pseudomonas cepacia) was first described by Burkholder as the 
causative agent of soft rot in onions (Burkholder 1950). In 1970 the similarity of a 
pseudomonad with metabolic versatility known as P. multivorans (Stanier & Doudoroff 
1966) to the previously described P. cepacia was noted (Ballard R.W. et al. 1970). Other 
names that have been assigned in the past are the eugenic oxidider group I, Pseudomonas 
kingii (Jonsson 1970) and Pseudomonas multivorans (Stanier & Doudoroff 1966).
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Vandamme et al proposed that within a species there is a high degree of DNA relatedness 
(70% or higher), low but significant DNA relatedness below the species level and no 
significant DNA relatedness (30%) or less (Vandamme et al. 1996) between unrelated 
species. This is demonstrated within Burkholderia. Different species within the Bcc have 
DNA-DNA hybridization values of 30-60%, isolates within the same species have a value 
of greater than 70%. Other Burkholderia spp. have a value of less than 30% (Coenye et al. 
1999; Coenye et al. 2001; Gillis et al. 1995; Vandamme et al. 1997).
1.6.3 Burkholderia pseudomallei and Burkholderia mallei
Many species of the genus Burkholderia are primarily plant pathogens or saprophytes. 
However two species; Burkholderia pseudomallei and Burkholderia mallei can cause life 
threatening human disease in patients that are not immunocompromised. B. pseudomallei 
is a soil saprophyte, causing meliodosis in humans and is endemic in the Far East and 
northern Australia. Transmission occurs via exposure of wounds to contaminated water or 
soil or by inhalation. The most common clinical manifestation is septicaemia with abscess 
formation, although it is also a major cause of pneumonia (Chaowagul et al. 1989). 
Asymptomatic infections occur and progression to disease depends on the immune status 
of the host and can manifest many years after exposure (Kingston 1971).
B. mallei is the causative agent of glanders in equines and can cause disease in humans 
exposed to infected animals. B. pseudomallei and B. mallei are closely related and no 
differences were found in the 16S rRNA genes of the two species (Gee et al. 2003). Both 
B. mallei and B. pseudomallei are considered potential biological weapons (USA CDC, 
Category B; Rotz et al. 2002) due to their mode of transmission and worldwide 
availability of these agents in the environment.
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1.6.4 Clinical Significance
1.6.4.1 Cystic Fibrosis (CF)
CF is an autosomal recessive disorder and is one of the most common genetic disorders in 
humans, affecting 1 in 2,500 live births in the Caucasian population (Ratjen & Doring 
2003). CF results from mutations in the cystic fibrosis transmembrane regulator (CFTR) 
gene, found on the long arm of chromosome 7. This protein is a chloride ion channel 
protein and patients homozygous for the mutant allele have defective electrolyte transport 
across the epithelial cell membrane, resulting in the production of thick, dehydrated mucus 
in organs, especially in ducts of the male genital tract, pancreas and in the airways. These 
secretions impair mucociliary clearance leading to the formation of mucus plugs in the 
lungs and pancreas and progressive decline in organ function. This thick mucus layer 
provides a protected niche within the lungs, for bacteria such as Bcc and P. aeruginosa.
Over 1000 CFTR mutations have been identified that result in CF (Govan & Deretic 
1996). These mutations may occur at different loci, resulting in a variation of CF 
phenotypes (Hart & Winstanley 2002). Over 70% of patients have a codon alteration 
resulting in loss of a phenylalanine residue at position 508 (AF-508) (Govan & Deretic 
1996; Hart & Winstanley 2002). CF genotype appears to affect the type and frequency of 
bacterial infection. For example in patients with the AF508 mutation, there is increased 
likelihood of infection with P. aeruginosa and the Bcc. Patients wih the R117H mutation 
are less likely to be colonisied with these organisms (McManus et al. 2005).
Death often results following lung infection by a number of bacterial species. These 
include P. aeruginosa, S. aureus, H. influenzae and the Bcc. As patients are surviving
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longer, other non-traditional pathogens are emerging. These include pathogens Aspergillus 
spp., S. maltophilia, MRSA, Alcaligenes xylosoxidans, Achromobacter xylosoxidans, 
Klebsiella spp., Pandoraea, Scedosprium apiospermum (Nagano et al. 2007) and 
mycobacteria other than tuberculosis (MOTT; Devine et al. 2004; Jordan et al. 2007; Hart 
& Winstanley 2002). In a retrospective study of 54 adult CF patients P. aeruginiosa was 
present in 48%, H. influenzae in 34%, Aspergillus sp. in 7%, mycobacteria other than 
tuberculosis in 11%, S. maltophilia in 9%, Acinetobacter sp. in 7% and B. cepacia 
complex in 2% (Paschoal et al. 2007).
There is a continuing improvement in the survival of CF patients; a child bom in 1990 
with CF has a life expectancy of 40 years whereas a child bom in 2000 with CF will have 
a life expectancy of approximately 50 years (Colten 1990; Dodge et al. 2007). 
Approximately 80% of CF patients now survive into adulthood (Elbom, Shale, & Britton 
1991).
Members of the Burkolderia cepacia complex are opportunistic pathogens and rarely 
cause disease in immunocompetent hosts. Immunocompromised hosts, especially patients 
with CF are at risk from B. cepacia lung infection (Isles et al. 1984) via person to person 
transmission (Govan et al. 1993). Nosocomial outbreaks of Bcc bacteraemia have also 
been described in non CF patients (Holmes et al 1999; Bressler et al 2007). In CF patients 
the most common clinical scenarios are asymptomatic carriage following colonization of 
the airways, or chronic infection resulting in decline in lung function. However in 
approximately 20% of colonized individuals a rapidly progressing necrotizing pneumonia 
occurs that often leads to death (Govan & Deretic 1996). This outcome has been termed 
‘cepacia syndrome’ (Isles et al. 1984) and is not observed with P. aeruginosa infection.
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Eradication of B. cepacia occurs very rarely once a CF patient becomes colonized. Bcc 
bacteria are acquired late in the disease course, following colonization by S. aureus, non 
encapsulated H. influenzae and P. aeruginosa. B. cepacia complex infection in CF has 
been associated with lower life expectancy, longer hospital stay and a poor prognosis 
(Isles et al. 1984; Mahenthiralingam et al. 2001; Tablan et al. 1987b). Long term 
colonisation can occur in some CF patients with no decline in lung function (Gilligan 
1991).
Colonisation of the CF lung by the Bcc is considered a contraindication to lung transplant 
by many transplant centres (Barlow et al. 2000). However lung transplant may be the final 
option for CF patients and can be beneficial. The survival rates for CF patients who have 
undergone lung transplants are 81%, 58% and 49% after 1, 3 and 5 years respectively 
(Aris et al. 2001). These survival rates are higher than those for CF patients with end stage 
disease that do not receive a lung transplant (Hosenpud et al. 1998). Reviews of the 
outcome following lung transplantation in CF patients demonstrated high mortality 
following lung transplantation in Bcc colonised CF patients (Chaparro et al. 2001; Snell et 
al. 1993). In contrast Egan et al reported that no significant difference in survival rates 
were observed between Bcc colonised and non colonised CF patients following 
transplantation (Egan et al. 1994). This group suggested that colonisation with Bcc alone 
was not sufficient to refuse lung transplantation.
1.6.4.2 Bcc species Distribution
B. multivorans and B. cenocepacia are the most commonly isolated species from CF 
patients, although B. multivorans is now the most prevalent in the UK (Mahenthiralingam,
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Baldwin, & Vandamme 2002; Mahenthiralingam, Urban, & Goldberg 2005; Vandamme et 
al. 1997; Baldwin et al 2008). In contrast the prevalence of B. cepacia, B. stabilis, B. 
anthina and B. pyrrocinia (Mahenthiralingam, Baldwin, & Vandamme 2002; Vandamme 
et al. 2002) among CF patients is low, while B. vietnamensis and B. ambifaria are rarely 
found (Mahenthiralingam, Baldwin, & Vandamme 2002; Mahenthiralingam, Urban, & 
Goldberg 2005). Further studies to assess incidence of each species among CF patients 
have supported the initial observations regarding species prevalence (Agodi et al. 2001; 
LiPuma et al. 2001; Speert 2002). For example Speert et al examined 905 isolates from 
447 CF patients in Canada and found that 83% of isolates were B. cenocepacia and 9.6% 
were B. multivorans. LiPuma et al demonstrated that 50% of Bcc isolates from CF 
patients in treatment centres across the United States were B. cenocepacia, 38% were B. 
multivorans and 5% were B. vietnamensis. The remaining 5% was comprised of all other 
species (LiPuma et al. 2001). Infection with B. cenocepacia is associated with a worse 
outcome than other species (Jones et al 2004) although the effect of the less commonly 
isolated species on prognosis is unclear.
1.6.4.3 Chronic Granulomatous Disease
Patients with chronic granulomatous disease are also at risk from infection with Bcc 
bacteria. These patients suffer recurrent, life threatening infections with catalase positive 
bacteria and fungi due to defects in oxidative killing in polymorphonuclear lymphocytes 
(Speert et al. 1994). Infection with Bcc is the second most common cause of death in this 
patient group, causing pneumonia and sepsis (Johnston, Jr. 2001).
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1.6.5 Transmission
1.6.5.1 Environmental Transmission
Outbreaks of Bcc have been attributed to contamination of disinfectants, antiseptics, dyes, 
nebulizers and medical devices (Hutchinson et al. 1996; Kaitwatcharachai et al. 2000; Oie 
& Kamiya 1996; van Laer et al. 1998). The ability of bacteria to survive drying allows 
their maintenance on environmental surfaces (Smith, Eng, & Padberg, Jr. 1996) and the 
possibility of transmission between hosts. B. cepacia complex bacteria can survive for 
extended periods in respiratory droplets on surfaces at room temperature (Drabick et al. 
1996). Bcc organisms were detected in air from patient rooms following physiotherapy 
and therefore this represents a risk for transmission to patients from the environment 
(Moore et al 2002).
1.6.5.2 Person to Person Transmission
Person to person infection was first documented in 1990 (LiPuma et al. 1990). However 
retrospective analysis of stored strains has shown that the first recorded case of patient to 
patient transmission of Burkholderia cepacia was in fact caused by a strain of B. dolosa 
(LiPuma et al 1990). Contact with respiratory secretions from CF patients infected with 
Bcc represents a risk for transmission (Moore et al. 2004). Highly transmissible epidemic 
lineages have been documented that have caused outbreaks. Social contact between CF 
patients has been associated with transmission at clinics and at Summer camp (Govan et 
al. 1993; Pegues et al. 1994). Segregation of colonised individuals ensued and CF 
Summer camps were closed. This has had an adverse psychological and social impact 
effect on CF patients and their families (Govan & Nelson 1993).
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1.6.5.3 Transmissible Strains of the Bcc
Epidemic B. cepacia, B. cenocepacia and B. dolosa have been described (Biddick et al. 
2003). However most cases of documented cases of transmission occur with B. 
cenocepacia (Mahenthiralingam, Baldwin, & Vandamme 2002). Infection with B. 
cenocepacia can replace B. multivorans during CF infection (Mahenthiralingam et al. 
2001). Vandamme et al have demonstrated by analysis of the recA gene that there are 4 
distinct B. cenocepacia lineages (Vandamme et al 2003).
B. cenocepacia ET-12 is the most studied transmissible Bcc strain which caused 
epidemics across Canada and the UK in the 1980s and 1990s. It is believed to have spread 
by person to person transmission (Clode et al. 2000; Ledson et al. 2002; Sun et al. 1995). 
This lineage was isolated from 50% of UK CF centres and from 38% of Bcc colonised 
patients (Pitt et al. 1996).
The enhanced capacity for spread of B. cenocepacia ET-12 is not fully understood. 
However this is the only strain that contains all three putative transmissibility markers, 
cable pili (Sajjan et al. 1995), the 22 kDa adhesin (Sajjan & Forstner 1993) and the B. 
cepacia epidemic strain marker (BCESM; Mahenthiralingam, Simpson, & Speert 1997). 
Cable pili are encoded by the cblA gene and mediate adherence to respiratory mucin (Sun 
et al. 1995). Although associated with epidemic strains of B. cenocepacia a variant form 
has been documented in B. cepacia (LiPuma et al. 2001). This lineage is highly resistant 
to antibacterials and is resistant to meropenem (Nzula, Vandamme, & Govan 2002).
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The BCESM, otherwise known as esmR, is a 1.4 kb putative ORF with homology to 
negative transcriptional regulators (Mahenthiralingam, Simpson, & Speert 1997). The role 
of BCESM in transmissibility is unclear. Other epidemic B. cenocepacia lineages that are 
causing outbreaks in CF patients include the PDHC clone and the Midwest clone. The 
PDHC clone causes infection in the Mid Atlantic region of the USA (Chen et al. 2001) 
while the Midwest clone causes infection of CF patients in the Midwest region of the USA 
(LiPuma et al. 1988). These isolates described do not contain BCESM or the cblA gene 
(Chen et al. 2001). Isolates of the PHDC clone have been isolated form soil, suggesting 
that transmission of epidemic clones from the environment can occur (LiPuma et al. 
2002).
Clinical outcomes following infection of CF patients by PHDC isolates and strains of the 
ET-12 lineage are variable. While a proportion of patients develop cepacia syndrome 
others are chronically infected with little effect on clinical status.
1.6.6 Identification
In the clinical laboratory, the Bcc are identified using a combination of selective media 
and biochemical tests. Bcc bacteria can be difficult to isolate in the clinical laboratory as 
these bacteria may be overgrown by other bacteria in a patient sample. The taxonomy of 
the Bcc is still changing and the potential of some of the newly recognized species to 
cause disease is not clear. There are variations in protocol for identification of Bcc 
between laboratories. Prior to the routine use of selective media only 32% of laboratories 
correctly identified B. cepacia from mock CF sputum (Tablan et al. 1987a). Members of 
the Bcc have been misidentified as a number of organisms including Alcaligenes spp,
85
Chapter 1 General Introduction
Pseudomonas spp., S. maltophilia, Flavobacterium spp. and Chryseobacterium (Kiska et 
al 1996). As some of these organisms can also cause disease in CF patients, the effects of 
these misidentifications can be serious. Identification of B. cepacia may be complicated as 
phenotypic changes can occur following long term colonization. Auxotrophic isolates of 
P. aeruginosa (Barth & Pitt 1995a), S. aureus (Gilligan et al. 1987) and B. cepacia (Barth 
& Pitt 1995b) have been found in the lungs of CF patients but not from non CF patients. 
Auxotrophic bacteria cannot synthesize compounds required for growth therefore these 
must be provided by the medium. Within the CF lung auxotrophic B. cepacia obtain 
necessary nutrients from sputum and are selected from the prototrophic population (Barth 
& Pitt 1995b). Colonies will grow on nutrient or blood agar and vary in appearance from 
grey, white and yellow to brown, red or purple.
Selective media are used to isolate Bcc bacteria from specimens as other bacteria are also 
likely to be present in greater numbers. The selective media employed make use of the 
high intrinsic resistance of the Bcc as other less resistant bacteria are killed. A number of 
selective agars are available that can be used to isolate B. cepacia from respiratory 
specimens. Oxidation-fermentation polymixin bacitracin lactose agar (OFPBL) contains 
lactose, polymixin and bacitracin. B. cepacia selective agar (BCSA) contains lactose, 
sucrose in a base of casein and yeast extract containing polymixin, gentamicin and 
vancomycin. Henry et al reported that this medium was superior to commercially 
available plates and the oxidation fermentation agar (Henry et al. 1997). Pseudomonas 
cepacia medium (PCA) contains polymixin and ticaricillin. However other Gram negative 
bacteria that are polymixin resistant are also able to grow on selective media. Further 
identification tests should follow.
86
Chapter 1 General Introduction
Most species cannot be identified phenotypically. A number of Polymerase Chain 
Reaction (PCR) based assays were developed, that amplified the 16S gene, to identify 
Bcc. However the majority of these assays were developed before it was recognized that 
organisms identified as B. cepacia, consisted of a complex of species and utilized 
sequence data that may not have been representative of the whole complex (Campbell, III 
et al. 1995; Karpati & Jonasson 1996; O'Callaghan, Tanner, & Boulnois 1994). The 
usefulness of 16S rDNA gene sequencing for species identification is limited because 
there is a high degree of sequence similarity between 16s rRNA genes of Bcc and 
discrimination of all members of the Bcc is difficult (LiPuma et al. 1999). Amplification 
of the 16S rRNA gene followed by restriction enzyme mediated fragmentation produces a 
Burkholderia species specific RFLP banding pattern (Segonds et al. 1999). 
Mahenthiralingam used species specific primers that amplified the recA gene and a recA 
based RFLP approach, to identify the Bcc (Mahenthiralingam et al. 2000).
Other techniques that have been used to identify members of the Bcc include sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) of whole cell proteins 
(Vandamme et al. 1997), amplified fragment length polymorphism (AFLP) fingerprint 
typing (Coenye et al. 1999) and whole cell fatty acid analysis (Vandamme et al. 1997).
Isolates survive well when stored in frozen tap water or as glycerol suspensions on beads. 
However viability is not maintained on plates or refrigerated slopes. The oxidase reaction 
is slow, nitrate is not reduced and members of the complex are lysine and ornithine 
decarboxylase positive.
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1.6.7 Treatment
Bcc bacteria are highly resistant to many individual antibacterial agents and as a result are 
difficult to eradicate. Prognosis is improved if transmission can be prevented. These 
bacteria are intrinsically resistant to aminoglycosides due to low permeability of the outer 
membrane as a result of an unusual structure of the core oligosaccharide of LPS (Cox & 
Wilkinson 1991). Lipopolysaccharide is unusual in that the core oligosaccharide contains 
less phosphate or 3-deoxy-D-manno-oct-2-ulosonic acid than other Gram-negative 
bacteria (Cox & Wilkinson 1991). Strains also exhibit high levels of resistance to P-lactam 
antibiotics due to altered penicillin binding proteins and inducible chromosomal P- 
lactamases (Hancock 1998). The ability of B. cepacia to use pencillin G as a carbon 
source is a well recognised example of its intrinsic resistance (Beckman & Lessie 1979). 
Semisynthetic penicillins, carbapenems, fluoroquinolones, ceftazidime and trimethoprim 
sulfamethoxazole can have activity against Bcc (Lewin, Doherty, & Govan 1993; LiPuma
1998). Nzula et al investigated the antibiotic susceptibility patterns of 65 Bcc isolates 
including the B. cepacia complex strain panel (Mahenthiralingam et a l 2000) and B. 
cenocepacia isolates cultured from soil (Nzula, Vandamme, & Govan 2002). All strains 
were resistant to polymixin and colistin; this is unsurprising as incorporation of these 
antibiotics into agar plates is used to allow selective growth of Bcc bacteria isolated from 
clinical samples. Most strains were resistant to tetracycline and all strains were susceptible 
to meropenem. Most strains were susceptible to ciprofloxacin (88%) and ceftazidime 
(97%; Nzula, Vandamme, & Govan 2002).
CLSI (Clinical and Laboratory Standards Institute) recommends susceptibility testing to 
ticaricillin plus clavulanic acid, ceftazidine, levofloxacin, minocycline, meropenem and 
trimethoprim-sulfamethoxazole (CLSI, 2006) as these antibacterials can have activity
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against the Bcc. Treatment options include meropenem, ciprofloxacin, minocycline, 
chloramphenicol and trimethoprim-sulfamethoxazole.
Two agents are recommended for exacerbations of CF (Gibson, Bums, & Ramsey 2003). 
Double antibiotic combinations have more effect and are therefore used as treatment 
(LiPuma 1998). Combinations including meropenem are particularly effective but 
combinations including co-trimoxazole, tetracyclines and chloramphenicol also exhibit 
activity.
1.6.8 Immunity
In the lungs of cystic fibrosis patients inflammation and deterioration is characteristic due 
to infiltration of inflammatory cells, primarily neutrophils and production of cytokines 
found in bronchial lavage samples of these patients. Compared to non CF patients lung 
inflammation is increased with an elevated neutrophil response in CF patients (Hendry et 
al. 1999). The response to infection with Bcc bacteria within the CF lung is undefined. 
However certain virulence factors have been implicated. These include LPS and flagellin.
Differences in the abilities of Bcc isolates to cause inflammation have been observed. B. 
cenocepacia isolates have the greatest propensity to cause inflammation through release of 
TNF and IL-1. Within isolates of the ET lineage, the potential of whole cell lysates to 
induce cytokine production from human monocytic cells has been shown to vary between 
strains (De Soyza et al 2004).
89
Chapter 1 General Introduction
It has been demonstrated that the supernatants from strains of B. cepacia, stimulate release 
of interleukin-8 (IL-8) from lung epithelial cells and peripheral blood monocytes 
(Palfreyman et al. 1997). This has been shown to be due to flagellin of B. cepacia 
interacting through a Toll-like receptor to initiate a signalling cascade that results in IL-8 
secretion and results in inflammation of the lung (Urban et al. 2004).
B. cenocepacia LPS produces increased amounts of TNFa and IL-6 compared to B. 
multivorans (Shaw et al 1995). Differences within the lipid A portion of LPS are likely to 
account for the differences in cytokine production as this component is the main 
determinant of induction of inflammation (Khan et al 1998). Cytokine induction from B. 
cepacia LPS is nine times greater than from P. aeruginosa LPS.
The genomes of Burkholderia spp. contain large numbers of these CpG motifs because of 
the large genome size (Coenye & Vandamme 2005). It has been shown that bacterial DNA 
containing unmethylated CpG motifs stimulate lymphocytes to produce an inflammatory 
response (Schwartz et al. 1997). It is likely, therefore, that CpG rich Burkholderia DNA 
can initiate an inflammatory response in the host, although it is not clear how this 
contributes to inflammation observed in CF patients.
1.6.9 Resistance to human antimicrobial peptides
Cationic antimicrobial peptides are produced by all organisms. (3 defensins 1 and 2 have 
an important role in the innate immune system and have antibacterial action against Gram- 
negative bacteria but not against Gram-positive bacteria (Raj & Dentino 2002; Schroder
1999). Genes encoding P defensins 1 and 2 are expressed throughout the respiratory
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epithelia. However the bactericidal activity of these defensins is thought to be inactivated 
by the high salt concentrations that are found in the CF lung (Goldman et al. 1997). 
Human P defensin (hBD-3) is active against both Gram-negative and Gram-positive 
bacteria and is not inactivated by high concentrations of salt. However Burkholderia spp. 
are unusual in that isolates are resistant to P defensins 1, 2 and 3 (Baird et al. 1999; Sahly 
et al. 2003).
The protegrins are also antimicrobial peptides. Protegin-1 is bactericidal, is not inactivated 
by high salt concentration and has a broad spectrum of activity (Harwig et al. 1996; 
Steinberg et al. 1997). Five isolates of B. cenocepacia investigated were more resistant to 
the bactericidal activity of protegrin-1 than P. aeruginosa. The increased resistance may 
be due to the reduced number of protegrin binding sites on the lipid A moiety of the LPS 
(Albrecht et al. 2002).
1.6.10 Genome
Members of the Bcc complex have large and unusual genomes which allow ecological and 
nutritional diversity. The genome sizes range from 6MB to 9MB and have a GC content of 
approximately 67%, a similar proportion to Pseudomonas spp. (Yabuuchi et al. 1992). 
The genomes are unusual in that they contain more than one chromosome and contain 
many insertion sequences and genomic islands (Mahenthiralingam, Urban, & Goldberg 
2005). The number of chromosomes and genome size can vary between strains of the 
same species (Parke 2001). Nine Burkholderia genomes have been sequenced. These 
completed genomes represent strains of B. pseudomallei, B. mallei, B. thailandensis, B. 
xenovorans, B. cenocepacia, B. cepacia complex Group K and B. dolosa. The genome
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sequences of strains of B. pseudomallei, B. mallei (Holden et a l 2004; Nierman et al. 
2004) have been published. B. cenocepacia J2315 is currently being annotated.
Bacteriophages with interspecies host ranges have been found in soil and could contribute 
to genetic transfer within the Bcc (Langley et al. 2003).
1.6.11 Virulence of the Bcc
Members of the Bcc exhibit a number of virulence determinants. These include 
siderophore production (Sokol et a l 1999; Visser et a l 2004), expression of flagellar 
proteins (Hales et al. 1998; Urban et al. 2004), biofilm formation (Conway, Venu, & 
Speert 2002), quorum sensing (Venturi et a l 2004; Sokol et al 2003), type III secretion 
(Glendinning et al. 2004; Tomich et al. 2003) and production of extracellular proteases 
(Corbett et a l 2003).
1.6.11.1 Invasion
There is evidence that B. cepacia can invade respiratory epithelial cells (Bums et al. 1996) 
and pulmonary macrophages to evade the immune response of immunocompromised 
patients. Using a modified protection assay, Bums et al demonstrated that invasion of a 
human alveolar epithelial carcinoma cell line (A549) monolayer occurs (Bums et al. 
1996).
The ET strain J2315 causes apoptosis via production of a haemolytic toxin in 
macrophages (Hutchison, Poxton, & Govan 1998). Bcc bacteria express one of two types 
of flagellin which can be distinguished by size (55 kDa and 45 kDa) and by RFLP analysis
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of the fliC  gene (Hales et al. 1998). Non motile J2315 strains are deficient in the ability to 
adhere to and invade epithelial cells in vitro (Tomich et al. 2003).
1.6.11.2 Quorum Sensing
At present members of the B. cepacia complex are known to contain at least two quorum 
sensing systems. The first pathway identified was the CepIR system, a homologue of the 
lasIR/systems of P. aeruginosa (Lewenza et al. 1999) and is widely distributed throughout 
species of the Bcc (Lutter et a l 2001). Analysis of gene expression of this system controls 
expression of virulence factors including production of chitinase, proteases and 
siderophores, swarming motility and maturation of biofilm (Aguilar et al. 2003; Huber et 
al. 2001; Lewenza et al. 1999; Lewenza & Sokol 2001). Mutations in these genes cause 
decreased virulence in infection models including killing of Caenorhabditis elegans 
(Kothe et al. 2003; Lewenza et al. 1999; Sokol et al. 2003), infection of rats and 
maceration of onion tissue (Aguilar, Bertani, & Venturi 2003). The autoinducer synthase 
is encoded the cepl gene and is responsible for the production of the two signalling 
molecules, A-hexanoyl-acylhomoserine lactone (C6-HSL) and TV-octanoyl-acylhomoserine 
lactone (Cs-HSL). The increase in cell density and signal concentration allows CepR to 
control expression of target genes. The second quorum sensing system was found within a 
pathogenicity island carried by epidemic strains of B. cenocepacia, designated ccilR, 
during random polymorphic DNA typing (Baldwin et al. 2004). The ceil gene is 
responsible for production of the same two signalling molecules as the cepIR system, N- 
hexanoyl-acylhomoserine lactone (C6-HSL) and small amounts of TV-octanoyl- 
acylhomoserine lactone (Cs-HS). Mutants in ceil demonstrated reduced protease 
production and swarming motility (Malott et al. 2005). In general Bcc bacteria produce 
two signalling molecules, N-octanoylhomoserinelactone (Cg-HSL) and N-
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hexanoylhomoserine lactone (C6-HSL). Some strains of B. vietnamiensis produce other 
long chain AHL molecules. The most common of the long chain AHL molecules was 
confirmed as N-decanoylhomoserine lactone (Cio-HSL).
1.6.11.3 Exopolysaccharide
Production of exopolysaccharide (EPS) has a role in biofilm formation in P. aeruginosa 
(Hoyle, Williams, & Costerton 1993). Overproduction of the polysaccharide alginate in 
the lungs affects long term survival of CF patients infected by P. aeruginosa (Govan & 
Deretic 1996). Approximately 80-90 % of CF Bcc isolates at a Portuguese centre were 
found to produce the polysaccharide cepacian (Richau et al. 2000), suggesting a role in the 
pathogenesis of Bcc in the CF lung. Cepacian consists of a branched acetylated 
heptasaccharide repeating unit made up of D-glucose, D-rhamnose, D-mannose, D- 
galactose and D-glucuronic acid (Sist et al. 2003). Random plasposon insertion 
mutagenesis was used to create mutants defective in EPS production and these mutants 
were unable to form thick biofilms. It is likely that cepacian is required for development 
of mature biofilms (Cunha et al. 2004).
1.6.11.4 Proteases
Between 69 and 88 % of clinical Bcc isolates produce extracellular proteases (Gessner & 
Mortensen 1990; Gilligan 1991; McKevitt & Woods 1984; Nakazawa, Yamada, & 
Ishibashi 1987). Gotschlich et al have reported that strains of B. cepacia, B. cenocepacia 
and B. stabilis have been shown to have extracellular protease activity while B. 
multivorans, B. dolosa and B. vietnamensis do not (Gotschlich et al. 2001). Two 
metalloproteases have been described in B. cepacia (McKevitt et al. 1989).
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The 36 kDa protease, described in B. cenocepacia, has been identified as a zinc 
metalloprotease (ZmpA; McKevitt et al. 1989). This protease had been shown to not 
cleave elastin (McKevitt & Woods 1984), unlike P. aeruginosa which can cleave elastin. 
Purified protease causes bronchopneumonia in rats with polymorphonuclear leukocyte 
infiltration and airway exudate. Sokol et al demonstrated that zinc metalloprotease 
peptides given as vaccines offer some protection against lung damage in lungs of rats 
(Sokol et a l 2000). At 109 CFU or higher, the ZymA protease is lethal in mice (Gonzalez 
& Vidaver 1979). Nonproteolytic strains colonised skin of burned mice and persisted at
7 0 t t c
10 - 10 CFU for 3 weeks after injection of 10 CFU. No organ invasion was observed 
(Stover, Drake, & Montie 1983). A second metalloprotease (ZmpB) has recently been 
identified in Bcc that can cleave immunoglobulins, lactoferrins and transferrin while 
ZmpA can not (Kooi et al. 2006).
1.6.11.5 Type III Secretion
Type III secretion is a mechanism by which Gram-negative bacteria translocate proteins 
from the bacterial cytoplasm into the host cell cytoplasm. When inside the host cell, these 
effector proteins subvert the host cell machinery to the advantage of the bacterium. Type 
III secretion dependent delivery of effector proteins is associated with invasion with S. 
typhimurium (Collazo & Galan 1996), lesion formation by enteropathogenic E. coli (Jarvis 
et al. 1995), cytotoxicity caused by P. aeruginosa (Finck-Barbancon et al. 1997), evasion 
of phagocytosis by Yersinia (Comelis & Wolf-Watz 1997) and intracellular survival by S. 
enterica (Cirillo et al. 1998).
95
Chapter 1 General Introduction
Burkholderia spp. possess TTS machinery. B. pseudomallei (Rainbow, Hart, & 
Winstanley 2002; Stevens et al. 2002) and B. mallei (Ulrich & DeShazer 2004) contain 
putative TTS gene clusters. TTS systems are present in all Bcc species, except B. cepacia 
(Parsons et al. 2001). A TTS mutant of B. cenocepacia J2315 was attenuated in a murine 
model, it is therefore likely that TTS have a role in virulence of the Bcc (Tomich et al. 
2003).
1.6.11.6 Siderophores
Iron is required as a co-factor for redox dependent enzymes in bacteria. However in many 
environments the concentration of soluble iron is insufficient to allow bacterial growth 
(Ratledge & Dover 2000). Siderophores are small molecules with high affinity for iron 
that compete with the host proteins to chelate iron molecules. Siderophore chelated iron 
can then be recognized by specific cell receptors and taken up by the cell, where iron is 
released. Bcc bacteria produce four types of siderophores; pyochelin, salicyclic acid, 
cepabactin and omibactin (Meyer, Hohnadel, & Halle 1989; Sokol 1986; Sokol, Lewis, & 
Dennis 1992; Stephan et al. 1993; Visca et al. 1993). In a study by Sokol et al pyochelin 
producers were associated with severe pulmonary disease while pyochelin negative strains 
were associated with mild disease (Sokol 1986). Addition of pyochelin to a pyochelin 
negative strain increased virulence in the rat lung model (Sokol & Woods 1988). 
Omibactins were found to be the most frequently produced siderophore in a study of 61 
Bcc isolates (Darling et al. 1998).
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1.6.11.7 Virulence Models
Animal models have been used to elucidate roles of virulence factors. However alternative 
models are required as using animal models is time consuming, labour intensive and 
expensive. Alternative model systems that have been described in other species, include 
Arabidopsis thaliana (Rahme et al. 1995; Rahme et al. 1997; Rahme et al. 2000), C. 
elegans (Tan & Ausubel 2000; Tan, Mahajan-Miklos, & Ausubel 1999), Drosophila 
melanogaster (D'Argenio et al. 2001) and Galleria mellonella (Jander, Rahme, & Ausubel 
2000). Alfalfa has been used successfully to measure virulence in Bcc (Bernier et al.
2003).
One of the most commonly used animal models used for studying Bcc lung infections is 
the mouse agar bead model. This involves intratracheal inoculation of mice with an agar 
bead containing 105 CFU organisms (Cieri et al. 2002). Intranasal or intraperitoneal 
administration of Bcc to immunosupressed mice are also used (Chu et al. 2002; Speert et 
al. 1999).
1.6.12 Use in Agriculture
Bcc bacteria are some of the most common culturable microorganisms in the plant 
rhizosphere (Tsuchiya et al. 1995). Some members of the genus are also bio-degraders of 
chlororganic pesticides and polychlorinated biphenyls. Burkholderia species have been 
used in agriculture as biodegraders and plant-growth-promoting rhizobacteria. The risks of 
transmission to immunocompromised patients are as yet unclear (Govan & Vandamme 
1998). The production of antibiotics can control soil borne plant pathogens. Bcc bacteria
97
Chapter 1 General Introduction
have been used to prevent damping off disease caused by Phythium sp., Rhizoctania solani 
and Fusarium sp. (Parke & Gurian-Sherman 2001). This offers an alternative to treatment 
to fungicides, which have adverse effects on the environment and human health. Strains of 
B. vietnamensis and B. ambifaria are favoured as biopesticides as these species are not 
commonly isolated from CF patients (Parke & Gurian-Sherman 2001). Isolates of B. 
vietnamensis are more susceptible to ceftazidime compared to isolates of other species 
(Nzula, Vandamme, & Govan 2002). B. vietnamensis, therefore, may be the most 
appropriate species for use as a bio-control agent. However the risk to CF patients of using 
strains in this way is unclear.
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1.7 Aims of thesis
The aims of this thesis were to investigate the evolution of fluoroquinolone resistance in 
Burkholderia cepacia complex bacteria. Fluoroquinolone antibiotic use is increasing and 
Bcc bacteria can be susceptible to this drug class. A method for estimation of mutation 
rate in topoisomerase genes was standardised and is described in chapter 3. 
Fluoroquinolone resistant B. cepacia, containing single and double topoisomerase 
mutations, were selected in vitro and characterised. Acquisition of resistance mutations 
may or may not incur a fitness cost and the extent of this cost may affect the ability of 
resistant bacteria to survive in the bacterial population. Fitness costs may be ameliorated 
by reversions or compensatory mutations that restore reproduction potential. Models, 
relevant to the transmission of B. cepacia, were used to assess the fitness cost of these 
characterised topoisomerase mutations and described in chapter 5. A method for 
quantifying biofilm formation is described in chapter 4. Application of tools developed in 
this thesis, have been used to investigate clinical isolates in chapter 6. Methods of 
detecting hypermutability of clinical B. cepacia complex bacteria isolated from CF 
patients isolates are described, also in chapter 6.
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Chapter 2 Materials and Methods
2.0 General Materials and Methods
2.1 Culture Conditions
To ensure that strains did not undergo further mutation all strains and antibiotic 
resistant mutants were stored at -70°C using the Microbank system, consisting of 
cryovials containing beads and cryopreservative solution (Pro-lab Diagnostics, 
Neston, UK). All FQ resistant mutants were derived from the NCTC 10661 B. 
cepacia strain. All clinical isolates were isolated from adult cystic fibrosis patients 
with well characterised infection attending a CF clinic at Belfast City Hospital, 
Northern Ireland (kindly provided by Dr J.E. Moore; Table 2.1).
To culture the strain, a bead was inoculated onto a Columbia blood agar plate (Oxoid,
Basingstoke, UK), spread with a disposable loop and incubated at 37°C for 18 hours.
Isolate Source
NCTC 10661 National Type Culture Collection, Health 
Protection Agency, Colindale
BCH 1 Belfast City Hospital
BCH 2 Belfast City Hospital
BCH 3 Belfast City Hospital
BCH 4 Belfast City Hospital
BCH 5 Belfast City Hospital
BCH 6 Belfast City Hospital
BCH 7 Belfast City Hospital
BCH 8 Belfast City Hospital
Table 2.1 Sources of B. cepacia isolates
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2.2 Preparation of Media
2.2.1 Muller Hinton broth
22 g Muller Hinton broth powder (BD, Le Pont de Claix, France) was dissolved in 1 L 
distilled water and autoclaved, according to the manufacturer’s instructions.
2.2.2 Luria-Bertani (LB) broth
25 g of Luria Bertani broth powder was dissolved in distilled water and autoclaved, 
according to the manufacturer’s instructions.
2.2.3 Muller Hinton agar
38 g Muller Hinton agar powder (BD, Le Pont de Claix, France) was dissolved in 1 L 
distilled water and autoclaved, according to the manufacturer’s instructions. The agar 
was allowed to equilibrate to 50°C in a water bath. 20 mL of liquid media was poured 
into sterile disposable Petri dishes (Sterilin, Supplied by Western Laboratory Service, 
Aldershot, Hampshire, UK) using sterile technique. Plates were allowed to set and 
stored upside down in plastic bags at 4°C. Plates were dried before use at 37°C for 15 
min.
2.2.4 Commercially Available Agar Plates
Ready prepared Nutrient agar, Columbia agar with horse blood and Isosensitest agar 
plates (Oxoid, Hampshire, UK) were used.
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2.3 Preparation of Buffers and Solutions 
2.3.1 1M Tris
121.1 g Tris base (Promega, Hampshire, UK), 42 mL of concentrated HCL stock was 
dissolved in 1 L of distilled water and adjusted to pH 8.0.
2.3.2 0.5 M EDTA
1.86 g EDTA disodium salt was dissolved in 800 mL distilled water and adjusted to 
pH 8.0 with NaOH (Sigma Aldrich, Steinheim, Germany) and stirred vigorously.
2.3.3 Tris-Borate EDTA (TBE) buffer
A 5 x solution was prepared by mixing of 54 g Tris base (Promega, Hampshire, UK),
27.5 g boric acid (BDH, Leicestershire, UK) and 20 mL 0.5M EDTA pH 8.0 in 1 L of 
distilled water. This was dissolved using a magnetic hot plate stirrer and flea.
2.3.4 5M NaCl
146.1 g sodium chloride (VWR International Ltd., Poole, UK) was dissolved in 500 
mL distilled water.
2.3.5 Phosphate Buffered Saline (PBS)
1 x PBS solution was prepared by dissolving 1 PBS tablet (BDH, Leicestershire, UK) 
in 100 mL distilled water. PBS was then autoclaved.
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2.3.6 Ciprofloxacin
0.025 g ciprofloxacin powder (98.4 % purity) (CellGro, Herndon, Virginia, USA) was 
dissolved in 24.61 mL sterile distilled water (SDW) to produce a 1000 mg/L stock 
solution. 1 mL aliquots were stored for later use at -70°C for no more than 4 weeks.
2.3.7 Clinafloxacin
0.025 g clinafloxacin powder (98%) (Sequoia Research Products, Pangboume, UK) 
was dissolved in 24.5 mL SDW to produce a 1000 mg/L stock solution. 1 mL aliquots 
were stored for later use at -70°C for no more than 4 weeks.
2.4 Growth Curve
A 25 mL conical flask containing 5 mL of Muller Hinton broth was inoculated with 
100 pi of an overnight Muller Hinton broth culture and sealed with a cotton wool 
bung. This was incubated at 37°C in an orbital shaker (200 r.p.m) (Barloworld 
Scientific, Staffordshire, UK). Samples (0.5 mL) were removed aseptically at 30 min. 
intervals
2.5 Miles and Misra Viable Cell Count (Miles & Misra 1938)
Muller Hinton agar plates were dried at 37°C for 15 min. prior to inoculation. 100 pi 
of Muller Hinton broth culture was diluted in 900 pi PBS, this was then vortexed and 
used to produce a bacterial dilution series (1 0 1 to 10'6). Each dilution was vortexed
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briefly and three replicate 20 pL volumes of diluted broth culture were spotted onto 
three segments of blood agar plates from approximately 1 cm above the surface of the 
plate. Plates were then incubated at room temperature for 30 min. to allow the drops 
to soak into the agar and incubated at 37°C overnight. Colonies were counted using 
the dilution that yielded between approximately 20 and 40 colonies. The mean 
number of colonies used to calculate the number of colony forming units per mL in 
the neat broth culture.
2.6 Determination of Minimum Inhibitory Concentration (MIC)
2.6.1 E-test
Minimum Inhibitory Concentrations (MIC) of parent and mutant strains were 
determined by E-test (AB Biodisk, Solna, Sweden), following the manufacturer’s 
guidelines. Organisms were suspended in 3 mL sterile distilled water to a turbidity of 
0.5 MacFarland. A cotton wool swab was immersed into this suspension and excess 
fluid removed and was swabbed three ways across an Isosensitest plate (Oxoid, 
Basingstoke, UK) an E-test strip was applied and the plate incubated (37°C, 18 hours) 
to obtain semi-confluent growth. Results were interpreted by recording the point of 
intersection between the ellipse of inhibition and the strip.
2.6.2 Agar Dilution
MIC was determined according to the CLSI guidelines for susceptibility testing of 
aerobic organisms (CLSI, 2006).
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For the agar incorporation method 1 mL of ciprofloxacin of a range of concentrations 
was added to 19 mL of molten agar. Approximately 104 organisms were spotted onto 
the surface of an agar plate using a multi prong inoculator. The lowest dilution that 
completely inhibited growth was recorded as the MIC.
2.6.3 Method for determination of mutation rate by the method of the median.
Isolates were removed from the -70°C freezer and one bead was used to sub culture B. 
cepacia onto a blood agar plate and incubated aerobically at 37°C. One colony of Bcc 
was suspended in 5 mL of Muller Hinton Broth in a 25 mL conical flask. This was 
sealed with a cotton wool bung and incubated at 37°C on a rotary shaker (200 r.p.m.) 
(Barloworld Scientific, Staffordshire, UK) for 2.5 hours until an optical density 
(OD60o) of approximately 0.1 OD units was reached (ensured that 100 pL of the 10'3 
dilution of this culture would contain approximately 10 cells. Serial dilutions of this 
broth culture were performed in PBS (neat to 10‘6). A 100 pL aliquot of the 10‘3 
dilution (containing approximately 103 cells) was added to each of 28 microcentrifuge 
tubes, containing Muller Hinton Broth (1 mL). These cultures were incubated at 37°C, 
200 r.p.m 18 hours (Barloworld Scientific, Staffordshire, UK). Muller Hinton Agar 
plates (Oxoid, Basingstoke) containing 2 x MIC of ciprofloxacin were prepared and 
inoculated the following day. Antibiotic free agar plates were also prepared (section 
2.2.3). Before inoculation, plates were allowed to dry at 37°C with the lids removed 
for 20 min. This ensured that drops were absorbed by the agar. At the end of the 
incubation period, a Miles and Misra plate count was performed on 3 randomly 
selected broths, section 2.5 (Miles 1938). Dilutions of 10'1 to 10'6 were prepared. 
Twenty microlitres of the 10'3, 10-4, 10'5 and 10'6 dilutions were spotted in triplicate 
onto duplicate drug free Muller Hinton plates.
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The microcentrifuge tubes were centrifuged at 4000 g , 3 min. and the supernatant 
discarded. Using a fine tipped pastette, the deposit was resuspended in residual broth 
(approximately 40 pL). The total volume was then inoculated onto ciprofloxacin 
containing Muller Hinton plates, spread with a plastic spreader and allowed to dry. 
All plates were incubated (37°C, 48 hours). Colony forming units per mL were 
calculated from the Miles and Misra drug free plates. The number of visible colonies 
on each plate were counted by eye and recorded. The median number of colonies was 
determined. The number of mutations per culture was calculated using the following 
equation 4.
r /m-ln(m) -  1.24 = 0 [Eq 4]
The mutation rate (ju) was calculated using Equation 5. 
m
ju = [Eq 5]
average cfu/mL
This experiment was repeated 4 times to give a median mutation rate.
2.6.4 Detection of Efflux
The ciprofloxacin MIC of the fluoroquinolone resistant strains was determined in the 
absence and presence of reserpine (25 mg/L) in Muller Hinton agar (Beyer et al.
2000). Reserpine (25 mg) was dissolved in 250 pi chloroform and immediately added 
to 1 L molten agar. Molten agar containing reserpine was mixed by agitation. Isolates 
were considered positive for reserpine inhibited efflux if there was a fourfold or 
greater decrease in the ciprofloxacin MIC in the presence of reserpine (Sigma
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Chemical Co., St. Louis, Mo., USA). The addition of the 250 pi chloroform alone did 
not affect MIC.
2.7 DNA Extraction
2.7.1 Crude Extraction
A loopful of B. cepacia was emulsified in 0.5 mL PCR grade water and heated at 
95°C for 10 min. Cellular debris was removed by centrifugation (3 min., 8000 g ). 
Supernatant was removed, using a fine tipped pastette, and transferred to a clean 
microcentrifuge tube.
2.7.2 DNA Extraction
DNA was extracted using the Promega Wizard DNA extraction kit (Promega, 
Hampshire, UK), following the manufacturers’ guidelines. 1 mL of an overnight 
culture was centrifuged in a microcentrifuge tubes at 16,000 g  for 2 min. and the 
supernatant discarded. Cells were resuspended in 600 pL of lysis buffer and mixed by 
pipetting. Tubes were incubated at 80°C for 5 min. and cooled to room temperature. 3 
pL of RNAse solution was added and the tubes were incubated at 37°C for 15-30 min. 
and cooled to room temperature. 200 pL of protein precipitation solution was added 
and the tubes vortexed for 20 seconds and incubated on ice for 5 min. Cell debris was 
precipitated by centrifugation at 16,000 g  for 3 min. and the supernatant transferred to 
a fresh microcentrifuge tube containing 600 pL of room temperature isopropanol 
(BDH, Leicestershire, UK). The suspension was mixed by gentle inversion until 
strands of DNA could be seen. Microcentrifuge tubes were centrifuged for 10 min. 
and the pellet washed in 70 % ethanol and dried for 15 min. at room temperature. 100
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pL of DNA rehydration solution was added and the tubes were incubated at 65°C in a 
water bath for 60 min, mixing by inversion every 20 min. Extracted DNA was stored 
at 4°C for no longer than 1 week.
2.8 Polymerase Chain Reaction and sequence analysis
2.8.1 Polymerase chain reaction (PCR)
PCR primers were rehydrated and diluted with PCR quality water (Royal Free 
Hospital Pharmacy) to 100 mM stock solutions and stored at -70°C. PCR water was 
exposed to UV light, in 1 mL aliquots, for 10 min. to eliminate DNA contamination. 
Working primer stocks were diluted to 10 mM and stored at 4°C. Bacterial DNA was 
diluted 1:10 in PCR quality water and 10 pL was added to each PCR reaction. This 
represented approximately 40 ng of DNA. The PCR mastermix contained 1.5 mM 
MgCl in KCL buffer (Bioline, London, UK), 10 pL of each primer at a 1 pM 
concentration (Sigma Aldrich, Steinham, Germany), 10 pM of deoxynucleoside 
triphosphates (Promega, Hampshire, UK) and 1 U of Taq polymerase (Bioline, 
London, UK). Cycling conditions consisted of 95°C for 3 min followed by 35 cycles 
of 95°C for 1 min, 55°C for 1 min and 72°C for 1 min. This was followed by strand 
elongation at 72°C for 7 min (GeneAmp PCR system 9700).
2.8.2 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used to visualise PCR products. 1.5 % agarose gels 
were prepared by addition of 0.45 g agarose powder (Bioline, London UK) to
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30 mL Tris Borate EDTA (TBE) buffer. This was mixed, melted by heating until 
boiling in a microwave oven and allowed to cool. Ethidium bromide (Sigma Aldrich, 
Steinheim, Germany) was then added to give a final concentration of 0.05 pg/mL. On 
each gel, 5 pL of 100 base pair ladder (Invitrogen, Paisley, UK) was loaded in order 
to determine size of PCR amplicons.
2.8.3 Gel Photography
Gels were photographed with a digital camera (DC 120 Kodak Digital) on a UV 
transilluminator (UVL Inc, California, USA) using camera software version 2.0 
(Kodak, California, USA). Images were stored as JPEG files.
2.8.4 PCR Product Purification
PCR products were purified using the MinElute Purification Kit (Qiagen, Crawley, 
West Sussex, UK) according to the manufacturer’s instructions. PCR products were 
then quantified by agarose gel electrophoresis. Intensity of the band was compared to 
lambda DNA of known concentrations to quantify the amount of DNA present.
2.8.5 Cycle Sequencing
Forward and reverse cycle sequencing reactions were performed in duplicate using 
the Big Dye Terminator Cycle sequencing ready reaction DNA sequencing kit v 2.0. 
(Applied Biosystems, Inc., Foster City, California, USA) according to the 
manufacturer’s instructions. Purified PCR products (approximately 40 ng), were 
added per cycle sequencing reaction. Each reaction consisted of 1 pL ready reaction 
mix, 10.8 pL PCR quality water and 3.2 pL mmol primer. PCR products were 
sequenced using an ABI Prism 377 DNA sequencer (Applied Biosystems, Foster
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City, CA, USA). Sequences were analysed using Bionumerics Version 2.0 (Applied 
Maths, Kortrijk, Belgium) and compared to the QRDR sequences of the susceptible 
parent.
2.8.6 Ethanol Precipitation
Labelled DNA was precipitated by the addition of 62.5 pL of 95 % ethanol (Royal 
Free Hospital Pharmacy), 3 pL sodium acetate (pH 4.6, 2.3 mol/L) (Sigma Aldrich, 
Steinheim, Germany) and 14.5 pL PCR quality water (RFH Pharmacy). The solution 
was vortexed and centrifuged at 13,000 g  for 15 min at 4°C and the supernatant was 
discarded using a fine tipped pastette (Western Laboratories, Hampshire, UK). 
Ethanol (200 pL, 70 %; RFH Pharmacy) was added to clean the DNA pellet and the 
sample was centrifuged at 13,000 g for 5 min. at 4°C. The supernatant was removed 
with a fine tipped pastette and the tubes were dried at 37 °C for 30 min. Formamide (4 
pL) and loading buffer (1 pL) was added to each sample (Sigma Aldrich, Steinheim, 
Germany) and 1.7 pL of the resulting mixture was loaded into each well. Samples 
were sequenced using an ABI 377 Applied Biosystems sequencer (Applied 
Biosystems, Foster City, California, USA).
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2.9 Fitness Assays
2.9.1 Biofilm Growth
2.9.1.1 Constant Depth Film Fermenter
2.9.1.1.1 Conditions
The constant depth film fermenter (CDFF) was maintained at a constant temperature 
of 37°C by housing it in an incubator. An aerobic atmosphere was maintained by 
exposure to the environment via a filtered air inlet in the top plate. Muller Hinton 
Broth was delivered to the fermenter at a flow rate of 0.5 litres/day.
2.9.1.1.2 Inoculum
The inoculum used was 10 mL of an overnight, shaken culture (200 r.p.m.) of B. 
cepacia grown in Muller Hinton Broth (37°C) taken from a single colony from a 
blood agar plate. A 10 mL volume of the overnight culture was aseptically added to 1 
L of autoclaved Muller Hinton Broth. This inoculum was pumped into the CDFF 
overnight via sterile tubing at the sampling port. Time point zero was taken as the 
time that this pump was activated.
2.9.1.1.3 Sampling
At 4 h and then every subsequent 24 h, from time point zero, a pan was sacrificed 
from the CDFF, using a sterile sampling tool. A Miles and Misra plate count was 
performed on Muller Hinton agar plates on three plugs and each dilution was plated in 
triplicate (section 2.5). To avoid contamination a surgical face mask was used during 
sampling and the port was ethanol flamed, using a portable Bunsen burner. A growth 
curve for the wildtype isolate and images of the developing biofilm were obtained.
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2.9.1.1.4 Confocal Laser Scanning Microscopy (CLSM)
Biofilms were analysed by CLSM using a modification of methods described 
previously (Hope & Wilson 2003). The discs were placed onto a petri dish 5 cm in 
diameter (held in place by vacuum grease) biofilm side up, then carefully submerged 
in itocLight™ LIVE/DEAD stain (Molecular Probes, Oregon, USA) which comprised 
of 2 pL each of component A and B in 8 mL of SDW, allowing minimum disruption 
and desiccation of the biofilms. This stain contains the two dyes SYTO 9 and 
propidium iodide. Viable cells appear green while non-viable cells appear red, due to 
damaged membranes. After incubation in the dark for 10 min., the biofilm was 
examined on a fixed stage microscope (BX51 stereomicroscope, Olympus UK 
limited, Southall, UK) with a Radiance 3000 laser scan head (Biorad, Jena, Germany) 
mounted on a vibration free platform. Lasers used were Helium Neon (543 nm) and 
Argon (488 nm). Image acquisition was performed using Biorad LASERSHARP 
2000.
The procedure was optimised for viewing of the cells. The settings selected, using the 
x 60 water objective were zoom 1.8, speed 166 lps, pixels x lines 1024 x 1024. Filter 
set 2 was used for visualisation via the microscope eye piece. The prism refractor was 
removed in order to scan and an empty filter case used. Captured images were 
visualised and a 3D representation of the spatial visualisation of the biofilm produced 
using the java based ImageJ software (National Institute of Health). The 3D images 
were created from live and dead colour channels using the 3D project option. These 
were combined to create a single RGB stack using the RGB Merge function.
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2.9.1.2 Crystal Violet Assay
Quantification of biofilm growth was achieved by spectrophotometric measurement 
of crystal violet binding using a previously published method (O'Toole & Kolter 
1998). Briefly 100 pL of a 1:100 overnight LB broth (BD, Le Pont de Claix, France) 
culture containing 0.5 % casamino acids (BD, Le Pont de Claix, France) was used to 
inoculate 8 independent wells of a 96 well polyvinyl chloride microtitre plate (Falcon 
3911 Microtest III flexible assay plate, Becton Dickinson LabWare, Becton 
Dickinson, Oxford, UK). Negative control wells contained broth only. This was 
incubated for 24 hours at 30°C in a humid atmosphere. The medium was gently 
removed and the wells washed 3 times with 200 pL SDW using a multi channel 
pipette. The microtitre plate wells were stained with 200 pL of 1 % (w/v) crystal 
violet for 15 min. at room temperature (Sigma Chemical Co., St. Louis, Mo., USA). 
Unbound crystal violet was removed by repeated washing with water. Bound crystal 
violet was solubilised with 2 x 200 pL of 95% ethanol, transferred to a 
microcentrifuge tube and the volume made up to 1 mL. The resulting absorbance was 
determined at wavelength 590 nm using a spectrophotometer (Pharmacia Biotech 
Ultraspec 2000). Each experiment was repeated in triplicate.
2.9.2 Planktonic Growth
The method of Youmans and Youmans (Youmans & Youmans 1949) was modified to 
determine growth rate.
The Bactec 9240 continuous, blood culture system with standard aerobic medium 
(Plus Aerobic/F) was used (Becton Dickinson, Oxford, UK). Aliquots of 100 pL of
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diluted exponentially growing culture (1/10 and 1/1000), were removed using a 0.5 
mL syringe and a needle and were aseptically inoculated into duplicate culture vials. 
The vials were then loaded immediately into the system. The length of time to 
detection (time to positivity) was measured for all strains. Gram stain and a purity 
plate were performed to confirm absence of contaminants. The growth rate constant k 
can be determined using the following equation (equation 6), where A is the largest 
inoculum employed, B is the smallest inoculum and t is the difference in time to 
positivity in hours. Generation time can then be determined by dividing log of 2 by 
the growth rate constant (equation 7). This experiment was repeated in triplicate.
k = log/4 -  logB [Eq.6] 
t
G = log2 [Eq.7]
k
2.9.3 Competition Assays
The optical densities of wild type and mutant overnight 1 pL Muller Hinton broth 
cultures were adjusted to the same value (1.0 OD600 units) using a spectrophotometer 
(Pharmacia Biotech Ultraspec 2000). Then 250 pL of each culture was inoculated into 
15 mL of LB broth, in the absence of antibiotics and this mixed culture was incubated 
for 10 hours, (200 r.p.m; Barloworld Scientific, Staffordshire, UK). The culture was 
then plated onto both drug free Muller Hinton plates and Muller Hinton plates 
containing twice the MIC of the susceptible parent. The number of parent susceptible 
cells was determined by subtracting the number of viable cells growing on drug 
containing plates from the total number of viable cells on drug free plates.
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The fitness of the strains was determined by calculation of the number of generations 
grown by the parent and resistant strains using the equation 8 (Gillespie, Voelker, & 
Dickens 2002):
G = logB-logA [Eq. 8] 
log2
where G is the number of generations, A is the number of CFU at time 0 and B is the 
number of CFU per mL after the incubation period. The relative fitness of each strain 
was calculated from the ratio of the number of generations grown by the resistant to 
susceptible strains. Five independent pair wise cultures were performed for each 
mutant.
2.9.4 Survival in water
Survival in water was assessed using the method employed by Sanchez et al (Sanchez 
et al. 2002). Overnight Muller Hinton 1 mL broth cultures were pelleted by 
centrifugation (13,000 g, 3 min.), washed three times in PBS (1 mL) and an inoculum 
of approximately 1 x 108 CFU was added to duplicate duran bottles, each containing 
19 mL of autoclaved tap water. Aliquots were aseptically removed at time intervals 
(Day 0, 1,2, 5, 7, 8, 9 and 13) and the viable CFU/mL determined, using the Miles 
and Misra technique (section 2.5). Each experiment was repeated in triplicate.
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2.9.5 Survival on dry surfaces
Survival on dry surfaces was assessed using the method employed by Sanchez et al 
(Sanchez et al. 2000). Overnight Muller Hinton 1 mL broth cultures were pelleted by 
centrifugation, washed three times in 1 mL PBS and concentrated 10 fold to a final 
cell concentration of approximately lx  109. Using a pipette aliquots (10 pL) of the 
concentrated culture were spotted into duplicate wells of a 96 well flat bottomed 
microtitre plate (Western Laboratories, Hampshire, UK) and allowed to dry at room 
temperature. Survival was determined by sampling at hourly intervals for 7 hours by 
the addition of 100 pL of PBS containing 0.25 % v/v Triton x 100 (BDH, 
Leicestershire, UK) to the wells, followed by mixing to form a bacterial suspension. 
The 100 pL was then added to 900 pL of PBS, vortexed, and numbers of viable 
bacteria were determined by the Miles and Misra technique (section 2.5). The addition 
of Triton x 100 to PBS did not reduce numbers of viable cells. Each experiment was 
repeated in triplicate.
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Chapter 3: Estimation of mutation rate in topoisomerase genes of B. cepacia
3.0 Introduction
3.1 Fluoroquinolone resistance
3.1.1 Fluoroquinolone Resistance in B. cepacia
The molecular mechanisms of fluoroquinolone resistance in B. cepacia have not previously 
been reported. Amino acid substitutions in the quinolone resistance determining regions 
(QRDR) of topoisomerase genes have been described in other Gram-negative bacteria 
including Proteus mirabilis, S. enterica, Chlamydia trachomatis, E. coli and P. aeruginosa 
(Chen & Lo 2003; Dessus-Babus et al. 1998; Eaves et al. 2004; Rafii, Park, & Novak 2005; 
Weigel, Anderson, & Tenover 2002).
Evidence from related organisms suggests that mutation in gyrA is most likely to be the 
primary resistance mechanism in B. cepacia. Amino acid substitutions at codon 83 in gyrA 
have been identified in oxolinic acid resistant strains of Burkholderia glumae (Maeda et al.
2004). Mutations at codon 83 and 87 of gyrA were identified in nalidixic acid resistant B. 
vietnamensis mutants (Miche & Balandreau 2001) and mutation in gyrA is the most primary 
cause of fluoroquinolone resistance in P. aeruginosa (Cambau et al. 1995; Kugelberg et al. 
2005; Yonezawa et al. 1995).
3.1.2 Double mutation in topoisomerase genes
Single mutations in subunit A of DNA gyrase are the most common cause of low to 
moderate increases in resistance in Gram negative organisms (Chen & Lo 2003; Hooper 
2003). To obtain high level FQ resistance a second mutation is required in parC  or gyrA.
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Double mutations in DNA gyrase/topoisomerase IV have been characterised in clinical and 
in vitro isolates of E. coli (Truong et al. 1997; Vila et al. 1994) and in isolates of P. 
aeruginosa and S. pneumoniae that have been selected in vitro (Gillespie et al. 2003; 
Gillespie, Voelker, & Dickens 2002; Kugelberg et al. 2005). A limited number of amino 
acid substitutions conferring resistance, have been reported and in Gram-negative bacteria 
the most common occurs at codon 83 (Drlica 2003; Ruiz 2003; Vila et al. 1995) and the 
second most common at codon 87 (Everett et al. 1996; Vila et al. 1994). Substitutions at 
these codons are also found in Gram-positive bacteria, including S. aureus and S. 
pneumoniae (Jones et al. 2000; Schmitz et al. 1998). Substitutions in gyrB conferring 
resistance in E. coli that have been described occur at codons 426 and 447 (Nakamura et al. 
1989; Yoshida et al. 1990a).
3.1.3 Applications of Mutation Rate Estimation Experiments
Oliver et al used the Crane method, (see section 1.2.9) (Crane, Thomas, & Jones 1996) to 
show that antibiotic resistant isolates of P. aeruginosa were present prior to antibiotic 
therapy due to the existence of hypermutable bacteria (Oliver et al. 2004). Mutation rate 
experiments have been used in S. pneumoniae to show that mutations in the gyrA gene occur 
at a lower rate than parC  mutations and that mutation in either gene predisposes to further 
mutation (Gillespie et al, 2003). There is a pressing need to develop or adapt methods to 
investigate mutation rate in Bcc.
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3.2 Aims of Chapter
The aims of this chapter were to generate FQ resistant mutants, optimise a method to 
estimate the mutation rate to fluoroquinolone resistance in B. cepacia and to characterise the 
genetic basis of resistance. The presence of mutations conferring resistance to 
fluoroquinolones was confirmed by MIC determination and sequence analysis of 
topoisomerase genes. Resistant mutants were screened for reserpine inhibited 
fluoroquinolone efflux to assess involvement of an efflux pump in observed resistance. 
Reserpine is a plant alkaloid that inhibits active efflux and has been used in assays to 
determine the contribution of efflux pumps to antibiotic resistance (Baranova & Neyfakh 
1997; Beyer et al. 2000; Brenwald, Gill, & Wise 1997; Markham 1999).
3.3 Materials and Methods
3.3.1 Bacterial Strain
All optimisation experiments were performed using B. cepacia NCTC 10661 which was 
obtained from the National Collection of Type Cultures, Centre for Infections, HPA, 
Colindale, UK. This isolate had a ciprofloxacin MIC of 1.0 mg/L. The bacteria were stored 
at -70°C in a tube containing storage media and beads (Prolab, Preston, UK). The inoculum 
for each mutation rate experiment was prepared by inoculation of one bead onto Columbia 
Blood Agar (Oxoid, Basingstoke, UK), which was spread and incubated at 37°C for 18 
hours.
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3.3.2 Choice of Selective Antibiotic
Ciprofloxacin was chosen as the selective antibiotic as fluoroquinolone resistance mainly 
occurs due to point mutations in the subunit A of gyrase in Gram-negative bacteria and 
because the type strain used was sensitive to this drug.
3.3.3 MIC Determination
The MIC of B. cepacia 10661 was determined by E-test (2.6.1) and by the agar dilution 
method, according to the CLSI guidelines for susceptibility testing of aerobic organisms 
(section 2.6.2).
3.3.4 Sequence Analysis of the QRDR of Fluoroquinolone Resistant Mutants
DNA was extracted from wild type and fluoroquinolone resistant mutants using either a 
crude extraction method (section 2.7.1) or the Promega Extraction Kit (section 2.7.2). 
Mutants were characterised by sequence analysis of the QRDRs of gyrA, gyrB, parC  and 
parE. Primers were designed using the sequenced genome of Burkholderia cenocepacia AU 
1054 chromosome 1 (accession number CP000378) (Markowitz et al. 2006) and the primer 
design programme, Primer3, (Rozen & Skaletsky 2000) to amplify gyrA, gyrB, parC  and 
parE and nucleotide sequences of the primers are shown in Table 3.1. In E. coli the QRDR 
comprises codons 67-106 of gyrA, therefore the primers were designed to amplify codons 
38-122 (Yoshida et al. 1990a). Mutations conferring resistance in E. coli, within gyrB are 
commonly found at codon positions 426 and 447 (Yoshida et al. 1990b; Yoshida et al. 
1991). Therefore primers were designed to amplify codons 400-500. PCR reaction
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composition, cycling conditions and amount of DNA added to reactions were optimised 
(data not shown). PCR and sequencing of topoisomerase genes were performed (section 2.8)
Gene Primer Position Sequence (5’-3*) Amplicon Size (b.p.)
(B. cenocepacia numbering)
gyrA 62-81
493-511
5’ ATCTCGATTACGCGATGAGC 
5’ GCCGTTGATCAGCAGGTT
449
gyrB 1127-1146
1502-1520
5’ GAGGAAGTTGTGGCGAAGG 
5’ AGTCTTCCTTGCCGATGC
400
parC 98-118
295-315
5’ ATTGGTCAGGGTCGTGAAGA 
5' GTAGCGCAGCGAGAAATCCT
229
parE 1178-1198
1557-1577
5' CAGGGCAAGGTAGTCGAAAA 
5’ GTGAGCAGCAAGGTCTGGAT
380
Table 3.1. Primers used to amplify the Quinolone Resistance Determining Region (QRDR) 
of gyrA, gyrB, parC  and parE  o f B. cepacia.
3.3.5 Detection of Efflux
The ciprofloxacin MIC of the fluoroquinolone resistant mutants was determined in the 
absence and presence of reserpine in Muller Hinton agar, (section 2.6.4) (Beyer et al. 2000).
3.4 Results
3.4.1 Development of Methodology
3.4.1.1 Inoculum
3.4.1.1.1 Cell Number
The assumptions of all mutation rate estimations require that in each parallel culture the 
final cell number (Nt) should be the same and that the number of cells at time zero (No) 
should always be negligible compared to Nt (section 1.2.6) and so an inoculum size of 10
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cells was used initially in this study. The number of colony forming units per mL was 
determined using the Miles and Misra plate count technique (section 2.5) (Miles & Misra
A '  ^ y
1938). The 10 dilution was found to contain 10 CFU per 100 pL and this was therefore 
used as the initial inoculum. An inoculum of 102 cells was added to 1 mL aliquots of Muller 
Hinton Broth (Oxoid, Basingstoke, UK) and incubated for 18 hours using an orbital shaker 
(37°C, 200 r.p.m,) (Barloworld Scientific, Staffordshire, UK). This resulted in a final 
number of cells of approximately 1-2 x 108 CFU/mL. Using 108 cells as the final cell 
number the proportion of cultures with mutations was below the level for the po to be 
considered valid i.e. the proportion of cultures without mutants was above the valid range of 
0.1 and 0.7. In five experiments, using this inoculum, the average number of plates with 
ciprofloxacin resistant mutants was zero or one. The initial inoculum was subsequently 
changed to an inoculum of 10 cells. This was achieved by the addition of 100 pL of the 10' 
dilution (of the original culture) to each mutation rate estimation culture aliquot. Upon 
selection at 2 x and 4 x MIC all plates contained ciprofloxacin resistant colonies. However 
no topoisomerase mutations (0/45 colonies sequenced) were found in colonies growing on 
plates containing 2 x MIC. At 4 x MIC colonies from one plate only (2/55) contain 
topoisomerase mutations (section 3.4.3). At 6 x MIC all colonies contained confirmed 
mutations in gyrA (section 3.4.3). In conclusion the final inoculum used was 10 cells.
3.4.1.1.2 Growth phase
A second assumption requires that cells added to a mutation rate estimation experiment 
should be in exponential phase. A growth curve experiment was performed to determine the 
time period that the initial broth should be incubated before inoculation of the mutation rate 
estimation to ensure cells were in exponential phase (figure 3.1). It was apparent that cells
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will be in mid exponential phase at 2-3 hours, following incubation of a 5 mL Muller Hinton 
broth (3 hour, 200 rpm), inoculated with a single colony.
10 n
o>
0.01
Time (hours)
Figure 3.1 Growth curve of B. cepacia
In order for inoculated cells to be in exponential phase the initial inoculum was incubated 
for 2.5 hours to an OD600 of approximately 0.1 OD units (Pharmacia Biotech Ultraspec 
2000).
3.4.1.1.3 Incubation Period
The final number of cells (Nt) was optimised so that the proportion of cultures with mutants 
(plates with resistant colonies) was high enough for the po method to be valid. This involved 
optimisation of the size of the initial inoculum and of the incubation conditions. Initially 
aliquots were incubated for 18 hours. Subsequently this was changed to 22 hours, increasing 
the final number of cells (Nt) and therefore increasing the proportion of cultures with 
mutants. Following the increase in incubation time, the average final number of cells, in a
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culture aliquot, increased from approximately 2 x 108 CFU to approximately 6 x 109 CFU. 
In summary the incubation period was increased to 22 hours.
3.4.1.2 Selective Antibiotic Concentration
The selective antibiotic concentration is an important parameter because it influences the 
numbers of observed resistant colonies and therefore will govern which method is most 
appropriate. Ciprofloxacin stock solution was prepared as described in section 2.3.6. 
Selective agar plates were used containing 2 x and 4 x the MIC of ciprofloxacin. The 
nucleotide sequences of the topoisomerase QRDR regions were determined (section 3.3.4). 
Following selection at 4 x MIC only one plate contained colonies. These colonies were 
confirmed as having a gyrase mutation in the QRDR, an Asp87Asn mutation. At 4 x MIC 
53/55 colonies did not contain QRDR mutations. No colonies (0/45) selected at 2 x MIC 
contained mutations within the QRDRs of gyrA, gyrB, parC  and parE. The observed 
increase in resistance of these colonies was due to increased FQ efflux (see section 3.4.5).
The MIC of each mutant was determined. The Asp87Asn gyrase mutant, selected at 4 x 
MIC, has an MIC of 12 mg/L compared to approximately 5 mg/L for the bacterial colonies 
not containing mutations in topoisomerase genes. The mutation rate calculated using a low 
concentration of selective antibiotic (2 x -  4 x MIC) is not a measure of the rate of 
mutations that occur in topoisomerase genes only because other mechanisms may be 
contributing to the observed resistance. To address this, the selective antibiotic 
concentration was increased to 6 x and 8 x MIC. As the majority of plates did not exhibit 
resistant colonies upon selection 6 x and 8 x MIC then the po method was the most 
appropriate method. To be valid the po method requires that >25 % of plates must contain 
resistant colonies, at 6 x MIC this criteria was met (42 % of plates contained colonies) and
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therefore this method was used to determine the mutation rate. Upon selection at 8 x MIC 
1/25 plates contained resistant colonies, 5/5 colonies sequenced contained a Thr83Ile 
mutation. All of the 50 mutants selected at 6 x MIC and sequenced contained the same 
Thr83Ile mutation.
The final estimate is a mean of four replicate mutation rate experiments. Each replicate was 
performed from different initial broth inoculums. The isolated mutant colonies were stored 
at -70°C (section 2.1) for measurement of fitness costs associated with topoisomerase 
mutations (chapter 5).
To ensure that colonies growing would be as a result of mutations that occurred prior to 
plating, plates were incubated for 24 hours at 37°C. A longer incubation may allow the 
occurrence of post plating mutation which would confound the calculation of the true 
mutation rate.
In conclusion resistant mutants were selected on 6 x MIC of ciprofloxacin.
3.4.1.3 Choice of mutation rate calculation method
3.4.1.3.1 Lea and Coulsons Method of the Median
Upon selection at 2 x and 4 x MIC each plate contained between 30 and 400 colonies. 
These colonies varied in size and colour. Confirmation as B. cepacia was performed on 24 
representative colonies (2 colonies from each of 12 plates) by Gram stain and API 20 NE, 
using the manufacturer’s instructions. This excluded the possibility of contaminants that 
could have been mistaken as B. cepacia colonies. At 24 hours it was difficult to distinguish 
and count colonies by eye and so colonies were counted at 48 hours. A median method was
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used to estimate the mutation rate (Lea & Coulson 1949) because all plates contained 
mutants, see section 2.6.3 for method. From each plate at least 2 colonies were picked, sub 
cultured and stored at -70°C (section 2.1). The QRDR sequence of gyrA, gyrB, parC  and 
parE  was sequenced for the mutant colonies to confirm their identity as topoisomerase 
mutants. However at 2 x and 4 x MIC the majority of resistant mutants did not contain 
topoisomerase mutations (section 3.4.3). Estimated mutation rates using the method of the 
median, from three rounds of selection at 4 x MIC, are shown in table 3.2. At 2 x MIC there 
were too many colonies to enumerate and data is not shown. Selection at 6 x MIC using the 
p 0 method was therefore used. The Method of the Median could not be used at 6 x MIC 
because approximately half of the plates did not contain mutants.
Replicate Estimated Mutation rate (mutations/division)
1 2 x 10'8
2 6.1 x l6_/
3 5.9 x 10''
Median 6.1 x 10'7
Table 3.2 Estimated mutation rates in B. cepacia using the method of the median. Each 
replicate consisted of 25 culture aliquots. Mutation rate was estimated by the Method of the 
Median at 4 x MIC.
3.4.1.3.2 p 0 method
For the purpose of these experiments the method used to estimate the mutation rate is the po 
method (section 1.2.5.1). Estimated mutation rates were the median value of four replicate 
experiments (see section 3.4.1.4 for optimised method).
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3.4.1.4 Optimised Method for Determination of Mutation Rate using the po method
Isolates were removed from the -70°C freezer and one bead was used to sub culture B. 
cepacia onto a blood agar plate and was incubated aerobically at 37°C. One colony of B. 
cepacia was suspended in 5 mL of Muller Hinton Broth in a 25 mL conical flask. This was 
sealed with a cotton wool bung and incubated at 37°C on an orbital shaker (200 r.p.m.) 
(Barloworld Scientific, Staffordshire, UK) for 2.5 hours until an optical density (OD460) of 
approximately 0.1 OD units was reached. Serial dilutions of this broth culture were 
performed in PBS (neat to 10'6). A 100 pL aliquot of the 10'3 dilution (containing 
approximately 10 cells) was added to each of 28 bijoux tubes, containing Muller Hinton 
Broth (3 mL). These cultures were incubated at 37°C, 200 r.p.m., 22 hours (Barloworld 
Scientific, Staffordshire, UK). Muller Hinton Agar plates (Oxoid, Basingstoke, UK) 
containing 6 x MIC of ciprofloxacin were prepared and inoculated the following day. 
Antibiotic free agar plates were also prepared, (section 2.2.3). Before inoculation, plates 
were allowed to dry at 37°C with the lid removed for 20 min. This ensured that drops were 
absorbed by the agar. At the end of the incubation period, a Miles and Misra plate count was 
performed on 3 randomly selected broths (Miles & Misra 1938), (section 2.5). Dilutions of 
10'1 to 10‘6 were prepared. Twenty microlitres of the 10‘3, 10"4, 10‘5 and 10'6 dilutions were 
spotted in triplicate onto duplicate drug free Muller Hinton agar plates. The contents of the 
remaining bijoux tubes were transferred to 10 mL centrifuge tubes and centrifuged (MSE 
centrifuge) at 4000 g. for 10 min. and the supernatant discarded. Using a fine tipped pastette 
the deposit was resuspended in 300 mL PBS. The total volume was then inoculated onto 
ciprofloxacin containing Muller Hinton plates, spread with a plastic spreader and allowed to 
dry.
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All plates were incubated (37°C, 24 hours) and colony forming units per mL were calculated 
from the Miles and Misra drug free plates. The proportion of cultures with no mutants (no 
growth on ciprofloxacin) was calculated (p0) using equation 9.
po = number of cultures with no mutants [Eq 9]
total number of culture aliquots
The number of mutations per culture was calculated using equation 10 
m = -\n(p0) [Eq. 10]
The mutation rate (ju) was calculated using equation 11 
m
M =  ------------------------  [Eq .  11]
average cfu/mL
This was repeated 4 times to produce a median mutation rate
3.4.1.5 Selection of Second Step Mutants
Second step fluoroquinolone resistant mutants were selected by inoculating first step 
mutants onto plates containing 2 x MIC of the mutants in a mutation rate experiment 
(section 3.4.1.4). All mutants were stored as previously described (section 2.1).
3.4.2 Estimated Mutation Rate
Estimated mutation rates of B. cepacia to ciprofloxacin resistance at 6 x MIC were 
determined by the po method (section 3.4.1.4) (Table 3.3). The mutation rate to 
ciprofloxacin resistance by mutation in gyrA was estimated by selecting mutants on 6 mg/L 
and was determined as 9.6 x 10'11.
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Replicate Estimated Mutation rate 
(mutations/division)
1 7.4 x 10 "
2 1.0 x 10'10
3 9.2 x 10'“
4 1.0 x 10'“
Median 9.6 x 10'“
Table 3.3 Estimated mutation rates in B. cepacia using po method. Each replicate 
consisted of 25 culture aliquots. Mutation rate was estimated by the po method at 6 x MIC.
3.4.3 Characterization of Ciproflox'acin Resistant Mutants
Ciprofloxacin resistant colonies were isolated using selection at 2 x, 4 x, 6 x and 8 x MIC 
and characterised. During three independent rounds of selection at 2 x MIC 45 colonies 
were isolated and characterised, at 4 x MIC 55 colonies were isolated and characterised and 
during three rounds of selection at 6 x MIC 50 colonies were isolated and characterised. At 
8 x MIC 5 colonies were isolated and characterised.
Mutants containing second step mutations were selected at twice the MIC of the single step 
topoisomerase mutation. All FQ resistant mutants that were selected had an MIC of at least 
five-fold higher than the susceptible parent. At 4 x MIC an Asp87Asn mutation, conferring 
a 12 fold increase in MIC, was found in one mutant on one plate only. All other mutants 
selected at this concentration contained no mutations in QRDRs of gyrA, gyrB, parC  or 
parE. These colonies had small increases in MIC (less than five-fold differences as 
compared to the parent strain). At 4 x MIC only 2/53 colonies contained a Thr83Ile 
mutation in gyrA. All mutants (50/50) selected at 6 x MIC contained the Thr83Ile mutation 
in the QRDR of gyrA. All mutants selected (5/5) at 8 x MIC contained the Thr83Ile
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mutation. No mutations in the QRDRs of gyrB, parC  or parE were identified and no silent 
mutations were observed. Mutations, MIC and selection step information is shown in Table 
3.4. Mutation rates for second step mutations (F3 and F4) were higher than for the first step 
mutations and are shown in table 3.4. A map of mutations observed is shown in figure 3.2.
QRDR Sequence
Mutant MIC (mg/L) Selection Step gyrA gyrB parC parE
Wildtype 1
FI 12 1st Asp87Asn wt wt wt
F2 64 1st Thr83Ile wt wt wt
F3 >256 2nd Asp87Asn wt Ser80Leu wt
F4 >256 2nd Thr83Ile wt Ser80Leu wt
Table 3.4 Mutations, MIC and selection step of fluoroquinolone resistant mutants. Strain 
FI isolated on 4 mg/L ciprofloxacin (4 x MIC) using the wildtype as the starting point, F2 
isolated on 6 mg/L (6 x MIC) using the wildtype as the starting point, F3 isolated on 24 
mg/L ciprofloxacin using FI as the starting point, F4 isolated on 128 mg/L ciprofloxacin 
using F2 as the starting point.
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Wildtype
C iprofloxacin  2 X MIC Ciprofloxacin 4  X MIC Ciprofloxacin 6 X MIC
First
Selection Step
2 mg/L I ^  4 mg/L 6 mg/L ^
Efflux M utan t F1 Efflux Mutant F2
Second 
Selection Step 24 mg/L 128 mg/L
F3 F4
Figure 3.2 Relationship of B. cepacia mutants selected stepwise with ciprofloxacin. 
Antibiotic concentration used in each selection step is shown
Isolate Median Mutation Rate per cell division (Range)
Wildtype 9.6 x 10'" (9.2 x 1 0 "  - 1 x 1 0 10)
FI 6.8 x 10‘10 (9.2 x 10 '°-1 x 10'9)
F2 1.1 x 10-10 (1.1 x 10 "  -1 x 10'9)
Table 3.5 Mutation rates of fluoroquinolone resistance. Median mutation rates, estimated by 
the po method of first step mutations of wildtype to FQ resistance and second step mutations 
from Asp87Asn (FI) and Thr83Ile (F2) to additional Ser80Leu mutation in parC, using 
ciprofloxacin as the selective agent. Median mutation rates represent four po replicate 
experiments.
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3.4.4 Confirmation of QRDR mutation
The QRDRs of gyrA, gyrB, parC and parE  were sequenced. The QRDR of 45 resistant 
mutants selected at 2 x MIC were sequenced but no isolates selected at this concentration 
contained a gyrA mutation. At 4 x MIC 2/55 colonies contained an Asp87Asn mutation. All 
fluoroquinolone resistant mutants selected at 6 x (50) and 8 x (5) MIC contained a gyrA 
mutation (Thr83Ile). Throughout the most commonly selected mutant was Thr83Ile, see 
figure 3.3. The consensus nucleotide sequence of the quinolone resistance determining 
region of gyrase A of the susceptible B. cepacia parent was determined. The translated 
amino acid sequence from this consensus is shown in figure 3.4.
195
190
190
247
247
247
349
349
349
 AATCGCCGCGTATCGTCGGTGACGTGATCGGTAAGTACCATCCTCACGGCG P a r e n t
ACAAGAATCGGCGCGTATCGTCGGTGACGTGATCGGTAAGTACCATCCTCACGGCG A s p 8 7 A s n
ACAAGAATCGGCGCGTATCGTCGGTGACGTGATCGGTAAGTACCATCCTCACGGCG T h r 8 3 I l e  
********************************************************
AC ACC 3CGGTGTA' 
AC ATC GCGGTGTA' 
AC ACC 3CGGTGTA'
:gac a c g a t c g t g c g g a t g g c g c a a g a c t t c t c g c t g c g t t a c  P a r e n t  
;gac a c g a t c g t g c g g a t g g c g c a a g a c t t c t c g c t g c g t t a c  A s p 8 7 A s n  
:aac a c g a t c g t g c g g a t g g c g c a a g a c t t c t c g c t g c g t t a c  T h r 8 3 I l e
If ★  1 ' k ' k ' k i c ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k + r ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k - k ' k ' k ' k ' k ' k ' k ' k i c i c ' k ' k ' k
ATGCTGATCGACGGGCAAGGCAACT-------------------------------------------------------------------P a r e n t
ATGCTGATCGACGGGCAAGGCAACTTCGGCTCGATCGACGGCGACAATGCCGCGGC A s p 8  7 A s n  
ATGCTGATCGACGGGCAAGGCAACTTCGGCTCGATCGACGGCGACAATGCCGCGGC T h r 8 3 I l e
Figure 3.3 Alignment of susceptible parent and mutant gyrA nucleotide sequences. 
Mutations shown in boxes (Thr83Ile) and (Asp87Asn).
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C o d o n  66 SARIVGDVTGKYHPHGI JIVRMAQDFSLRYMLIDGQG P a r e n t
C odon  66  SARIVGDVT GKYHPHGI >
C odon  66 SARIVGDVIGKYHPHGI >TAVYN
IVRMAQDFSLRYMLIDGQG A sp87A sn  
IVRMAQDFSLRYMLIDGQG T h r 8 3 l le
Figure 3.4 A comparison of the translated amino acid sequences of the QRDR of the 
characterised B. cepacia gyrA mutant and susceptible parent.
Only one mutant (2/55) selected at 4 x MIC contained a mutation in DNA gyrase subunit A. 
This mutant Asp87Asn had a corresponding MIC of 12 mg/L. All other colonies 
characterised at this ciprofloxacin concentration had MIC levels of 4-5 mg/L and no 
topoisomerase QRDR mutations were found by sequencing. The elevated MIC of these 
mutants was attributed to alteration in efflux activity, because incorporation of reserpine 
into the media reduced the MIC to wild type levels. Reserpine is an inhibitor of efflux and 
therefore the MIC of isolates exhibiting increased resistance to FQs will decrease in the 
presence of reserpine. However it is possible that topoisomerase mutations occurred outside 
the QRDR of the topoisomerase genes. Upon selection at 6 and 8 x MIC a change at 
position 83 from threonine to isoleucine was observed. The corresponding MIC for these 
mutants was 64 mg/L. No mutations were found in gyrB, parC  and parE  in the single step 
mutants. Second step mutants containing high level resistance additionally contained a 
Ser80Leu mutation in parC , see figure 3.5.
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165  GGATGCCGATTCCAAGCACAAGAAGTCGGCGCGGCACCGTCGGCGACGTGCTCGGCAAGTTCC P a r e n t :
165  GGATGCCGATTCCAAGCACAAGAAGTCGGCGCGGCACCGTCGGCGACGTGCTCGGCAAGTTCC S e r 8 0 L e U
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
23 0  ACCCGCACGGCGAC TCG<5CCTGCTACGAGGCCATGGTGCTGATGGCGCAGCCGTTCTCTCCTA P a r e n t
23 0  ACCCGCACGGCGAC TTG'JCCTGCTACGAGGCCATGGTGCTGATGGCGCAGCCGTTCTCTCCTA S©r80LeU
* * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
29 5  t c g c t a t  P a r e n t
295  t c g   Ser80L eu
* * * * * * *
Figure 3.5 Alignment of susceptible parent and mutant parC  sequences. Mutation shown in 
box (Ser80Leu).
1 1 8 0  GGCGCGCACGCGCGCCGGCCAGAAGGTCGAGAAGCGCAAGAGCTCGGGCGTCGCGGTGCTGCCCGGC P a r e n t  
1 1 8 0  GGCGCGCACGCGCGCCGGCCAGAAGGTCGAGAAGCGCAAGAGCTCGGGCGTCGCGGTGCTGCCCGGC FI
' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k - k ' k ' k i t i c ' k ' k ' k ' k ' k i c ' k ' k ' k ' k - i r ' k - k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k - k ' k i r ' k ' k ' k ' k ' k - k ' k i c ' k ' k ' k ' k ' k - k ' k - k ' k j c ' k ' k ' k ' k ' k
12 5 0  AAGCTGACCGATTGCGAGACGGAAGATATCGCGCGCAACGAACTGTTCCTGGTCGAGGGCGACTCGG P a r e n t  
12 5 0  AAGCTGACCGATTGCGAGACGGAAGATATCGCGCGCAACGAACTGTTCCTGGTCGAGGGCGACTCGG FI
1 3 0 0  CGGGCGGCTCCGCGAAGATGGGCCGCGACAAGGAATACCAGGCGATCCTGCCGCTGCGCGGCAAGGT P a r e n t  
13 0 0  CGGGCGGCTCCGCGAAGATGGGCCGCGACAAGGAATACCAGGCGATCCTGCCGCTGCGCGGCAAGGT FI
13 5 0  GCTGAATACGTGGGAAACCGAGCGCGACCGCCTGTTCGCGAACAACGAGGTGCACGACATCTCGGTC P a r e n t  
13 5 0  GCTGAATACGTGGGAAACGCGCGACCGCCTGTTCGCGAACAACGAGGTGCACGACATCTCGGTC FI
Figure 3.6 Alignment of susceptible parent and resistant mutants for gyrB sequences. No 
mutations were found in the QRDR of gyrB. Presumptive QRDR (codon 426) shown in red.
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1 2 1 0  GTCGGTCGAACGTGAATCGGCGGAAATCGCCTTCGAACAGCGGGATCAGCAGTTCGCTGC P a r e n t :
1 2 1 0   TCGAACGTGAATCGGCGGAAATCGCCTTCGAACAGCGGGATCAGCAGTTCGCTGC FI
1 2 7 0  CCGTTGCTTTCGTCGAGCAGGCGCTGTAGCCGCGCAGGCCGTCTTCATACTTCCACGTCT P a r e n t
1 2 7 0  CCGTTGCTTTCGTCGAGCAGGCGCTGTAGCCGCGCAGGCCGTCTTCATACTTCCACGTCT FI
★ ★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★•it*
1 330  GGCGCTTGCCGGTCTTCTCGTTGACGAGCACGACCTCGACGCCCGGCAGCAGCACGGCCT P a r e n t
1 3 3 0  GGCGCTTGCCGGTCTTCTCGTTGACGAGCACGACCTCGACGCCCGGCAGCAGCACGGCCT FI
1 3 9 0  TCGAGCGCAGCAGGCGCTGCAGCTCGCCGAGCGGCAGGTTCGGCGAATCGAAGTACTTCG P a r e n t
1 3 9 0  TCGAGCGCAGCAGGCGCTGCAGCTCGCCGAGCGGCAGGTTCGGCGAATCGAAGTACTTCG FI
14 5 0  GATTCGGCCACACCTGCACGCGCGTGC—
14 5 0  GATTCGGCCACACCTGCACGCGCGTGCCG
P a r e n t
FI
Figure 3.7 Alignment of susceptible parent and resistant mutants for parE  sequences. No 
mutations were found in parE. Presumptive QRDR (codon 425 and 445) shown in red.
3.4.5 Detection of Efflux Pumps
The MICs of all mutants, selected at 2 x MIC and the majority selected at 4 x MIC, 
decreased five-fold in the presence of reserpine to the level of the wild type, shown in Table 
3.6. Presence of reserpine did not affect the ciprofloxacin MIC of mutants containing 
topoisomerase mutations. It is likely therefore that these mutants exhibit increased 
expression of ciprofloxacin extruding efflux pumps.
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QRDR genotype
Isolate gyrA parC MIC(mg/L) MIC+ Res<
WT wt wt 1 1
El wt wt 5 1
E2 wt wt 5 1
E3 wt wt 5 1
E4 wt wt 5 1
E5 wt wt 5 1
FI Asp87Asn wt 12 12
F2 Thr83Ile wt 64 64
F3 Asp87Asn Ser80Leu >256 >256
F4 Thr83Ile Ser80Leu >256 >256
Table 3.6 MICs (mg/L) of ciprofloxacin in the presence and absence of reserpine (25 mg/L) 
for representative FQ resistant mutants. E1-E5 were selected at 2 x and 4 x MIC and 
contained no topoisomerase mutations.
3.5 Discussion
Most previous studies have measured mutation frequency as opposed to mutation rate 
(Bjorkholm et al. 2001; Gustafsson et al. 2003; Henderson-Begg, Livermore, & Hall 2006). 
This measure provides no information on when the mutation occurred or of the rate at which 
mutants occur. Mutations that occur early in the culture, known as ‘Jackpot’ mutations, 
produce large numbers of progeny and will cause large variance in results. Mutation rate 
methods, as used here, are more reproducible and can be used to predict how rapidly 
antibiotic resistance will develop.
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Ideally mutation rates should be estimated using an antibiotic to which resistance arises via 
a single amino acid substitution caused by a change in a single base pair. This allows 
methods to be adapted between organisms. Antibiotics which are susceptible to point 
mutations that occur in chromosomal genes include the fluoroquinolones, rifampicin, 
pyrazinamide and isoniazid. Resistance to fluoroquinolones occurs mainly due to 
chromosomal mutations in target genes. Therefore the mutation rate contributes to the 
proportion of a bacterial population that are resistant to fluoroquinolones. It is unlikely that 
a mutation will occur in a population if the size of the population is less than the inverse of 
the mutation rate. As the population increases the probability of a resistance mutation 
occurring that increases the MIC to the antibiotic in question also increases. The mutation 
rate estimated here implies that a B. cepacia infection must involve at least 9.6 x 10 11 cells 
for one cell to mutate to resistance.
Of the gyrA mutations that cause bacterial fluoroquinolone resistance in vitro those that 
occur at codons 83 and 87 in gyrA occur most frequently (Bachoual et al. 2001; Dessus- 
Babus et a l 1998; Mouneimne et al. 1999; Ruiz et al. 1998; Vila et al. 1995). These codons 
encode the amino acids that form the DNA binding region of gyrase and therefore changes 
here result in a reduced capacity for fluoroquinolones to form a complex with the DNA and 
gyrase. Of the two amino acid changes observed one was at codon 83 and the other at 87. At 
codon 83 the change was from a hydrophilic threonine residue to a hydrophobic isoleucine 
residue. Mutation of codon 83 to a hydrophobic amino acid generally confers more 
resistance than mutation at codon 87 (Drlica & Zhou 1997). This data shows substitution at 
position 83 confers a greater level of resistance than substitution at position 87 and therefore 
supports this interpretation. Most fluoroquinolone susceptible organisms have an aspartic
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acid residue at codon 87. If the amino acid at this position is not negatively charged then 
there will be increased resistance to fluoroquinolones. The change at codon 83 conferred a 
64 fold change in MIC while alteration at codon 87 conferred a 12 fold increase in MIC. 
The substitution Thr83Ile in gyrA was the mutation most commonly identified in the in vitro 
mutants. Previous studies have also found this mutation to be the most common in clinical 
isolates of P. aeruginosa (Akasaka et al. 2001; Mouneimne et al. 1999; Oh et al. 2003). A 
common double mutation Thr83Ile and Asp87Asn, previously reported in E. coli and P. 
aeruginosa (Akasaka et al. 2001; Oh et al. 2003; Saenz et al. 2003) was not detected in 
these in vitro isolates. Changes at both of these codons have previously been described in 
other Gram-negative bacteria but the Thr83Ile mutation has only been described in P. 
aeruginosa (Drlica 2003).
When selection with lower concentrations of fluoroquinolone (2 x MIC) was used no 
mutations were found in the QRDRs of gyrA , gyrB , parC  and parE. It is possible that 
mutations occurred outside the QRDR. However the MIC of these mutants was reduced to 
levels comparable to that of the wildtype following incorporation of reserpine into the agar. 
Therefore it is likely that the observed resistance is due to altered expression of an efflux 
pump. Similar results have been obtained by Zhou et al who found that low concentrations 
of fluoroquinolone selected non gyrase mutants in M. smegmatis (Zhou et al. 2000). These 
isolates may contain other mutations that confer resistance to other antibiotics as these 
mutants additionally exhibit decreased susceptibility to chloramphenicol and ampicillin 
(Zhou et al. 2000). It has previously been reported that at low plating concentrations 
colonies growing usually do not contain mutations in the QRDR of mycobacteria (Sindelar 
et al. 2000). On exposure to higher drug concentrations mutants conferring low levels of
138
Chapter 3: Estimation of mutation rate in topoisomerase genes of B. cepacia 
resistance are unable to grow. Mutations that interfere significantly with gyrase may cause 
cell death and so will not contribute to the observed mutation rate.
At higher selection concentrations of ciprofloxacin (4, 6 and 8 x MIC) mutations in the 
topoisomerase genes were found. Moderate level resistance (12-64 mg/L) was caused by 
single mutations in gyrA that occurred during the initial selection step at 6 x MIC. High 
level resistance (256 mg/L), achieved following second step selection, was associated with 
double mutation in gyrA and parC.
Second step mutations were selected, using Asp87Asn and Thr83Ile as the respective 
starting points, on high concentrations of ciprofloxacin. The second round of mutant 
selection resulted in the occurrence of a mutation at codon 80 of parC, irrespective of the 
starting point. This mutation has previously been implicated in conferring fluoroquinolone 
resistance in clinical isolates of P. aeruginosa (Akasaka et al. 2001; Mouneimne et al. 1999; 
Oh et al. 2003). This mutation has been also been described in P. aeruginosa resistant 
isolates, selected in vitro (Kugelberg et al. 2005). O f the gyrA mutations that cause bacterial 
fluoroquinolone resistance in vitro those that occur at codons 83 and 87 in gyrA occur most 
frequently in other bacterial species (Bachoual et al. 2001; Dessus-Babus et al. 1998; 
Mouneimne et al. 1999; Ruiz et al. 1998; Vila et al. 1995). There is evidence that single 
mutations in gyrase or topoisomerase IV may predispose the genome to further mutation. As 
described previously Gillespie et al investigated the mutation rates of S. pneumoniae using 
ciprofloxacin and gemifloxacin as the selective agents. The mutation rate of second step 
mutations in isolates already containing a gyrA or parC  alteration was higher than the first 
step mutation rates (Gillespie et al. 2003). In Bcc mutation rates of second step mutants are 
higher than the mutation rate of the first step mutation confirming this original observation.
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The rate of mutation occurring in B. cepacia topoisomerase genes estimated by the 
experimental procedures described here is 9.6 x 10'11. This is a lower rate than those 
estimates already published for related organisms but is of the same order of magnitude. 
There are no reported mutation rates in B. cepacia. Published measurements of mutation 
rate in other organisms are higher and range from of 10'6 to 10'8. Published estimates 
include those in E. coli (Boe et al, 1994), S. pneumoniae (Gillespie et al, 2003), P. 
aeruginosa (Oliver et al. 2000) and M. tuberculosis (Billington, McHugh & Gillespie,
1999).
Mutation frequencies are reported more commonly than mutation rates. Mutation 
frequencies of single step spontaneous mutations resistant to FQs are low in comparison to
nalidixic acid, which are typically > 10'9 when selected at 8 x MIC. Mutation frequencies of
10 8Gram-negative bacteria selected at 4 x and 8 x MIC ranged from >10' to 5.3 x 10" for 
temafloxacin, lomefloxacin and flerofloxacin (Chin et al. 1988; Chin, Novelli, & Neu 
1988). Mutation frequency to tosufloxacin resistance at 8 x MIC for S. aureus, E. coli and P.
aeruginosa were < 10'10 (Espinoza et al. 1988). Phenotypic mutation frequency to
-8ciprofloxacin resistance in C. jejuni is approximately 1 x10 '  (Gootz & Martin 1991).
Mutation rate experiments (estimated using alteration in phenotype from susceptible to 
resistance) have estimated a mutation rate of 1.1 x 1 O’9 using ciprofloxacin as the selective 
antibiotic and 1.6 x 10'11 using gemifloxacin (Gillespie et al, 2003) for S. pneumoniae. 
Similarly in M. tuberculosis the estimated mutation rate in rpoB, conferring rifampicin 
resistance, was found to be 1 x 10'10 divisions per generation (Billington, McHugh, & 
Gillespie 1999). However phenotypic increases in MIC can occur due to induction of efflux
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pumps that reduce accumulation of antibiotic within the cell. These changes are not due to 
point mutations in topoisomerase genes. Thus an estimated phenotypic mutation rate may 
result from numerous genotypic changes in different genes and at different loci within these 
genes. A mutation rate calculated including confirmed mutations in a single target gene 
only, is likely to be lower than a phenotypic mutation rate. For example the mutation rate in 
B. cepacia in gyrA, using the Lea and Coulson method of the median (Lea & Coulson 1949) 
at 4 x MIC without genotypic confirmation gives an estimate of 2 x 10"8 compared to 9.6 x 
10'11 as measured by the po on agar containing 6 x MIC with genotypic confirmation. 
Genotypic mutation rate could not be determined at 4 x MIC because the number of cultures 
in which a topoisomerase mutation occurred was very small. This may be due to the 
presence of multiple target genes and non heritable changes. Both approaches are valid but 
are essentially different measures. Previous measurements of mutation rates vary depending 
on the selective antibiotic concentration and the fluoroquinolone agent tested.
Increase in efflux activity results in smaller elevations of MIC than mutations in 
topoisomerase genes. If incorporation of reserpine into agar reduces the MIC of a drug then 
it can be concluded that efflux pumps have a role in the observed increase in resistance. In 
this thesis it is hypothesised that the low level increase in antibiotic resistance in mutants not 
containing topoisomerase mutations is due to altered expression of efflux pumps. Bast et al 
considered strains to contain active efflux if there was a four fold or greater decrease in MIC 
to the drug in question in the presence of reserpine (Bast et al. 2000). The advantages of this 
assay are that it is convenient and does not rely on measurement of fluorescence. However 
reserpine is labile and should be used immediately once in solution (Brenwald, Gill, & Wise 
1998). Neyfakh et al demonstrated that reserpine can be inactivated by incorporation into 
agar (Neyfakh, Bidnenko, & Chen 1991). However Brenwald et al found no difference in
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the effect of reserpine on MIC between MICs determined in broth or by agar incorporation 
(Brenwald, Gill, & Wise 1998).
Exclusion of antibacterial agents from the cell by efflux pumps is a major cause of antibiotic 
resistance in bacteria. In Gram- negative bacteria multi drug efflux pumps can extrude 
antibiotics from multiple classes to cause multiple resistance (Nikaido 1996). Increase in 
fluoroquinolone accumulation in a resistant strain that was promoted following addition of 
energy inhibitor such as carbonyl cyanide m-chloro phenylhydrazone (CCCP) has been used 
to identify efflux. However increase in accumulation following CCCP treatment can occur 
in the absence of efflux mechanisms (Furet, Deshusses, & Pechere 1992). Therefore in order 
to demonstrate efflux reduced accumulation of fluoroquinolone must occur in the resistant 
cell compared to the susceptible cell.
The estimated mutation rate in topoisomerase genes in B. cepacia is low. This would mean 
that large numbers of bacteria will be required for a mutation to resistance to occur during 
infection. However this experimental protocol would tend to result in low estimates and 
higher values would have been observed if a phenotypic mutation rate estimating method 
was chosen instead. All of the available methods only give an estimate of mutation rate. 
Each method relies on a set of pragmatic assumptions that are made in order to make 
estimations possible and therefore each mutation rate is only an estimate and can not 
represent exactly what is happening in vivo. Mutation rates in the same system estimated by 
separate groups via different methods can give very different estimates. For example it was 
noted that estimated mutation rates of purine analogue resistance in a Chinese Hamster V79 
cell line by two groups differed by more than 1000 times (Chu & Mailing 1968; Harris 
1971; Kendal & Frost 1988).
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In conclusion a standardised protocol for estimation of mutation rate in B. cepacia has been 
developed. The mutation rate in topoisomerase genes in the Bcc is low, although the 
mutation rate to phenotypic resistance is higher and this most likely occurs due to 
fluoroquinolone efflux from the cell. These studies provide important data that assist in the 
understanding of resistance development in this important organism.
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Chapter 4 Measurement of fitness using a biofilm assay
4.0 Introduction
4.1 Biofilms
4.1.1 Biofilms of B. cepacia
It is likely that the ability of bacteria of the Bcc complex to form biofilms limits 
eradication by antimicrobial therapy and promotes long term persistence in the CF lung. 
For example, in a study of 21 cystic fibrosis patients those patients that died were 
colonised by biofilm forming isolates of Bcc bacteria (Cunha et al. 2004). The extent of 
biofilm formation varies between genomovars of the Bcc. B. multivorans and B. 
cenocepacia are capable of greater biofilm formation than B. cepacia, B. stabilis and B. 
vietnamensis (Conway, Venu, & Speert 2002). However B. dolosa has since been 
demonstrated to be comparable to B. cenocepacia and B. multivorans in biofilm formation 
(Caraher et al. 2006).
B. cepacia has been shown to form biofilms in vitro and it is likely that this occurs in the 
cystic fibrosis lung as has been demonstrated for P. aeruginosa (Mathee et al. 1999).
4.1.2 Multispecies Biofilms
Most biofilms in nature are undoubtedly composed of more than one species (Stoodley et 
al. 2002). However single species biofilms are important clinically. Polymicrobial 
biofilms tend to more stable and thicker than single species biofilms (Allison, McBain, & 
Gilbert 2000). In the CF lung, P. aeruginosa colonisation of the cystic fibrosis lung 
occurs before colonisation by B. cepacia (Govan & Deretic 1996; Koch & Hoiby 1993) 
leading to the conclusion that Bcc bacteria are able to adhere to the P. aeruginosa biofilm.
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P. aeruginosa colonisation occurs before Bcc colonisation. B. cepacia must therefore be 
able to adhere to a P. aeruginosa biofilm. Dual species biofilms can develop following 
continuous challenge irrespective of the species forming the primary biofilm. However P. 
aeruginosa is always dominant and this may be due to the production of a substance that 
is inhibitory to B. cepacia (Al Bakri, Gilbert, & Allison 2004). Communication between 
these organisms has been documented; B. cepacia can detect and respond to acyl 
homoserine lactones produced by P. aeruginosa. Addition of supernatant from stationary 
phase P. aeruginosa culture fluid to B. cepacia culture increased siderophore, lipase and 
protease production (McKenney, Brown, & Allison 1995). This communication is 
unidirectional as P. aeruginosa cannot respond to the B. cepacia signals (Riedel et al. 
2001). As many Gram-negative bacteria produce acyl homoserine lactones and inhabit 
similar niches, it is likely that further interspecies communication occurs.
4.1.3 Biofilm Models
There are numerous systems that have been developed and used to model growth of 
bacterial biofilms. These include growth on sorborod filters (Hodgson et al. 1995), the 
constant depth film fermenter (Peters & Wimpenny 1987), microtitre plates (O'Toole & 
Kolter 1998), flow cells and rotating disc bioreactors (Zelver et al. 1999). No single 
model is ideal for all experimental scenarios as each has been designed for a specific 
purpose. For bacteria that grow as biofilms during infection, a biofilm quantification 
assay should be included as a measure of fitness. This is because the propensity to form 
biofilms is likely to affect fitness. For use as a fitness assay, the model of biofilm growth 
should be simple and reproducible with sufficient replicate biofilms to allow statistical 
analysis. However, other criteria are important in selection of a model. It is desirable that
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the biofilm is grown in as steady a state as possible. Depending on the question being 
asked of the system, the conditions of the biofilm should mimic the environmental 
conditions of the in vivo biofilm, therefore the ability to control the environment should 
exist. Simplicity of operation is advantageous. Capacity to substitute the substrata and 
vary the depth of the biofilm allows flexibility. Aseptic conditions are required with a 
means of inoculating the biofilm without contamination. Other factors that should be 
considered while selecting a model include incubation temperature, presence of 
antibiotics, organism and cell numbers required, flow rate, sheer and presence of a 
conditioning film.
4.1.4 Quantification of biofilm growth
Growth within a biofilm can be measured by sacrificing cells from the biofilm by 
sonication and/or vortexing before determining viable cell numbers estimated by plate 
counting, although using this method biofilm specific characteristics may be lost. No 
difference in bacterial counts was observed between P. fluorescens and B. subtilis 
biofilms disrupted by vortexing, sonication or shaking with beads (Lindsay & von Holy
1997). Biofilm growth can also be visualised in situ with fluorescent probes and reporter 
genes (Geesey 2001) as well as using imaging software to estimate biofilm coverage of 
the surface. Bioluminescence is particularly useful in vitro and in vivo as it allows 
biofilms to be monitored in real time (Kadurugamuwa et al. 2003; Kadurugamuwa et al.
2003). Selected models used for quantifying biofilm formation, are shown in table 4.1.
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Model Organisms Flow Substratum Method of
quantifying
biofilm
Reference
Constant
Depth
Film
Fermenter
(CDFF)
B. cepacia,
P. aeruginosa, 
oral bacteria
Continuous Variable Vortex plug, viable 
count. Can be 
observed directly 
by SEM and CLSM
(Hengtrakool, 
Pearson, & Wilson 
2006; Hope & 
Wilson 2006; Peters 
& Wimpenny 1987; 
Pratten, Barnett & 
Wilson 1998)
CDC
Biofilm
Reactor
Gram negative 
bacteria
Continuous Plastic
connectors
Sonicate, vortex, 
homogenise, 
viable count
(Murga, Miller, & 
Donlan 2001)
Modified
Robbins
device
B.
pseudomallei, 
P. aeruginosa
Batch Variable Viable count (Honraet & Nelis 
2006; Mikuniya et 
al. 2005; Vorachit et 
al. 1993)
Calgary
biofilm
device
P. aeruginosa, 
S. aureus,
E. coli
Batch Plastic pegs Sonicate peg, 
viable count
(Ceri et al. 1999)
Sorborads
Filter
S. aureus,
P. aeruginosa
Continuous Filter paper Vortex, viable count (Hodgson et al. 
1995)
Table 4.1 Models that have been used to quantify bacterial biofilm growth 
4.1.5 Examples of biofilm models
4.1.5.1 Constant Depth Film Fermenter
A constant depth film fermenter (CDFF; University of Wales, Cardiff) was used to grow a 
B. cepacia biofilm. A photograph of the apparatus is shown below (figure 4.1). The CDFF 
was originally chosen for use as a fitness assay for a number of reasons. Firstly this model 
allows the growth of many replicate biofilms (up to 75) that can be maintained in a semi
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steady state, the environmental conditions can be controlled and the fermenter can be 
incubated in an aerobic or anaerobic atmosphere. Media can be supplied at a constant rate, 
effluent removed and inoculum can be added aseptically. The CDFF consists of an 
autoclavable, enclosed, stainless steel turntable which rotates underneath 
polytetrafluoroethylene (PFTE) scraper blades (figure 4.2) (Peters & Wimpenny 1987). 
This action removes excess growth and media. This model has previously been used to 
study mixed biofilms of B. cepacia and P. aeruginosa (Al Bakri, Gilbert, & Allison
2004), Candida albicans (Lamfon et al. 2003) and oral bacteria (Hengtrakool, Pearson, & 
Wilson 2006; Hope & Wilson 2003; Hope & Wilson 2006; Pratten, Barnett & Wilson 
1998).
Figure 4.1 Photograph of a Constant Depth Film Fermenter
Figure 4.2 Photograph of PFTE Scraper Blades
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The turntable contains 15 holes that contain PFTE pans, which can be removed via a 
sampling port. Each pan in turn contains 5 plugs (figure 4.3).
Figure 4.3 Photograph of Sample Pan
The depth of these plugs and therefore the depth of the biofilm can be set to a 
predetermined level. Media enters the apparatus through a port in the stainless steel top 
and is delivered via a peristaltic pump at a constant rate.
4.1.5.2 Sorborods Filter
The sorborods filter consist of a cylindrical paper sleeve encasing a concertina of 
cellulose fibres. Single filters are inserted into lengths of PVC and sterilized by 
autoclaving (Maira-Litran, Allison, & Gilbert 2000). Sorborods filters can be incubated 
and media is supplied at a constant rate via a peristaltic pump. In order to enumerate cell 
numbers, filters can be sacrificed and vortexed in saline and a plate count can be 
performed. This system has been used to model mixed biofilms of B. cepacia and P. 
aeruginosa (Al Bakri, Gilbert, & Allison 2004).
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4.1.5.3 Drip Flow Reactors
This biofilm model consists of petri dishes containing stainless steel slides onto which 
media drips onto at a constant rate (Huang et al. 1998).
4.1.5.4 Flow Cells
Flow cells are small continuous flow systems that allow direct observation of the intact 
biofilm via a viewing port. Media may be recycled or may be ‘once flow’, meaning that 
media enters the system, passes through the cell, and is then collected as waste. Flow cells 
are often used for short term colonization studies because adhesion can be observed in 
real time.
4.1.5.5 Crystal Violet Microtitre Plate Method
The crystal violet microtitre plate biofilm assay is a simple and rapid method which 
quantifies biofilm formation indirectly via the extent of crystal violet binding to bacterial 
peptidoglycan to the wells of a microtitre plate. Bacteria are grown in wells of a microtitre 
plate that contain media. Wells are washed to remove planktonic cells and incubated with 
crystal violet. Unbound crystal violet is removed by repeated washing with water. Bound 
crystal violet is solubilised with ethanol and the resulting optical density determined. 
O’Toole et al initially used the assay to assess the impact of growth conditions and as a 
screen for mutants deficient in biofilm formation in P. fluorescens (O'Toole & Kolter
1998). Modifications of this assay have been used to study biofilm formation in a number 
of bacteria including E. coli (Pratt & Kolter 1998), V. cholerae (Watnick & Kolter 1999), 
S. aureus (Stepanovic et al. 2003) Listeria monocytogenes (Djordjevic, Wiedmann, &
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McLandsborough 2002) and Streptococcus gordonii (Loo, Corliss, & Ganeshkumar
2000). This method has also been used to quantify biofilm growth in B. cepacia mutants 
that are defective in biofilm formation and of a panel of Bcc strains of different 
genomovars (Conway, Venu, & Speert 2002; Huber et al. 2001).
A novel assay, the BioFilm Ring Test, has been described that measures biofilm 
formation based on the immobilization of magnetic beads embedded in the bacterial 
aggregate. Biofilm formation has been measured in L. monocytogenes, E. coli, 
Staphylococcus carnosus and S. xylosus (Chavant et al. 2007). This method gives faster 
comparable results to the crystal violet assay and does not include any washing or staining 
steps, which can lead to poor reproducibility.
4.1.6 Effect of Incubation Conditions
Incubation atmosphere may affect biofilm formation. For example, S. aureus forms less 
biofilm in CO2 than in aerobic incubation (Stepanovic et al. 2003). Different 
environmental conditions may stimulate different development pathways. O’Toole et al 
demonstrated that in P. fluorescens there are multiple biofilm development pathways that 
are regulated by nutrient status (O'Toole 2003).
4.2 Aims of chapter
Aims were to select and optimize a model of biofilm growth which could be used as a 
fitness assay to measure fitness costs associated with topoisomerase mutations, selected in 
vitro and characterized in chapter 3.
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4.3 Materials and Methods
4.3.1 Constant Depth Film Fermenter
Biofilms were grown in a CDFF, (section 2.10.1.1.) Viable CFU counts were performed 
at 4, 24, 48, 72 and 120 hours, (section 2.10.1.1.3.) Biofilms and visualized using 
Confocal Scanning Laser Microscopy (CSLM), (section 2.10.1.1.4).
4.3.2 Crystal Violet Microtitre Plate Assay
Quantification of biofilm growth was facilitated by spectrophotometric measurement of 
crystal violet binding using a previously published method (O'Toole & Kolter 1998) and 
has previously been used to quantify biofilm growth in Bcc bacteria (Conway, Venu, & 
Speert 2002), (section 2.9.1.2). Microtitre plates were incubated for 0, 1,4,  7, 24 and 48 
hours in order to optimize incubation period, see figure 5.7. For each time point 8 
replicate wells were used. Three replicate experiments were performed.
4.4 Results
4.4.1 Growth of B. cepacia biofilm
Viable CFU counts were used to construct a growth curve of the B. cepacia biofilm 
(figure 4.4).
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Figure 4.4 Growth curve of B. cepacia 10661. Mean colony forming units for four 
replicate runs. Error bars show 1 standard deviation at each sample point.
4.4.2 Confocal laser scanning microscopy of the B. cepacia biofilm
Sample plugs were removed at 4, 24, 48, 72 and 120 hours. Confocal images 
demonstrating development of the B. cepacia biofilm at 4 and 72 hours are shown below. 
Images at other time points are not shown. A single slice of a completed 3D project was 
saved as a TIFF file and these are shown below. These images show progression of the B. 
cepacia biofilm. At 4 hours there is approximately 5% coverage and at 24 hours 25% 
coverage. At 48 hours coverage was approximately 40%. However the biofilm was less 
dispersed than at 24 hours. At 72 hours coverage was approximately 90% and 100% at 
120 hours. At 72 and 120 hours water channels throughout the biofilm were visible.
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Figure 4.5 Image of biofilm at 4 hours. Single slice of a 3D representation of the biofilm, 
using ImageJ software. Viable cells appear green and non viable cells appear red.
Water
Channels
Figure 4.6 Image of biofilm at 72 hours
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4.4.3 Effect of incubation period on biofilm formation
0 .2-1
0 .1-
0.0
0 1 2 4 7 24 48
Time (h)
Figure 4.7 Biofilm growth at 0, 1, 2, 4, 7, 24 and 48 hours measured using the crystal 
violet microtitre plate method. Error bars represent SEM. Each experiment consisted of 8 
replicare wells and the experiment was repeated three times.
4.5 Discussion
Although there is a limited understanding of biofilm biology, P. aeruginosa, P. 
fluorescens, E. coli and V cholerae have been used extensively as models in biofilm 
research. For other bacterial species, less is known.
Scanning confocal laser microscopy (SCLM) is well suited to the study of biofilms 
(Shotton 1989) and has elucidated their three dimensional structure. The technique lacks 
resolution compared to electron microscopy but has the advantage of being able to
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visualise living, hydrated biofilms. Biofilms of B. cepacia, visualized by SCLM, 
contained visible water channels between microcolonies (figure 4.6). These permeable 
water channels have been compared to primitive circulatory circuits and allow of 
exchange nutrients and toxic metabolites (Stoodley, Debeer & Lewandowski 1994). 
Biofilm architecture is affected by flow conditions (Stoodley et al. 1999). P. aeruginosa 
biofilms in turbulent flow form streamlined patches while in laminar flow monolayers 
interspersed with small circular microcolonies are formed (Purevdorj, Costerton, & 
Stoodley 2002).
Despite precautions taken, including ethanol flaming of the sampling port each time that a 
sample was taken, use of a surgical mask to prevent contamination during sampling and 
overnight inoculation through sterile tubing, contamination was a problem using the 
CDFF. Together with laborious and time consuming nature of the CDFF it does not 
appear to be suitable for use as a fitness assay in the context of these studies.
The crystal violet assay involves multiple washing steps resulting in loss of cells and 
variability was observed between wells using this assay. A fixation step has not been 
included in assays used to quantify biofilm formation in the Bcc (Conway, Venu, & 
Speert 2002; Huber et al. 2001) and was not included here. However a fixation step has 
been included in some crystal violet biofilm assays (Stepanovic et al. 2003) and this step 
may increase reproducibility between assays. Reflectance assays have been developed to 
measure biofilm formation, utilizing changes in optical reflectance. Various surfaces 
(opaque or non opaque) can be used and biofilm samples can be fixed and stored before 
taking a measurement (Broschat et al. 2005). The ability to form biofilms of 14 strains of 
Enterococcus was assessed using both the crystal violet assay and the reflectance assay.
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Similar results were obtained independently with both assays as the same isolates were 
identified as the highest and lowest biofilm producers. However 2 isolates forming 
abundant biofilms in the crystal violet assay, did not form biofilms in the reflectance 
assay (Broschat et al. 2005).
Huber et al used the crystal violet assay to assess the ability of B. cepacia H i l l  to form 
biofilms containing cepl and cepR genes that had been inactivated by random transposon 
mutagenesis (Huber et al. 2001). Biofilm formation was not affected by composition of 
the media or incubation temperature (30°C or 37°C). Although biofilms grew on 
polystyrene microtitre plates, B. cepacia cells could not form a biofilm on polypropylene. 
The cepl and cepR mutants were defective in their ability to form AHLs and in biofilm 
formation. Addition of AHLs to the media restored biofilm formation (Huber et al. 2001). 
It is likely that the cep quorum sensing system has a role in biofilm formation in B. 
cepacia.
In this study LB broth (0.5% casamino acids) was used with incubation at 30°C for 24 
hours. Following longer incubation, the amount of biofilm detected decreased, see figure 
4.7. It is likely that this is due to dispersal of the cells from the biofilm following a 
reduction in available nutrients in the LB broth.
In this thesis the crystal violet binding assay was adopted as a biofilm model to measure 
fitness. This method was chosen as it is simple, rapid and allows investigation of large 
numbers of isolates.
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Chapter 5: Fitness cost of fluoroquinolone resistance in B. cepacia
5.0 Introduction
5.1 Determination of fitness
5.1.1 Choosing appropriate fitness models
The probability of resistance mutations occurring in target genes and any fitness deficit 
associated with them are important as these factors affect the likelihood of resistance 
developing and being maintained in the population. Growth rate is an accepted measure of 
fitness to measure fitness deficits associated with antibiotic resistance (Billington, McHugh, 
& Gillespie 1999; Gillespie, Voelker, & Dickens 2002). Laboratory growth conditions 
usually involve growth in rich media and these conditions may vary dramatically from 
natural growth conditions in the environment or human body. Growth in rich media provides 
a selective advantage to fast growing strains and therefore faster growing strains may be 
selected for in the laboratory. No single measure of fitness is sufficient to describe the 
impact of resistance on the survival ability of bacterial strains. Hence, models have been 
selected that represent growth and survival conditions for B. cepacia to increase the clinical 
relevance (Conway, Venu, & Speert 2002; O'Toole & Kolter 1998; Sanchez et al. 2002). 
Fitness models can be adapted for use in many bacterial species by changing growth 
conditions.
P. aeruginosa is known to form biofilms within the human body, for example within the CF 
lung (Govan & Deretic 1996; Singh et al. 2000) and it is likely that Bcc bacteria also grow as 
biofilms in the CF lung. In these cases a biofilm model may be included when measuring 
fitness in order to reflect growth and environmental survival conditions of the species of 
interest. Similarly environmental survival e.g. resistance to drying or survival in water is
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relevant for nosocomial pathogens which can be transmitted via contaminated surfaces. Bcc 
bacteria are introduced into the environment by cystic fibrosis patients during physiotherapy 
and this may allow cross infection to occur (Ensor et al. 1996). The risk of transmission 
remains unclear but the ability of bacteria to survive drying allows their maintenance on 
environmental surfaces (Smith, Eng, & Padberg, Jr. 1996) and also the possibility of 
transmission between hosts. Bcc bacteria can survive for extended periods in respiratory 
droplets on surfaces at room temperature (Drabick et al. 1996). These bacteria have also been 
identified in shower drains, soil (Nelson et al. 1991) and homes of CF patients (Butler et al. 
1995).
5.1.2 Semi automated liquid culture system
Viable cell count estimation is subjective and dependent on enumeration of colonies that 
grow under the growth conditions provided, introducing sampling error. In using an 
automated system which is less time consuming and less prone to operator variation, it is 
possible to perform replicate growth rate estimations for large numbers of strains.
In this study the Bactec 9240 continuous, blood culture system with standard aerobic medium 
(Plus Aerobic/F) was used to determine growth rate. The Bactec 9000 (9240/9120/9050) 
series of automated blood culture systems are used to rapidly detect viable microorganisms in 
clinical specimens. Bactec Plus Aerobic vials, contain 25 mL of enriched soybean-caesin 
digest broth, 0.05% sodium polyanetholesulfonate (SPS), resins, C 0 2, 0 2 and a sensor. This 
sensor, within each vial, responds to changes in oxygen and carbon dioxide levels as a result 
of bacterial metabolism. These changes are measured by an increase in the fluorescence of
159
Chapter 5 Fitness cost of fluoroquinolone resistance in B. cepacia
the sensor which is monitored every ten minutes. A positive fluorescence reading indicates 
an increase in CO2 or decrease in oxygen and the presence of microorganisms in that vial.
5.2 Aims of chapter
B. cepacia was used as a model to assess the fitness costs of FQ resistance mutations as these 
bacteria are highly resistant to many antibacterial agents, form biofilms within the lungs and, 
due to the chronic nature of cystic fibrosis infection, are exposed to long term antibiotic 
treatment. The fitness costs of single and double topoisomerase mutations, selected in vitro 
and characterised in chapter 3 were assessed using fitness models relevant to transmission. 
These included models of biofilm and planktonic growth and environmental survival. A 
method using a semi-automated liquid based culture system to measure growth rates was 
developed.
5.3 Materials and Methods
5.3.1 Culture Conditions
The strain used in these studies was B. cepacia 10661 (National Collection of Type Cultures, 
HP A, Colindale, UK) and subsequent mutants of this strain. The ciprofloxacin MIC of this 
strain was 1.0 mg/L as determined by E-test (see section 2.6.1). To ensure uniformity of 
strains the isolate was stored at -70°C using Cryobank cryogenic beads (Pro-lab Diagnostics, 
Neston, UK). For each fitness assay the culture was initiated by inoculating a bead, from a 
stored culture, onto nutrient agar (Oxoid, Basingstoke, UK) then incubated at 37°C for 18 
hours.
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5.3.2 MIC Determination
The MIC of parent and mutant strains were determined by ciprofloxacin E-test (AB Biodisk, 
Solna, Sweden; section 2.6.1) and by the agar doubling dilution method, according to the 
CLSI guidelines for susceptibility testing of aerobic bacteria (CLSI, 2006; section 2.6.2).
5.3.3 Selection of Resistant Mutants
Fluoroquinolone resistant mutants of B. cepacia, containing single and double mutations 
were selected in vitro (see chapter 3). First step spontaneous ciprofloxacin resistant mutants 
were selected at 2, 4, 6 and 8 x MIC, as described in chapter 3. Colonies were stored at 
-70°C for subsequent study using Microbank beads (Prolab Diagnostics, Neston, UK).
5.3.4 Miles and Misra Viable Cell Count
The number of CFU in 20 pi drops of diluted broth culture was determined using the Miles 
and Misra method, as described previously in section 2.5 (Miles & Misra 1938).
5.3.5 Fitness Assays
5.3.5.1 Biofilm Growth
Quantification of biofilm growth was achieved by spectrophotometric measurement of 
crystal violet binding using a previously published method (O'Toole & Kolter 1998). This 
method has been used to quantify biofilm growth in Bcc bacteria (Conway, Venu, & Speert 
2002) and is described in detail in section 2.9.1.2.
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5.3.5.2 Planktonic Growth
The method of Youmans and Youmans was modified (Youmans & Youmans 1949) to 
determine growth rate (as described previously in section 2.9.2).
5.3.5.3 Competition Assays
Fitness of the fluoroquinolone resistant mutants, containing single and double topoisomerase 
mutations, was compared to the susceptible parent using a modification of a previously 
published method (section 2.9.3) (Billington, McHugh, & Gillespie 1999; Gillespie, Voelker, 
& Dickens 2002).
5.3.5.4 Environmental survival
The ability of the resistant mutants to survive in water and survive drying was compared to 
the susceptible parent, described in sections 2.9.4 and 2.9.5
5.3.5.4.1 Statistical Analysis
The statistical significance of differences in survival in water and during drying between the 
clinical isolates was assessed by one way ANOVA, using GraphPad software version 3.00 
for Windows (GraphPad Software, California, USA). Differences in generation time were 
assessed by Student’s t-test.
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5.4 Results
5.4.1 Fitness Assays
Using the modified Youmans and Youmans method, relative fitness of Asp87Asn (FI) and 
Thr83Ile (F2) compared to the susceptible parent were 1.01 +/- 0.01 SEM and 1.01 +/- 0.152 
SEM, respectively using paired competitive cultures. Differences in relative growth rates of 
the single gyrA mutants found during paired competition assays were not significant, as 
determined by Students t-test. Relative fitness of the double mutants F3 and F4 was 0.88 +/- 
0.12 and 0.78 +/- 0.18 respectively. Double mutation in topoisomerase genes, therefore, did 
incur a fitness deficit as measured by competitive growth culture.
Strain Generation Time 
(min) (+/- 95% 
confidence interval)
Generation 
Time 
P value 
(Students T 
test)
Relative 
Fitness (+/- 
S.E.M)
Relative 
fitness 
P value 
(Students T 
test)
WT 38.0(37 .06-38 .94)
FI Asp87Asn 37.0 (36.77 -  37.23) 0.331 1.01 +/-0.01 0.831
F2 Thr83Ile 37.1 (36.90 -  37.3) 0.377 1.01 +/-0.152 0.868
F3 Asp87Asn 
Ser80Leu
43.0 (41.85-44 .15) 0.004 0.88+/- 0.12 0.003
F4 Thr83Ile 
Ser80Leu
45.7 (44.2 -  47.2) 0.001 0.78+/- 0.18 0.002
Table 5.1 Generation times (+/- 95% confidence intervals) and relative fitness (+/- S.E.M) of 
the susceptible parent and topoisomerase mutants FI and F2 are the single gyrA mutants, 
Asp87Asn and Thr83Ile respectively. F3 contains Asp87Asn and the additional Ser80Leu 
parC  mutation. F4 contains Thr83Ile and Ser80Leu. Differences in growth rate between wild 
type, FI and F2 are not significant, as determined by Students t test and therefore do not have 
a measurable fitness cost. However F3 and F4 exhibit significantly slower growth.
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Mutation in gyrA andparC  did not affect biofilm formation in B. cepacia, see figure 5.1.
The transmissibility of B. cepacia isolates could be affected by the ability to survive in water 
and survive during drying. A decrease in viability over time was observed for the susceptible 
parent and the fluoroquinolone resistant mutants but there were no statistically significant 
differences between the mutants and the susceptible parent.
As shown in figure 5.2 and figure 5.3, no significant differences were found at any time point 
in the ability of the gyrA and parC  mutants to survive in water or survive drying, as 
compared to the parent B. cepacia strain.
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Figure 5.1 Effect o f topoisomerase mutations on ability of B. cepacia to form biofilms. 
Mutation in gyrA and parC  did not affect biofilm formation in B. cepacia. Error bars 
represent SEM. Differences are not significant, determined by one way ANOVA using the 
GraphPad Prism software.
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Figure 5.2 Effect of topoisomerase mutations on the survival of B. cepacia in water. 
Sampled at 0, 1, 2, 5, 7, 8, 9 and 13 days. Survival of B. cepacia in water was not affected by 
mutation in gyrase subunit A or topoisomerase IV. Error bars demonstrate SEM. Differences 
in survival are not significant.
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Figure 5.3 Effect of topoisomerase mutations on the survival of B. cepacia on dry surfaces. 
Survival of B. cepacia on dry surfaces was not affected by mutation in gyrase subunit A or 
topoisomerase IV. Error bars demonstrate the standard error of the mean. Error bars are not 
shown if obscured by the symbol. Differences in survival are not significant.
5.5 Discussion
No fitness cost was found in fluoroquinolone resistant mutants containing a single 
topoisomerase mutation as measured by growth rate, biofilm growth and environmental 
survival. A significant fitness cost was found in gyrA and parC  double mutants, in growth 
rate and competitive culture only. Fitness was not impaired in any other assay (Pope et al. 
2007).
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The cost of mutations conferring fluoroquinolone resistance depends on the bacterial species, 
the number of resistance gene mutations and the level of resistance conferred as reported in 
E. coli (Bagel et al. 1999), S. pneumoniae, (Gillespie, Voelker, & Dickens 2002) S. 
typhimurium (Giraud et al. 2003) and P. aeruginosa (Kugelberg et al. 2005). Single 
topoisomerase mutations in S. pneumoniae incur no or low cost while double mutations in 
gyrA and parC  incur a significant cost of approximately 0.85 relative to the susceptible 
parent (Gillespie, Voelker, & Dickens 2002). Topoisomerase mutations in S. typhimurium 
(Giraud et al. 2003), conferring small increases in resistance, are also associated with either 
no reduction in fitness or a small loss. In E. coli the cost varies between strains (Bagel et al. 
1999). The fitness cost has been shown to vary between organisms and depends on the 
resistance mutations present.
Common mutations in rpoB, conferring resistance to rifampicin in clinical isolates of M. 
tuberculosis, incur a lower cost than mutations that occur more rarely (Billington, McHugh, 
& and Gillespie 1999; Gagneux et al. 2006; Mariam et al. 2004). The most common rpoB 
mutations, His481Asn and Ser529Leu, found in clinical isolates of S. aureus do not exhibit a 
fitness cost (O'Neill et al. 2006). Moderate level fluoroquinolone resistance in P. aeruginosa, 
conferred by single mutations in gyrA and gyrB, incurs a fitness cost depending on the 
location and identity of the mutation in P. aeruginosa (Kugelberg et al. 2005).
Multiple mutations in topoisomerase genes, associated with high levels of resistance exhibit 
reduced fitness in other organisms. High level fluoroquinolone resistant P. aeruginosa 
mutants (>256 mg/L) containing double mutations in topoisomerase genes or other genes, all 
demonstrate reduced fitness (relative fitness of approximately 0.5, compared to wildtype), as 
measured by growth rate (Kugelberg et al. 2005). In E. coli double mutations in gyrA
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(Ser83Leu and Asp87Gly), had a decrease in fitness as measured by increase in generation 
time of 33% (Bagel et al. 1999). These measurements of fitness cost are greater than the 
fitness costs of gyrA and parC  mutations in B. cepacia that have been measured in this study. 
Triple mutations in topoisomerase genes are required for high level fluoroquinolone 
resistance (256 mg/L) in S. typhi (Turner, Nair, & Wain 2006). The MIC of mutants 
containing Ser83Phe/Tyr, Asp87Asn and Glu84Lys mutations was 32-64 mg/L. However 
this is a lower level of resistance than conferred by the Asp87Asn Ser83Ile double mutation 
in B. cepacia. Mutations in parC  did not affect MIC without existing mutation in gyrA 
(Turner, Nair, & Wain 2006). The fitness cost depends on the resistance conferring mutation, 
the genetic background of the strain and the presence of compensatory mutations.
In vitro resistance to antibacterial agents, other than the fluoroquinolones, occurs via 
stepwise accumulation of mutations in target genes. Chromosomal resistance to mupiricin in 
S. aureus is attributed to mutations in isoleucyl tRNA synthetase, the most common 
mutations being Val588Phe and Val631Phe (Hurdle, O'Neill, & Chopra 2004). In agreement 
with the results reported in this thesis, first step mutations confer no measurable cost while 
second step mutations confer a fitness cost in vitro and in vivo. Hurdle et al reported relative 
growth rates of second step mutations range from 0.24-0.63 compared to wildtype. Fitness 
was restored following compensatory mutation occurring during sub culture (Hurdle, O'Neill, 
& Chopra 2004).
Expression of many genes is dependent on appropriate supercoiling (Steck et al. 1993). It has 
been reported that the observed fitness cost of fluoroquinolone resistance mutations is 
associated with alterations in supercoiling efficiency (Bagel et al. 1999). Growth rates of 
resistant mutants may be reduced as positive coils may accumulate in front of the replication
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fork due to the decreased supercoiling activity of the altered DNA gyrase (Drlica & Zhou 
1997). Compensatory mutations may occur that restore supercoiling activity of gyrase and 
may restore growth rates to levels comparable to the susceptible parent. This has been 
demonstrated in P. aeruginosa (Kugelberg et al. 2005). Alterations in supercoiling were 
measured by separation of topoisomers on agarose gels containing chloroquine. Variations 
exist in the electrophoretic mobilities depending on the extent of supercoiling (Bagel et al.
1999).
No cost resistance mutations have been reported in a number of organisms, conferring 
resistance to various antimicrobial agents. These include; fluoroquinolone resistance in S. 
pneumoniae (Gillespie, Voelker, & Dickens 2002), glycopeptide resistance in Enterococci 
(Ramadhan & Hegedus 2005) and aminoglycoside and spectinomycin resistance in Borrelia 
burgdorferi (Criswell et al. 2006).
However fitness assays lack sensitivity, failing to detect fitness costs of <1% (Andersson & 
Levin 1999). Small but significant deficits may therefore not be detected. These ‘no cost’ 
mutations may vary in impact in different environments. It is possible that mutation in gyrA 
did have an associated fitness deficit that could not be measured by these methods. For 
example due to large values of error in the biofilm assay, only large fitness costs could be 
detected. During the paired competition assays relative fitness was assessed after 10 hours. 
Small differences in relative growth between two strains may have been detected if 
successive cycles of pairwise competitive cultures were performed. It is unlikely that 
compensatory mutations have occurred that ameliorate fitness costs as mutants were 
immediately stored at -70°C following selection.
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Youmans and Youmans measured the difference in time to positivity of cultures of M. 
tuberculosis inoculated with serial dilutions of a culture to calculate the growth constant k 
and generation time (Youmans & Youmans 1949). A liquid based automated culture system 
has been used in this thesis to determine growth rate and generation time, avoiding time 
consuming and laborious standard growth curve techniques. This has proved to be a reliable, 
reproducible and simple method for measurement of growth rate (Pope et al. 2007). It is 
possible that differences in lag time result in a delayed time to positivity. Cells were therefore 
added when they were in exponential phase to minimise the affect of differences in lag time. 
Laurent et al have also used an automated liquid culture system (MS2 Research System, 
Abbott Laboratories, Dallas, Tx, USA) and paired competitive cultures to determine growth 
rate, as a measure o f fitness in MRSA. Epidemic MRSA clones that are susceptible to 
gentamicin have been increasing in France and these clones have a fitness advantage over 
MRSA clones that are gentamicin resistant (Laurent et al. 2001). The growth rate differences 
provide an explanation for the predominance of nosocomial gentamicin susceptible MRSA 
clones in France.
Growth rates determined in the laboratory using rich media may not correspond to growth 
rates during infection. However it is reasonable to assume that if  there is a measurable cost 
for bacteria in rich media then there is likely to be a cost in vivo. Gustavson et al 
demonstrated that fitness costs associated with antibiotic resistance in Staphylococcus 
epidermidis were similar for in vitro growth rates and the ability to survive on the skin of 
healthy human volunteers (Gustafsson, Cars, & Andersson 2003). Fitness measurements may 
differ for the same bacterium when measured in different conditions (Remold & Lenski
2001) and may be affected in stressful environments (Kishony & Leibler 2003).
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Few studies have used human colonization or infection to measure fitness cost. Andersson et 
al have assessed the fitness costs conferred by parC  and fusR  mutations, conferring 
resistance to fluoroquinolones and fusidic acid respectively, in S. epidermidis using a human 
competition model (Gustafsson, Cars, & Andersson 2003). Susceptible and resistant bacteria 
were inoculated onto human skin and relative numbers monitored. No loss of fitness 
associated with parC  mutation was found. However fusA  mutations resulted in a considerable 
loss of fitness as compared to the susceptible isogenic strain during competition (Gustafsson, 
Cars, & Andersson 2003).
In this chapter assays to measure fitness costs in the Bcc were optimised and used to 
investigate the fitness cost of single and double topoisomerase mutations. No measurable 
cost was associated with single mutations while double mutation occuring in gyrA and parC 
conferred a fitness cost as measured by growth rate. These methods will be used to measure 
the fitness of clinical Bcc isolates.
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Chapter 6 Characterisation of clinical isolates of Burkholderia cepacia 
complex
6.0 Introduction
6.1 Hyper mutability
6.1.1 Hyper mutability of P, aeruginosa in Lungs of Cystic Fibrosis Patients
Oliver et al have described a correlation has been found that links high mutation rate with 
increased antibiotic resistance in isolates of P. aeruginosa from lungs of CF patients (Oliver 
et al. 2000). Strains exhibiting the mutator phenotype were found in the lungs of 37% of CF 
patients and in these patients 43% of the total P. aeruginosa population were mutators. This 
group have also shown that hypermutable strains of P. aeruginosa exist in the CF lung 
before initiation o f antimicrobial therapy (Oliver et al. 2004). Resistant mutants can readily 
occur in P. aeruginosa within the lungs o f CF patients before or during treatment. This 
would imply that treatment of chronic infections of this type should include multiple 
antimicrobials rather than a single agent. This environment is indeed unstable characterised 
by changing host immune responses and varying antibiotic levels. Although conditions for 
B. cepacia growing in the lungs of cystic fibrosis patients are likely to be similar to those for 
P. aeruginosa, no evidence of hypermutable populations of B. cepacia has been reported to 
date.
6.1.2 Detection of Hyper mutability by E-test
Associations have previously been demonstrated between high levels of antibiotic resistance 
and hypermutability (Oliver et al. 2000). These hypermutable strains have defects in DNA 
repair systems, most commonly in the mismatch repair system (Miller 1996), (section
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1.3.13). Macia et al. used E-test and disc diffusion to detect hypermutable strains of P. 
aeruginosa isolated from sputum of CF patients (Macia et a l 2004). It is assumed that 
resistant mutant colonies which appear within the E-test inhibition ellipse are unlikely to 
occur in bacterial populations which are non hypermutable. This also allows MIC 
determination of both the susceptible and resistant subpopulations. Strains were defined as 
hypermutable if  resistant colonies were observed to three or more antibiotics of ceftazidime, 
imipenem, meropenem, tobramycin and ciprofloxacin. Hypermutable strains were 
associated with higher MICs (Macia et al. 2004). E-tests are expensive but have the 
advantage of providing precise MICs, as compared to disc diffusion which do not. 
Estimation of mutation rate and mutation frequency are time consuming and labour 
intensive procedures and would not be possible to incorporate into diagnostic clinical 
microbiology laboratories.
6.2 Aims of chapter
Hypermutability has been demonstrated in a number of pathogenic bacteria but has not been 
described in B. cepacia. However hypermutability has been described in P. aeruginosa 
isolated from the CF lung. As both organisms have a similar niche and lifestyle it is likely 
that hypermutability occurs in Bcc bacteria. Clinical CF isolates of Bcc bacteria, were 
collected in order to determine if mutator bacteria exist in these populations. The mutation 
rate method, discussed in chapter 3, was modified because the clinical isolates were resistant 
to ciprofloxacin and an alternative selective agent was required. A mutation rate estimation 
method was therefore optimised using clinafloxacin as the selective agent as the Bcc isolates 
were susceptible to this agent and this method was used to estimate the mutation rate in 
these bacteria.
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The fitness of these clinical isolates was determined as measured by growth rate, biofilm 
formation, survival in water and survival to drying. Antimicrobial susceptibility of these 
isolates was determined and the sequence of the gyrA QRDR determined to assess the role 
of gyrA mutations in the development of FQ resistance.
6.3 Materials and Methods
6.3.1 Clinical Strains
Clinical strains of Bcc complex bacteria including isolates of B. multivorans (genomovar II) 
and B. cenocepacia (genomovar III) were obtained from Dr. John Moore, Belfast City 
Hospital. These bacteria were isolated from sputum samples from CF patients (see section
6.3.2 for recovery o f Bcc from sputum).
6.3.2 Isolation of Bcc from sputum
Sputum containing Bcc was diluted with Sputasol (Oxoid, Basingstoke, UK) and spread 
onto B. cepacia selective agar (Mast Diagnostic, Bootle, UK) containing ticarcillin and 
polymixin, to obtain single colonies. On this medium, B. cepacia grows as 1-2 mm colonies 
and turns the medium pink within 48 hours. Plates were incubated aerobically (48 hours at 
37°C). Isolates were confirmed as B. cepacia by Gram stain and API 20 NE as it is reliable 
in identification of the Bcc (van Pelt et al. 1999). Isolates were previously identified as Bcc 
and the species status determined at Belfast City Hospital. In brief expectorated sputum 
(50:50 sputasol; sputum) was inoculated onto B. cepacia selective agar (Mast Diagnostic, 
Bootle, UK). Bcc confirmed by API 20 NE and species status was previously determined by 
recA sequence typing (Mahenthiralingam et al 2000).
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Colonies were stored at -70°C on beads, as described previously (section 2.1).
6.3.3 MIC determination
MICs were determined using E-test, for the following antibiotics; amoxicillin-clavulanic 
acid, ceftazidime, ciprofloxacin, colistin, gentamicin, meropenem, piperacillin-tazobactam, 
temocillin, tetracycline, tigecycline and trimethoprim sulphamethoxazole, using the 
manufacturer’s instructions (section 2.6.1). CLSI interpretive breakpoints for non 
Enterobacteriacea were used if Burkholderia breakpoints were unavailable. Isolates were 
recorded as resistant, intermediate or susceptible.
6.3.4 Sequence analysis of the QRDR of gyrA
The QRDR o f the subunit A of DNA gyrase was sequenced (section 2.7 and 2.8) using 
primers described in Table 3.1.
6.3.5 Detection of Hypermutability
The presence of hypermutability was measured using mutation rate (section 6.3.6.3). 
Alternatively, the presence of hypermutability was determined using the E-test method 
(section 2.6.1) which identifies hypermutators by the presence of resistant colonies observed 
within the inhibition ellipse to determine if resistant colonies are observed within the 
inhibition ellipse. The antibiotics used were ceftazidime, meropenem, ciprofloxacin, 
imipenem and gentamicin (Macia et al. 2004).
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6.3.6 Assay development for determination of mutation rate of clinical Bcc isolates
6.3.6.1 Choice of selective antibiotic
The clinical Bcc isolates (BCH1-BCH8) exhibited variable susceptibility to ciprofloxacin. 
Isolates BCH2, BCH3, BCH6, BCH7 and BCH8 (5/8) had ciprofloxacin MIC values of >32 
mg/L (Figure 6.4). An alternative agent was therefore required in order to estimate mutation 
rates from susceptibility to resistance in these isolates. The clinical Bcc isolates were tested 
for susceptibility to clinafloxacin. Clinafloxacin was more active against the Bcc isolates 
than ciprofloxacin (Table 6.4).
6.3.6.2 Selective Antibiotic Concentration
Using NCTC strain 10661 as the test isolate, at 4 x and 6 x MIC of clinafloxacin, no 
resistant mutants grew irrespective of incubation conditions and final cell numbers. A 1 mL 
culture, inoculated with 102 cells, that was spread onto plates containing 2 x MIC of 
clinafloxacin, gave rise to single colonies that were visible at 48 hours of plate incubation. 
When higher broth culture volumes were used a film of growth covered every antibiotic 
plate. Between 3 and 90 colonies were present on each plate. Therefore the Lea and Coulson 
method of the median was used to determine mutation rate (section 6.3.6.3). All mutants 
selected at 2 x MIC had an MIC of 0.5 mg/L. This represents a 2 fold increase in MIC. 
However mutants selected at 2 x MIC (25/25) did not contain mutations in gyrA. MIC was 
reduced in the presence of reserpine. Therefore the observed increase in resistance is likely 
to be due to an increase in efflux, as was the case with in vitro ciprofloxacin resistant 
mutants selected at 2 x MIC.
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6.3.6.3 Method for determination of mutation rate for the clinical Bcc isolates by the 
method of the median using 2 x MIC clinafloxacin.
Isolates were removed from the -70°C freezer and one bead was used to sub culture Bcc 
onto a blood agar plate and incubated aerobically at 37°C. One colony of Bcc was 
suspended in 5 mL o f Muller Hinton Broth in a 25 mL conical flask. This was sealed with 
a cotton wool bung and incubated at 37°C on a rotary shaker (200 r.p.m.) (Barloworld 
Scientific, Staffordshire, UK) for 2.5 hours until an optical density (OD6oo) of 
approximately 0.1 OD units was reached. Serial dilutions of this broth culture were 
performed in PBS (neat to 10’6). A 100 pL aliquot of the 10'3 dilution (containing 
approximately 103 cells) was added to each of 28 microcentrifuge tubes, containing Muller 
Hinton Broth (1 mL). These cultures were incubated at 37°C, 200 r.p.m 18 hours 
(Barloworld Scientific, Staffordshire, UK). Muller Hinton Agar plates (Oxoid, 
Basingstoke, UK) containing 2 x MIC of clinafloxacin were prepared and inoculated the 
following day. Antibiotic free agar plates were also prepared (section 2.2.3). Before 
inoculation, plates were allowed to dry at 37°C with the lids removed for 20 min. This 
ensured that drops were absorbed by the agar. At the end of the incubation period, a Miles 
and Misra plate count was performed on 3 randomly selected broths, section 2.5 (Miles 
1938). Dilutions of 10'1 to 10'6 were prepared. Twenty microlitres of the 10'3, 10“4, 10'5 
and 1 O'6 dilutions were spotted in triplicate onto duplicate drug free Muller Hinton plates. 
The microcentrifuge tubes were centrifuged at 4000 g , 3 min and the supernatant 
discarded. Using a fine tipped pastette, the deposit was resuspended in residual broth 
(approximately 40 pL). The total volume was then inoculated onto clinafloxacin 
containing Muller Hinton plates, spread with a plastic spreader and allowed to dry. All 
plates were incubated (37°C, 48 hours). Colony forming units per mL were calculated 
from the Miles and Misra drug free plates. The number of colonies on each plate were
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counted and recorded. The median number of colonies was determined. The number of 
mutations per culture was calculated using equation 10:
r/m-\n(m) -  1.24 = 0 [Eq 10]
The mutation rate (ju) was calculated using equation 11:
m [Eq 11]
H = -------------------
average cfu/mL 
This was repeated 4 times to give a median mutation rate.
6.3.7 Fitness of Clinical Bcc Isolates
As previously, a comprehensive approach to measuring the fitness of clinical isolates was 
adopted and biofilm formation (section 2.10.1.2), growth rate (section 2.10.2), survival in 
water (section 2.10.4) and survival to desiccation (section 2.10.5), was determined for each 
isolate.
6.3.8 Statistical Analysis
6.3.8.1 Calculation of t XA
Data was entered into GraphPad software version 3.00 for Windows (GraphPad Software, 
California, USA) and statistical analysis was performed. The mean and standard error values 
were calculated from the three experiments for each clinical isolate. The t lA (time at which 
half of the cells will have died) was calculated using non-linear regression analysis with a
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monophasic exponential decay curve. Exponential decay curves were calculated for each 
clinical isolate.
The correlation coefficient (r ) was calculated as an estimate of goodness of fit using 
GraphPad Prism by the following equation:
r2 = (sum of squares of the distance from the best fit curve)
(sum of squares of distance from the mean Y value)
The Global comparison of fits was used to determine if the survival of the isolates to drying 
were significantly different to each other. A two way ANOVA, followed by the Bonferroni 
multiple comparison test, was performed in order to determine if survival in water between 
isolates was different at time points.
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6.4 Results
6.4.1 Antibiotic Susceptibility Testing
MIC mg/L
Antibiotic BCH  1 B CH  2 BCH  3 BCH 4 B CH  5 BC H  6 BC H  7 B CH  8
Amoxicillin- 
clavulanic acid
>256 >256 >256 >256 >256 >256 >256 >256
Ceftazidime 3 6 4 1 1 64 24 12
Ciprofloxacin 6 >32 >32 1.5 3 >32 >32 >32
Colistin 128 >1024 >1024 >1024 192 >1024 >1024 >1024
Gentamicin 24 96 96 16 32 >256 >256 >256
Meropenem 2 4 12 2 0.75 >32 12 >32
Piperacillin-
Tazobactam
64 >256 3 16 16 >256 >256 >256
Temocillin 12 4 32 24 32 24 8 12
Tetracycline >32 >32 >32 >32 >32 >32 >32 >32
Tigecycline 6 8 24 128 32 24 8 6
Trimethoprim
sulfmethoxazole
>32 >32 >32 >32 >32 >32 >32 >32
Table 6.1 Antibiotic susceptibilities of clinical Bcc isolates. Isolates BCH 2, BCH 3, BCH 5,
BCH 6, BCH 7 and BCH 8 are isolates of B. cenocepacia. BCH 1 and BCH 4 are isolates of B. 
multivorans. MICs to amoxicillin-clavulanic acid, ceftazidime, ciprofloxacin, colistin, 
gentamicin, meropenem, piperacillin-tazobactam, temocillin, tetracycline, tigecycline and 
trimethoprim sulfamethoxazole of clinical Bcc isolates, as determined by E-test according to 
the manufacturer’s instructions.
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6.4.2 Biofilm Growth
Isolate
Figure 6.1 Comparison of biofilm formation between clinical isolates. Mean OD units 
obtained in the crystal violet assay are plotted to represent biofilm formation. Error bars 
represent SEM.
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6.4.3 Environmental Survival
6.4.3.1 Survival during drying
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Figure 6.2 A comparison between the fitness of different Bcc isolates using survival during 
drying as a measure. The survival curve is obtained by plotting the mean viable count 
Sampled at 0, 1, 2, 3, 4, 5, 6 and 7 hours. Error bars represent the SEM. Error bars are not 
shown if  obscured by the symbol. No significant differences found by F test of survival 
curves, using Graph Pad Prism.
To test the hypothesis that clinical isolates varied in their ability to survive drying, the tl/2  
was calculated for each clinical isolate using non linear regression analysis. No significant 
difference was found in the ability of the clinical isolates to survive drying (global p value 
0.2394). Because the viable cell count of Bcc isolates in water did not decline significantly 
after 3 days (figure 6.3) the tl/2  was not calculated for survival in water.
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6.4.3.2 Survival in water
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Figure 6.3 A comparison between the fitness of different Bcc isolates using survival in 
water as a measure. The survival curve is obtained by plotting the mean viable count. 
Survival in water of the clinical Bcc isolates. Sampled at 0, 1, 3, 5, 8 and 13 days. Error 
bars demonstrates SEM. Error bars are not shown if obscured by the symbol. For the 
survival in water data, there was a trend to declining CFU with time. However the 
difference in CFU between isolates at time points was found to be not significant (p value 
0.0714) by two way ANOVA, using GraphPad Prism.
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6.4.4.1 Growth Rate
Isolate Generation Time 
(min +/- S.E.M)
Antibiotics to 
which resistant
BCH 1 54.8 +/- 0.61 5/10
BCH 2 76.4 +/- 0.93 8/10
BCH 3 83.1 +/- 0.48 8/10
BCH 4 54.7 +/- 1.12 6/10
BCH 5 54.6 +/- 0.63 5/10
BCH 6 120.7+/- 1.13 10/10
BCH 7 71.6 +/- 0.76 10/10
BCH 8 85.07 +/-1.25 8/10
Table 6.2 Association between generation times of clinical Bcc isolates (min +/- S.E.M) and 
antibiotic resistance. Shows proportion of antibiotics tested (amoxicillin-clavulanic acid, 
ceftazidime, ciprofloxacin, colistin, gentamicin, meropenem, piperacillin-tazobactam, 
temocillin, tetracycline, tigecycline and trimethoprim sulphamethoxazole) to which each 
strain is resistant.
6.4.4 Hypermutability
6.4.5.1 E-test
No resistant colonies were visible within the E-test ellipse for any clinical Bcc isolate tested.
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6.4.5.2 Mutation rate
Isolate Mutation rate (mutation per 
division)
Range
BCH 1 4 .9 x 1  O'5 3.4 x 1 O'8 - 5.5 x 10"8
BCH 2 1.9 x 10'8 1.8 x 10’* - 7.0 x 10'8
BCH 3 4.2 x 10'* 2.6 x 10'" - 6.9 x 10"8
BCH 4 2.3 x 10'8 1.7 x 10 2.6 x 10""
BCH 5 2.2 x KT8 2.2 x 10'8- 8.2 x 10"8
BCH 6 5.0 x 10'* 2.3 x 10'8 - 5.8 x lO'"
BCH 7 3.8 x 10'" 2.7 x 10'5 - 4.2 x 10""
BCH 8 2.6 x 10'" 1.1 x 10"*-2.7x10'"
Table 6 3  Median mutation rates of Bcc isolates of three independent experiments.
Determined by Lea and Coulsons method of the median (Lea & Coulson, 1949) using 
clinafloxacin as the selective antibiotic at 2 x MIC (section 2.3.6).
6.4.5 Sequence Analysis of the QRDR of gyrA
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Figure 6.4 Amino acid sequences of QRDRs of gyrA of clinical isolates. Polymorphisms 
found at codon 83 (shown in red) and 87 (shown in blue). At codon 83 a serine residue 
would be expected in a susceptible isolate. Isolates BCH 4 and BCH 5 contain a serine 
residue at codon 83. Isolate BCH 2 contains a mutation to alanine residue at codon 83, while 
BCH 1, BCH 3, BCH 6, BCH 7, and BCH 8 contain mutations to threonine. At codon 87 an
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BCH 4, BCH 5, BCH 7 and BCH 8 contain an aspartic acid at this position while BCH 2 
and BCH 6 contain a glycine mutation. No synonymous mutations were found.
Isolate Ciprofloxacin 
MIC (mg/L)
Clinafloxacin
MIC(mg/L)
BCH 1 6 2
BCH 2 128 16
BCH 3 64 8
BCH 4 1.5 1
BCH 5 3 8
BCH 6 32 8
BCH 7 256 16
BCH 8 32 2
Table 6.4 Comparison of ciprofloxacin and clinafloxacin MIC of clinical Bcc isolates
Ciprofloxacin and ciprofloxacin solutions were prepared (sections 2.3.6 and 2.3.7).
MICs were determined in duplicate using the agar incorporation method (section 2.6.2) 
according to the CLSI guidelines (CLSI, 2006).
6.5 Discussion
To characterise the pattern of resistance and the potential for resistance to be fixed in the 
bacterial population a series of clinical isolates were compared for mutation rate, antibiotic 
susceptibility and fitness as measured by planktonic growth rate, biofilm growth rate and 
environmental survival.
Isolates did exhibit variation in growth rate. Growth rates of the different isolates were 
statistically significant, as measured by a modified Youmans and Youmans method (Table 
6.2). There appeared to be an intriguing association between generation time and the relative 
resistance of each isolate (Table 6.2). However isolate numbers were not large enough to 
determine if there was a relationship between extent of antibiotic resistance and growth rate.
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Isolate BCH 6, a B. cenocepacia strain, has the longest generation time (120.7 min. +/- 1.13) 
and is also the most resistant of the eight strains studied and is resistant to all antibiotics 
tested. Isolates BCH 1, BCH 4 and BCH 5 have the shortest generation times 54.8 min. +/- 
0.63, 54.7 +/- 0.61 and 54.6 min. +/- 1.12 respectively but these are also the most 
susceptible strains. Caraher et al demonstrated differences in growth rate and that generation 
times in B. cepacia, B. multivorans, B. cenocepacia, B. stabilis, B. vietnamensis and B. 
dolosa ranged from 70 -  186 min. (Caraher et a l  2006) and that there was no association 
between generation time and genomovar status. However this study did not examine the 
association between antimicrobial susceptibility and growth rate. This thesis lends support 
to the idea that multidrug resistance does incur fitness costs in the Bcc. The mechanisms of 
this resistance were not investigated in this thesis.
No significant differences in biofilm formation were found between the majority of the Bcc 
isolates, as measured by the crystal violet assay (Figure 6.1). However isolate BCH 1 
produced extensive biofilm in the crystal violet assay, compared to the other Bcc isolates. 
The reasons for the propensity of this isolate for forming biofilms are unclear. Conway et al 
also demonstrated differences in ability to form biofilms between isolates of the Bcc and 
found that there was no correlation between the ability to form biofilms and growth rate. 
However the correlation between biofilm formation, growth rate and virulence was not 
explored (Conway, Venu, & Speert 2002). However recA type A organisms formed more 
biofilms than type B organisms (Conway, Venu, & Speert 2002).
However in this study, no significant difference was found in environmental survival, as 
measured by survival during drying and survival in water, between the clinical Bcc isolates. 
Drabick et al demonstrated Bcc strain to strain differences in survival on environmental
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surfaces and differences in survival on different surfaces with the greatest survival occurring 
on PVC (Drabick et al. 1996). Isolates survived longer if suspended in sputum (Drabick et 
a l  1996).
Zhou et al reported the in vitro activity of antimicrobial agents that were tested in synergy, 
using checkerboard testing. The most active antibiotics were minocycline, meropenem and 
ceftazidime, inhibiting 38%, 26%, 23% of strains respectively, while 18% were resistant to 
all agents tested (Zhou et al. 2007). Aaron et al performed in vitro synergy studies for the 
Bcc using multiple combination bactericidal tests (MCBT). This measures the activity of 
peak serum concentrations of antibiotics (Aaron et al. 2000). Meropenem combined with 
minocycline, amikacin or ceftazidime was bactericidal against 76%, 73% and 73% of 
isolates, respectively. Triple antibiotic combinations such as tobramycin, meropenem and 
other agents exhibited bactericidal activity against 81-93% of isolates (Aaron et al. 2002). In 
this study all isolates were resistant to colistin. This is unsurprising as colistin is 
incorporated into B. cepacia selective media to isolate Bcc. Additionally all isolates were 
resistant to trimethoprim-sulfamethoxazole, tetracycline and gentamicin. Variable 
susceptibility was found for tigecycline, piperacillin-tazobactam, and temocillin. The most 
active antibiotics against Bcc are meropenem, ciprofloxacin and ceftazidime.
The nucleotide sequences of the gyrA QRDRs of the isolates were determined (Figure 6.4). 
Clinical isolates of the Bcc contain polymorphisms within the gyrA QRDR at positions 83 
and 87 and there appears to be a correlation between MIC and the identity of amino acids at 
codon 83 and 87. The direct effect of QRDR polymorphisms in Bcc clinical isolates on 
growth rate was not assessed in this thesis and therefore. It is not possible to comment on 
whether differences in observed growth rate were directly related to the identity of amino
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acids within the QRDR. At codon 83 a serine residue would be expected in a susceptible 
isolate, while at codon 87 an aspartic acid residue would be expected in a susceptible 
isolate. Isolates of P. aeruginosa and C. jejuni are 10 fold less susceptible to 
fluoroquinolones than wildtype E. coli because they contain a threonine residue rather than 
serine at codon 83 (Chen & Lo 2003; Okazaki et al. 1991). Codons 83 and 87 encode the 
hydrophilic a helical domain of DNA gyrase. When mutations occur at these positions 
fluoroquinolones are less able to form a complex with DNA and DNA gyrase, reducing 
susceptibility to the drug. Isolates BCH 4 and BCH 5 contain Ser83 and Asp87, the most 
common genotype in susceptible isolates. Isolates BCH 1, BCH 5 and BCH 4 exhibited low 
level FQ resistance (Table 6.5). However isolate BCH 1 contains Thr83 and Asp87 and has 
a higher MIC (6 mg/L) than BCH 5 (3 mg/L) and BCH 4 (1.5 mg/L). Mutations in gyrA 
initially result in substitution o f Ser83 and subsequently by substitution of Asp87 (Chen & 
Lo 2003; Hooper 2003). The altered gyrase reduces binding of fluoroquinolones, even if 
only one resistance mutation is present (Willmott & Maxwell 1993). Although it might be 
expected that BCH 6 exhibit the highest level of resistance since this strain contains both 
Thr83 and Gly87, the ciprofloxacin MIC is 32 mg/L. Of the eight clinical strains isolate 
BCH 7 exhibited the highest level of resistance at 256 mg/L. This isolate contains Thr83 and 
Asp87 and it is therefore likely that other resistance mechanisms are contributing to the 
observed resistance. The BCH 2 isolate contained an alanine residue at codon 83 and is 
highly resistant to ciprofloxacin (128 mg/L). This resistance mutation is not common but 
has been documented in fluoroquinolone resistant E. coli (Tavio et al. 1999). The isolate 
BCH 2 also contains a Gly87 mutation. It is likely that differences in the QRDR sequence of 
gyrB, parC  and parE  would have been found in the clinical isolates if sequenced and that 
these mutations may have contributed to FQ resistance. However the primers used in this 
thesis to amplify gyrA failed to amplify gyrB, parC  and parE  genes of the clinical isolates,
189
Chapter 6 Characterisation of Clinical isolates of Burkholderia cepacia complex
despite further optimisation of annealing temperatures and MgCh concentration. These 
regions have, therefore, not been sequenced in the clinical Bcc isolates. Differences in 
nucleotide sequences between the primer and the parC  region of the clinical isolates may 
have prevented the primers from annealing. It is likely that other fluoroquinolone resistance 
mechanisms will be contributing to the observed levels of resistance.
Varied aspects of fitness may be more important depending on growth conditions and mode 
of growth. An isolate which is more able to survive environmental conditions may have an 
advantage over other isolates during transmission from the environment to patients. 
Similarly isolates that are capable of forming abundant biofilms may have an advantage in 
the lungs of CF patients. However it is possible that an isolate fittest one assay may not be 
fittest in all assays that have been selected.
Large SEM values were observed for the environmental survival experiments. Therefore 
these assays would only be able to detect reliably large differences in fitness.
Clinafloxacin is a broad spectrum FQ, contains a chlorine atom at C8, and is more active 
against Gram-positive bacteria than ciprofloxacin. Activity of clinafloxacin against 354 
Gram-positive and Gram-negative organisms was compared to ciprofloxacin, levofloxacin, 
sparfloxacin, trovafloxacin, piperacillin, piperacillin-tazobactam, trimethoprim- 
sulfamethoxazole, ceftazidime and imipenem (Brisse et al. 1999). MICs of clinafloxacin 
were lowest of the FQ drugs tested and had the lowest overall MICs of compounds tested. 
Clinafloxacin was also the most active against B. cepacia (Ednie, Jacobs, & Appelbaum 
1998). Resistance to clinafloxacin was used to determine mutation rate in the clinical 
isolates. In this study mutants selected at low selective concentrations (2 x MIC) of
190
Chapter 6 Characterisation of Clinical isolates of Burkholderia cepacia complex
clinafloxacin did not contain mutations in the QRDR of gyrA. MIC values were reduced in 
the presence of reserpine, therefore it is likely that this low level resistance was due to an 
increase in efflux activity. No mutants were selected at 4 x and 6 x MIC of clinafloxacin. It 
was not possible to select clinafloxacin resistant mutants that contained confirmed 
topoisomerase mutations.
The pattern of clinafloxacin resistance is different to that of other FQ antibiotics. A 
combination of gyrA and parC  mutations is required for clinically significant FQ resistance 
to emerge (Nagai et al. 2000; Pan & Fisher 1998). This is because single step mutations in 
gyrA or parC  confer a two fold increase in clinafloxacin MIC. This does not raise the MIC 
above the susceptibility breakpoint. Mutation frequencies of this initial mutation were very 
low and have been reported to be in the region of 10'10 to 10'11. Pan et al also found that it 
was difficult to select clinafloxacin resistant mutants and proposed that clinafloxacin had no 
target preference and targeted both gyrase and topoisomerase IV equally (Pan & Fisher 
1998). As spontaneous acquisition of two mutations is required for significant resistance, the
o
mutation rate would therefore be very low. If an average mutation rate is 10' 
mutations/division the mutation rate of two spontaneous mutations occurring would be 10~16, 
which is unlikely to occur. Nagai et al selected FQ resistant mutants by sequential 
subculture in sub inhibitory concentrations of clinafloxacin, ciprofloxacin and trovafloxacin 
(Nagai et al. 2000). Observed clinafloxacin mutation frequencies for each mutation step 
were lower than ciprofloxacin and trovafloxacin. This suggests that clinafloxacin would be 
less likely than trovafloxacin or ciprofloxacin to result in the development of resistance. 
Most clinafloxacin mutations did not raise the MIC above the susceptibility breakpoint. The 
mutation frequency o f initial resistance mutation to low level resistance in clinical isolates
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of S. pneumoniae, which were fully susceptible (MIC 0.06 mg/L), ranged from 8.8 x 10'10- 
1.0 x 10"11 (Nagai et al. 2000).
Alternative selective tools that could have been used to detect point mutations are heavy 
metals e.g. copper, mercury, lead, boron, cadmium and tungsten. Bacteria have a number of 
resistance mechanisms that allow survival in the presence of heavy metals. These include 
sequestration of heavy metals, reduction of the metal to a less toxic species and efflux (Nies 
1999; Nies & Silver 1995). Heavy metal resistance has been described in Acinetobacter spp, 
Staphylococci, P. aeruginosa and S. typhi (Dhakephalkar & Chopade 1994; Du Bois, 
Davison, & Pinney 1995; Harnett et al. 1998; Nucifora et al. 1989; Teitzel & Parsek 2003).
Hypermutability was not observed in this limited panel of clinical Bcc isolates investigated 
by E-test or estimation of mutation rate but this does not preclude the possibility of 
observing hypermutability in a wider screen. In this chapter, the necessary methods to 
determine mutation rate in clinical Bcc isolates have been optimised and used to screen for 
hypermutability in a small number of isolates that could be applied to screen larger numbers 
of isolates.
Between the isolates, differences in growth rates were observed. However the isolate 
numbers were not large enough to determine if there was a relationship between species 
status or extent of antibiotic resistance in growth rate.
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7.0 Final Discussion
The extensive use of antimicrobial compounds has led to the emergence and dissemination 
of multidrug resistant pathogens (Rogues et al 2007; Mutnick et al 2004). Additionally the 
lack of new antimicrobials being developed and introduced into clinical use (Norrby et al 
2005) has limited treatment options. Approval of new antimicrobials by the U.S. Food and 
Drug administration decreased by 56% from 1983-1987 to 1998-2002. Since 1998 only 10 
new antibiotics have been developed. Of these only linezolid, daptomycin and tigecycline 
have novel mechanisms of action (Spellberg et al 2004). Antibiotic resistant Gram-negative 
pathogens that are resistant to treatment by almost all available drugs are becoming a 
particular problem, especially due to their involvement in nosocomial outbreaks (Canton, 
Coque, & Baquero 2003). Members of the B. cepacia complex are highly antibiotic 
resistant opportunistic pathogens causing lung infection in cystic fibrosis patients. 
Resistance to fluoroquinolones in the Bcc emerges via mutation in topoisomerase genes 
and by upregulation of efflux pathways which extrude antimicrobial compounds from the 
cell.
Most resistance acquisitions, occuring by chromosomal point mutations, are associated 
with a fitness cost (Andersson & Levin 1999). When this is the case a resistant strain will 
be outcompeted by a susceptible strain in the absence of the antibiotic selective pressure. 
Mutants with a low or non existent fitness cost, as described in chapter 5, are therefore 
more likely to become fixed in the population than those with large fitness deficits. 
Mutations that confer no cost in vitro, with moderate levels of resistance, commonly occur 
in B. cepacia while high level resistant mutants (less common) incur a significant fitness 
deficit, as measured by growth rate. Programmes to restrict use of antibiotics in order to 
reduce rates of resistance are based on the assumption that antibiotic resistance has an
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associated cost. Where there are no or low cost mutations these strains may remain in the 
population following the cessation or judicious control of fluoroquinolone use in the 
community, hospital (Shlaes et al. 1997) and within animal husbandry (Nawaz et al. 2003; 
Wallmann 2006). These pre-existing mutants may then re-emerge rapidly in the bacterial 
population as a consequence of resumed prescribing of fluoroquinolone, as illustrated by 
Cohen and Murray in their studies of multidrug-resistant tuberculosis (Cohen & Murray
2004). Exposure of a bacterial population already containing resistance conferring 
mutations to the antibiotic will select subsequent mutations that will further increase MIC 
and will select in favour of the pre-existing resistant mutants rather than the wildtype. The 
extent to which the resistant subpopulation will take over the population will depend on 
three factors; the level of resistance conferred by the genetic change, the fitness deficit 
associated with the mutation and the level of antibiotic exposure. The probability of 
resistance mutations occurring and the extent of the associated fitness deficit are important 
as these factors affect the likelihood of resistance emerging and being maintained in the 
population. This thesis addresses these factors.
In this thesis novel methods for measuring fitness in the Bcc have been developed. 
Measures of fitness are context specific and appropriate models of fitness should be 
relevant to the organism, simple to perform and able to detect small fitness deficits. 
Growth rate is an accepted method for measuring fitness deficits and has been used 
previously both as monocultures, or in paired competition assays (Billington, McHugh, & 
and Gillespie 1999; Gillespie, Voelker, & Dickens 2002), to measure fitness deficits. 
However no single measure of fitness is sufficient. As Bcc bacteria are likely to form 
biofilms within the CF lung a biofilm assay was included as a fitness assay, described in 
chapter 4. Models have been selected for this study, described in chapter 5, that represent
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growth and survival conditions for B. cepacia (Conway, Venu, & Speert 2002; O'Toole & 
Kolter 1998; Sanchez et al. 2002). These were planktonic growth rate, pair wise 
competitive culture (Gillespie, Voelker, & Dickens 2002), biofilm growth (Conway, Venu, 
& Speert 2002; O'Toole & Kolter 1998), survival in water and resistance to drying 
(Sanchez et al. 2002). To measure planktonic growth rate a liquid based semi automated 
growth rate determination method, modified from the method of Youmans and Youmans 
(Youmans & Youmans 1949) has been used. This method avoids the use of laborious 
growth curve techniques and has been shown to be reproducible in this study (Pope et al. 
2007).
No measurable fitness cost was associated with single mutations in gyrA. As these models 
can not detect fitness costs of <1% it is not possible to conclude that gyrA mutations were 
‘no cost’ and are likely to be ‘no cost or low cost’. It was notable that mutants containing 
mutations in both gyrA and parC  were significantly impaired in fitness compared to the 
susceptible parent (chapter 4). Cystic fibrosis patients are frequently colonised by Bcc 
bacteria that exhibit high level FQ resistance (Zhou et al) even when there is not an FQ 
selective pressure. As described in chapter 6, clinical Bcc isolates often exhibit moderate to 
high level fluoroquinolone resistance and exhibit polymorphisms with in the QRDR 
regions of gyrA As multiple mutations are required for moderate and high level resistance it 
is likely that the fitness costs measured in this thesis do not impair the ability of Bcc to 
cause clinical disease. Additionally the isolates studied in this thesis were obtained from 
CF patients with chronic Bcc infection. The size of fitness cost that would be required to 
have an effect clinically is not known and may be hard to investigate as these are likely to 
be the isolates that do not survive.
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Mutants selected in vitro or mutations that occur during treatment may have an undefined 
genetic background. In order to interpret the effect of resistance on fitness the nucleotide 
sequence of the susceptible parent and resistant mutants should be determined. 
Consecutively isolated isogenic clinical strains, containing successive resistance mutations, 
may be available. It is not possible to establish with confidence the contribution to 
resistance of topoisomerase mutations selected in vitro because it is not possible to exclude 
the presence of other mutations that may have occurred and contributed to the observed 
resistance. In this study only the QRDR regions of the topoisomerase genes of mutants 
selected in vitro were sequenced. The possibility of mutations affecting fitness outside 
these regions cannot be excluded. Use of directed mutagenesis could overcome this 
limitation. Bagel et al. examined the effects of point mutations, created by directed 
mutagenesis, on fluoroquinolone resistance and found that extent of the fitness cost varied 
depending on the gyrA and parC  mutations present (Bagel et al. 1999). Different gyrA 
mutations had different effects on the degree of supercoiling. It is therefore likely that 
supercoiling alterations affect growth rate (Bagel et al. 1999). Compensatory mutations 
may occur that restore supercoiling activity of gyrase and may restore growth rates to 
levels comparable to the susceptible parent therefore restoring the fitness deficit. 
Restoration of growth rate by compensatory mutation has been demonstrated in P. 
aeruginosa (Kugelberg et al. 2005).
During drug development the likelihood of resistance arising is affected by mutation rate. 
The cost of these mutations may be relevant as even if the mutation rate is high resistant 
mutants will not proliferate in the population if the fitness cost is high. Novel 
antimicrobials to which only resistance mechanisms that incur large fitness costs are likely 
would be promising agents to develop. Previous data show that use of low dose
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fluoroquinolone as therapy may increase the rate of resistance mutations occurring in other 
pathogens that may have colonised the cystic fibrosis lung due to ability of 
fluoroquinolones to increase mutation rate at sub inhibitory concentrations (Gillespie et al.
2005).
Previous treatment with fluoroquinolones may allow amplification of a mutant 
subpopulation to over 70% resistance if fluoroquinolone treatment is re-initiated (Peloquin 
et al. 1989). It is accepted that fitter more susceptible bacteria can out compete resistant 
bacteria when the antibiotic selective pressure is removed. However it is apparent that 
resistance may persist in the population for longer than previously thought. Resistant S. 
epidermidis were found on human skin 4 years after single course of clarithromycin 
(Sjolund et al. 2005). Resistant bacteria are unlikely to disappear even if antibiotic use is 
reduced and can persist due to no cost mutations, compensatory mutations and co-selection 
of resistance markers. In the UK a 97% reduction in sulphonamide use was observed 
during the 1990s as a consequence of a national prescribing restriction prompting a switch 
from trimethoprim-sulfamethoxazole to trimethoprim. The prevalence of sulphonamide 
resistance in E. coli remained at 40-45% (Enne et al. 2001). Antibiotic resistance 
determinants responsible for resistance to a drug which is no longer in use can be linked to 
genes conferring resistance to antibiotics still in use. The sul2 plasmid, containing genes 
conferring sulphonamide resistance, did not disappear during decreased sulphonamide use, 
even though these plasmids reduce fitness (Enne et al. 2004).
The risk of resistance arising depends on the mutagenicity of the fluoroquinlone, the dose 
and length of treatment. Use of antimicrobial agents in the hospital and the community can 
be rationalised. However we can not control the remaining factors. Rational use of
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antibiotics will not alone reduce the rate of infections caused by resistant bacteria as 
resistant bacteria may already have become fixed in the population. This could include 
prescribing an antibiotic dose that does not select resistant mutants and effective methods 
for reducing transmission.
A method for measurement of mutation rate has been standardised in this thesis. In 
bacterial populations some clones may have a higher mutation rate than the rest of the 
population due to defects in proof reading and repair mechanisms. Hypermutability in 
populations of pathogenic bacteria has been described in E. coli (LeClerc, Li, & Payne 
1996; Matic et al. 1997), Salmonella spp. and P. aeruginosa isolated from the lungs of CF 
patients (Oliver et al. 2000; Oliver et al. 2004). Although Bcc inhabit a similar niche to P. 
aeruginosa within the CF lung hypermutability has not been reported in the Bcc. In this 
study no evidence for hypermutability in the Bcc has been found (chapter 6).
Although the rate of mutation in topoisomerase genes conferring FQ resistance in B. 
cepacia is low (chapter 3) the mutants containing a single mutation in gyrA which arise, are 
not associated with a fitness cost (chapter 5). Mutants are likely therefore to persist in the 
population. The mutation rate of the second step mutation is higher than the mutation rate 
of the first step mutation (chapter 3). Our group have previously found that the mutation 
rate of second step mutations in S. pneumoniae isolates already containing a gyrA or parC  
alteration was higher than the first step mutation rates, using ciprofloxacin and 
gemifloxacin as the selective agents (Gillespie et al. 2003). This is evidence that single 
mutations in gyrase or topoisomerase IV may predispose the genome to further mutation.
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Differences in antibiotic susceptibility were observed between the clinical Bcc isolates. 
Polymorphisms at codons 83 and 87 of the gyrA QRDR were found and the identity of the 
amino acids affects level of FQ resistance (chapter 6). Variation in generation times was 
observed for the Bcc clinical isolates. The determinants responsible for the reduced growth 
are unknown. One isolate was an abundant biofilm producer, compared to the other isolates 
(chapter 6). However no statistically significant differences in environmental survival were 
found between clinical isolates.
In this thesis appropriate methods were developed to measure fitness and mutation rate in 
the Bcc. The path to fluoroquinolone resistance in B. cepacia is initially by an efflux 
mechanism at low selective concentrations, the genetic basis of which was not elucidated. 
At higher selective concentrations mutations in gyrA occur, conferring moderate level 
resistance, that incur no fitness cost. Second step mutants contain mutation in gyrA and 
parC, conferring step wise increases in resistance with significant fitness deficits. No 
evidence for hypermutability in the Bcc was found.
F u tu re W o rk
In this thesis appropriate methods have been developed to measure fitness and mutation 
rate in the Bcc. The isolates investigated in this thesis represented a small number of B. 
cenocepacia and B. multivorans CF strains. To build on the experience gained in this 
study the tools standardised in this thesis can now be used to investigate mechanisms of 
fluoroquinolone resistance and fitness and to screen for hypermutability in a larger panel 
of isolates to include isolates from other genomovars.
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Mutation rate in planktonic culture in Bee was determined in this thesis. It would be 
interesting to determine the mutation rate of Bcc cells growing as a biofilm and to 
compare this to the planktonic rate as the biofilm mutation rate may be higher and there 
may be a link between increased mutation rate and antibiotic resistance in biofilms. The 
maximum final inoculum of bacterial cells growing as a biofilm in the CDFF that could be 
obtained was too low to enable estimation of mutation rate. Use of the microtitre plate 
would not have been suitable for measurement of biofilm mutation rate because this model 
may not adequately represent an in vivo biofilm. Therefore this was not pursued in this 
thesis.
Creation of genetically defined topoisomerase and efflux mutations in isogenic strains 
would have allowed the fitness costs of each mutation to be measured without the 
possibility of other mutations occurring elsewhere in the genome. Additionally this would 
allow the contribution of each mutation on MIC to be elucidated.
Efflux mechanisms were not a primary focus of this thesis. However FQ efflux has 
emerged as an important mechanism of FQ resistance in Bcc. Fitness of the FQ resistant in 
vitro mutants where resistance was presumptively conferred by increase in efflux activity 
was not measured and therefore the fitness cost of increased efflux is not known. 
Additionally the mechanism of FQ efflux in these isolates was not characterised.
Characterisation of the quinolone resistance determining regions of topoisomerase genes 
from a larger number of clinical Bcc isolates from all genomovars could be performed and 
correlated with the level of fluoroquinolone MIC. This would enable clarification of the
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role of topoisomerase point mutations in FQ resistance and would serve to enhance our 
understanding of the evolution of antibiotic resistance in Bcc.
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Fluoroquinolone-resistant Burkholderia cepacia mutants were selected on ciprofloxacin. The rate of mutation 
in gyrA was estimated to be 9.6 x  10“ 11 mutations per division. Mutations in gyrA conferred 12- to 64-fold 
increases in MIC, and an additional parC  mutation conferred a large increase in MIC (>256-fold). Growth 
rate, biofilm formation, and survival in water and during drying were not impaired in strains containing single 
gyrA mutations. Double mutants were impaired only in growth rate (0.85, relative to the susceptible parent).
Exposure to fluoroquinolones increases mutation rates (9, 
12, 20, 26) to various degrees (23). The main mechanism of 
resistance in gram-negative bacteria develops via stepwise ac­
cumulation of mutations in the quinolone resistance-determin­
ing region (Q R D R ) of topoisomerase genes (4, 7, 8, 13).
Opportunistic pathogens of the Burkholderia cepacia com­
plex (BCC) consist o f genomovars that are important in cystic 
fibrosis patients (14, 17). Genomovars are species which are 
phylogenetically distinguishable but phenotypically indistin­
guishable from each other. Here, BCC refers to the complex, 
while B. cepacia refers to genomovar I. BCC bacteria can 
survive in respiratory droplets on surfaces (6) and are resistant 
to many antibacterial agents.
Resistance to drying allows maintenance on environmental 
surfaces (24) and transmission between hosts. Transmission 
between colonized patients has been documented (18).
The objective of this work was to investigate the effects of  
fluoroquinolone resistance mutations on growth rate, biofilm 
formation, and environmental survival.
B. cepacia 10661 (National Collection o f Type Cultures, 
HPA, London, United Kingdom) and mutants derived from 
this strain were used. The MICs of parent and mutant strains 
were determined by the ciprofloxacin Etest (AB Biodisk, 
Solna, Sweden).
The ciprofloxacin MIC of B. cepacia 10661 was 1 |xg/ml. 
Putative resistant mutants were selected at 2 x ,  4 x ,  and 6X 
MIC in three separate experiments. Estimation of the muta­
tion rate was performed using ciprofloxacin at 6 x  MIC. Char­
acterized first-step mutants were used to obtain second-step 
mutants by selecting first-step mutations on media containing 
twice the MIC of the first-step mutants. The numbers of viable 
cells, from three aliquots (approximately 10%), were deter­
mined using the method o f Miles and Misra in order to deter­
mine total cell numbers (3, 11). The plates were incubated at 
37°C for 18 h, and the proportion o f cultures with mutant 
colonies were recorded. The mutation rate (p.) was determined 
using the p 0 method (10, 19, 21).
* Corresponding author. Mailing address: Centre for Medical Mi­
crobiology, Royal Free and University College Medical School, Row­
land Hill Street, London NW3 2PF, United Kingdom. Phone: 44 20
7472 6402. Fax: 44 20 7794 0500, ext. 3540. E-mail: t.mchugh@medsch
.ucl.ac.uk.
v Published ahead of print on 26 December 2007.
Approximately 102 exponentially growing cells were inde­
pendently inoculated into 28 tubes, each containing 3 ml of 
Mueller-Hinton broth (Oxoid, Basingstoke, United Kingdom), 
and incubated at 37°C for 22 h on an orbital shaker (250 rpm; 
Barloworld Scientific, Rochester, NY). The cells were har­
vested by centrifugation (2,000 X  g , 10 min), the supernatant 
was removed with a pipette, and the pellet was resuspended in 
400 p.1 of Mueller-Hinton broth and then plated onto Mueller- 
Hinton agar (Oxoid, Basingstoke, United Kingdom) contain­
ing ciprofloxacin.
The mutants were characterized by sequencing the QRDRs 
of gyrA, gyrB, parC, and parE  by using the primers listed in 
Table 1. Standard PCR conditions were employed. Sequencing 
was performed by the dideoxy method as previously described 
(15).
No mutations (0/45) were found in the QRDRs of the topo­
isomerase genes of B. cepacia selected at 2 x  MIC. The MIC of 
these nontopoisomerase mutants was 4 to 5 p,g/ml. At 4X MIC, 
an Asp87Asn mutation, conferring a 16-fold increase in MIC, 
was found in colonies from one plate (2/55). All other mutants 
(53/55) selected at this concentration contained no mutations 
in the Q RDRs (MICs between 4 and 5 p-g/ml). All first-step 
mutants selected at 6 X  MIC (50/50) contained a Thr83IIe muta­
tion in gyrA and had an MIC of 64 p-g/ml. Mutations, MIC, and 
selection step information are shown in Table 2. Mutation rates 
for second-step mutations were higher than those for the first-step 
mutations.
To detect efflux activity, the ciprofloxacin MIC of the fluo­
roquinolone-resistant mutants was determined in the absence 
and presence o f  reserpine (25 (xg/ml) in Mueller-Hinton agar 
(2). The MICs of all mutants that did not contain gyrA muta­
tions, selected at either 2 x  MIC (45 mutants tested) or 4 x  
MIC (55 mutants tested), decreased fivefold in the presence of 
reserpine to the level o f the wild type. The MICs of mutants 
containing topoisomerase mutations did not decrease.
The quantification of biofilm growth was achieved by the 
spectrophotometric measurement o f crystal violet binding by 
following a previously published method (5). Mutation in gyrA 
and parC  did not affect biofilm formation in B. cepacia. All 
fitness assays were carried out with one mutation of each type 
(data not shown).
We modified the method of Youmans and Youmans (25) to 
determine time to positivity as an indicator of the growth rate.
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TABLE 1. Primers used to amplify the QRDRs of the 
topoisomerase genes of B. cepacia
G ene Prim erpositions" S equence  ( 5 '- 3 ')
A m plicon 
size (bp)
gyrA 62-81
493-511
5' ATCTCGATTACGCGATGAGC 
5' GCCGTTGATCAGCAGGTT
449
gyrB 1127-1146
1502-1520
5' GAGGAAGTTGTGGCGAAGG  
5' AGTCTTCCTTGCCGATGC
400
parC 98-118
295-315
5' ATTGGTCAGGGTCGTGAAGA 
5' GTAGCGCAGCGAGAAATCCT
229
parE 1178-1198
1557-1577
5' CAGGGCAAGGTAGTCGAAAA 
5' GTGAGCAGCAAGGTCTGGAT
380
" B. cenocepacia  num bering.
The Bactec 9240 continuous blood culture system with stan­
dard aerobic medium (Plus Aerobic/F) was used. Aliquots of 
100 |xl of the diluted exponential culture (1/10 and 1/1,000) 
were removed using a 0.5-ml syringe and a needle and were 
aseptically inoculated into duplicate culture vials. The length 
of time to detection (time to positivity) was measured for all 
strains. Gram staining and a purity plate assay were performed 
to confirm the absence of contaminants.
The growth rate constant, k, was determined using equation 
1 (where A  is the largest inoculum employed, B  is the smallest 
inoculum, and t is the difference in time to positivity in hours). 
The generation time (G) was determined using equation 2.
k =
log A  — log B
G  =
log 2
( 1)
(2 )
This experiment was repeated in triplicate. The growth rates of 
the double mutants relative to those of the parent were 0.88 
and 0.83 for mutant strains F3 and F4, respectively, as shown 
in Table 2.
Competition assays were used to measure the fitness of the 
fluoroquinolone mutants compared to that of the susceptible 
parent by the use of a modified version of our previously 
published method (3 ,11). The optical densities of the wild-type 
and mutant isolates were adjusted to the same value (1.0 op­
tical density unit). Then, 250 pi o f each culture was inoculated
1.00E+06-
1.00E+05
0 1 2 3 4 5 6 7 8 9 10 11 12 13
• Parent 
F1 
F2 
F3 
F4
Time (days)
FIG. 1. Effect of topoisomerase mutations on the survival of B. 
cepacia in water. Survival of B. cepacia in water was not affected by 
mutation in gyrase subunit A or topoisomerase IV. Error bars indicate 
the standard errors of the means. Differences in survival are not sig­
nificant.
into 15 ml o f LB broth in the absence of antibiotics. This mixed 
culture was incubated for 10 h (200 rpm). The relative fitness 
of each strain was calculated from the ratio of the number of 
generations grown by the resistant strains to the number grown 
by the susceptible strains. Five independent pairwise cultures 
were performed for each mutant. The relative growth rates of 
mutant strains F3 and F4 were 0.80 and 0.78, respectively. The 
differences in relative growth rates of the strains with the single 
gyrA mutations found during paired competition assays were 
not significant, as determined by Student’s t test. However, 
these assays cannot measure differences of >1%.
Survival in water and survival during drying were assessed 
using the method employed by Sanchez et al. (22). No signif­
icant differences in environmental survival were found between 
the mutants and the susceptible parent, as shown in Fig. 1 and 
Fig. 2.
Selection at lower concentrations of fluoroquinolone re­
sulted in mutants in which resistance was apparently due to an 
altered expression of an efflux pump. Similarly, Zhou ct al. 
demonstrated that low concentrations of fluoroquinolone se­
lected nongyrase mutants o f Mycobacterium smegmatis (27).
At higher selection concentrations of ciprofloxacin (4 x  and 
6 X  MIC), mutations in the topoisomerase genes were found. 
Lower-level resistance (12- to 64-fold) was caused by single 
mutations in gyrA. Higher-level resistance (MIC of >256 ixg/
TABLE 2. Characteristics of fluoroquinolone-resistant B. cepacia mutants selected in vitro"
Strain
M utation
ra te
(m u ta tion /
division)
M IC
(p-g/ffl)
S election
step
Sequence found in Q R D R s  of: G en e ra tio n  tim e 
[m in (95%  
confidence in terval)]
F
value
Relative
fitness
( ± S E M f
F
value
gyrA gyrB parC parE
WT 1 WT WT WT WT 38.0 (37.06-38.94)
FI mutant 9.6 X 10“ 11 12 1st Asp87Asn WT WT WT 37.0 (36.77-37.23) 0.331 1.01 ± 0.01 0.831
F2 mutant 9.6 X 10"11 64 1st Thr83Ile WT WT WT 37.1 (36.9-37.3) 0.377 1.01 ± 0.152 0.868
F3 mutant 1.1 X 10"10 >256 2nd Asp87Asn WT Ser80Leu WT 43.0 (41.85-44.15) 0.004 0.80 ± 0.12 0.003
F4 mutant 6.8 x  10"10 >256 2nd Thr83Ile WT Ser80Leu WT 45.7 (44.2-47.2) 0.001 0.78 ± 0.18 0.002
" Strain F I was iso la ted  on 2 (o-g/mt ciprofloxacin (2 x  M IC ); F2 was iso la ted  on 6 M-g/ml (6X  M IC ), F3 was iso la ted  on 24 p.g/ml ciprofloxacin by the use o f FI as 
the starting  point; F4 was iso la ted  on 128 p.g/ml ciprofloxacin by the use o f F2 as the starting  point. T he statistical significance o f genera tion  tim e differences is shown 
by a P  value. W T, wild type.
h C om petition  assays w ere  used to  m easu re  the  fitness o f th e  fluoroquinolone m utants relative to  tha t o f the susceptib le parent.
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FIG. 2. Effect of topoisomerase mutations on the survival of B. 
cepacia on dry surfaces. Survival of B. cepacia in water was not affected 
by mutation in gyrase subunit A  or topoisomerase IV. Error bars 
indicate the standard errors of the means. Error bars are not shown if 
obscured by the symbol. Differences in survival are not significant.
ml) required mutations in both gyrA and parC. The same sec­
ond-step mutation occurred irrespective o f the starting point.
Single-step fluoroquinolone resistance in gyrA occurs at low 
or no cost to B. cepacia, and this has been observed for other 
bacteria (11, 1, 16). These mutants may, therefore, remain in 
the bacterial population in the absence of an antibiotic selec­
tive pressure.
We thank Tyrone Pitt (HPA, London, United Kingdom) for advice 
and for kindly providing reference strains.
REFERENCES
1. Bagel, S., V. Hullen, B. W iedem ann, and P. H eisig . 1999. Im pact o f gyrA and 
parC  m utations on  qu ino lone  resistance , doub ling  tim e, and  supercoiling 
degree o f Escherichia coli. A n tim icrob . A gen ts  C hem other. 43:868-875.
2. Beyer, R., E. Pestova, J. J. M illichap, V. Stosor, G. A. N oskin, and L. R. 
Peterson. 2000. A  conven ien t assay fo r estim ating  the possible involvem ent 
o f efflux o f  fluoroqu ino lones by Streptococcus pneum oniae  and Staphylococ­
cus aureus: evidence fo r d im in ished  m oxifloxacin, sparfioxacin, and trova- 
floxacin efflux. A ntim icrob . A gen ts C hem o th er. 44:798-801.
3. Billington, O. J., T . D. M cHugh, and S. H. G illespie. 1999. Physiological cost 
o f rifam pin resistance induced  in v itro  in M ycobacterium  tuberculosis. A n ti­
microb. A gents C hem other. 43:1866-1869.
4. Chen, F. J., and H. J. Lo. 2003. M olecu la r m echanism s o f  fluoroquinolone 
resistance. J. M icrobiol. Im m unol. Infect. 36 :1-9.
5. Conway, B.-A. D., V. Venu, and D. P. Speert. 2002. Biofilm  fo rm ation  and 
acyl hom oserine lac tone  p ro d u c tio n  in the  Burkholderia cepacia com plex. J. 
B acteriol. 184:5678-5685.
6. Drabick, J. A., E. J. Gracely, G. J. Heidecker, and J. J. LiPum a. 1996. 
Survival o f Burkholderia cepacia on  env ironm en ta l surfaces. J. H osp . Infect. 
32:267-276.
7. Drlica, K., and M. M alik. 2003. F luoroqu ino lones: action and resistance. 
C urr. T op . M ed. C hem . 3:249-282.
8. Drlica, K., and X. Zhou. 1997. D N A  gyrase, topo isom erase IV , and the 
4 -qu ino lones. M icrobiol. M ol. Biol. Rev. 61:377-392.
9. G illespie, S. H., S. Basu, A. L. D ickens, D. M. O'Sullivan, and T. D . M cHugh. 
2005. E ffect o f sub inh ib ito ry  concen tra tions of ciprofloxacin on M ycobacte­
rium  fo r tu itum  m u ta tion  rates. J. A ntim icrob. C hem other. 56:344-348.
10. G illespie, S. H., L. L. Voelker, J. E. Ambler, C. Traini, and A. Dickens. 2003. 
F luo ro q u in o lo n e  res is tance  in Streptococcus pneum oniae: evidence tha t gyrA 
m u ta tions  arise  a t a  low er ra te  and tha t m uta tion  in gyrA o r parC  p redisposes 
to  fu r th e r  m u ta tion . M icrob. D rug  Resist. 9:17-24.
11. G illespie, S. H., L. L. Voelker, and A. Dickens. 2002. Evolutionary barriers  to  
q u ino lone  res is tance  in Streptococcus pneum oniae. M icrob. D rug Resist. 
8 :79-84.
12. Gocke, E. 1991. M echan ism  o f qu ino lone  m utagenicity  in bacteria . M utat. 
R es. 248:135-143.
13. Hooper, D. C. 2003. M echan ism s o f  quino lone resistance, p. 41-67. In  D. C. 
H o o p e r  an d  E. R u b en s te in  (ed .), Q uino lone  antim icrobial agents. ASM  
P ress, W ash ing ton , D C.
14. Isles, A., I. M aclusky, M . Corey, R. Gold, C. Prober, P. Fleming, and H. 
Levison. 1984. P seudom onas cepacia  infection in cystic fibrosis: an em erging 
p rob lem . J. P ed ia tr . 104:206-210.
15. Jenkins, C. 2005. R ifam p ic in  resistance in tuberculosis ou tbreak , London, 
E ngland. E m erg . Infect. D is. 11:931-934.
16. Kugelberg, E., S. Lofm ark, B. W retlind, and D. I. Andersson. 2005. R educ­
tion  o f th e  fitness b u rd en  o f  qu ino lone  resistance in Pseudom onas aentginosa. 
J. A n tim icrob . C h em o th e r. 55:22-30.
17. LiPuma, J. J. 1998. Burkholderia cepacia. M anagem ent issues and new in­
sights. C lin . C hest M ed. 19:473-486.
18. LiPum a, J. J ., S. E. D asen, D. W. N ielson, R. C. Stern, and T. L. Stull. 1990. 
P e rson -to -person  transm ission  o f Pseudom onas cepacia  betw een patien ts  
w ith cystic fibrosis. L ance t 336:1094-1096.
19. Luria, S., and M. D elbruck. 1943. M utations o f bac teria  from  virus sensitivity 
to  virus resistance . G en e tics  28:491-511.
20. M am ber, S. W., B. K olek, K. W. Brookshire, D. P. Bonner, and J. Fung- 
Tomc. 1993. A ctiv ity  o f qu in o lo n es  in th e  A m es Salm onella  TA 102 m utage­
nicity te st an d  o th e r  b ac teria l genotoxicity  assays. A ntim icrob. A gents C he­
m o ther. 37 :213-217.
21. Rosche, W. A., and P. L. Foster. 2000. D eterm ining m utation rates in bacterial 
populations. M ethods 20:4-17.
22. Sanchez, P., J. F. L inares, B. Ruiz-Diez, E. Campanario, A. Navas, F. 
Baquero, and J. L. M artinez. 2002. F itness of in vitro selected Pseudom onas 
aeruginosa na lB  an d  n fxB  m u ltid rug  resistan t m utants. J. A ntim icrob. C he­
m o ther. 50:657-664.
23. Sierra, J. M ., J. G. C abeza, C. M. Ruiz, T. Montero, J. Hernandez, J. M ensa, 
M. Llagostera, and J. Vila. 2005. T he selection  of resistance to  and the 
m utagen icity  o f  d iffe ren t fluo roqu ino lones  in Staphylococcus aureus and 
Streptococcus p n eu m o n ia e . C lin. M icrobiol. Infect. 11:750-758.
24. Sm ith, S. M ., R. H . Eng, and F. T. Padberg, Jr. 1996. Survival o f nosocom ial 
pa thogen ic  b ac te ria  at am b ien t te m p era tu re . J. M ed. 27:293-302.
25. Youmans, G. P., and A. S. Y oum ans. 1949. A  m ethod  for the determ ination  
o f  the ra te  o f grow th  o f  tub e rc le  bacilli by the use o f small inocula. J. 
B acterio l. 58:247-255.
26. Y sem , P., B. C lerch, M . C astano, I. Gibert, J. Barbe, and M. Llagostera. 
1990. Induction  o f  SOS genes  in Escherichia coli and m utagenesis in Salm o­
nella typhim urium  by fluoroqu ino lones. M utagenesis 5:63-66.
27. Zhou, J., Y. D ong, X. Zhao, S. Lee, A. Amin, S. Ramaswamv, J. Domagala, 
J. M. M usser, and K. D rlica. 2000. Selection o f an tib io tic-resistan t bacterial 
m utan ts: allelic divcrsitv  am ong  fluoroqu ino lone-resistan t m utations. J. In­
fect. D is. 182:517-525. ’
D
ow
nloaded 
from 
aac.asm
.org 
by 
on 
N
ovem
ber 27, 2008
A n t im ic r o b ia l  A gents a n d  Ch e m o t h e r a p y , Apr. 2008, p. 1209-1214 
0066-4804/08/$08.00+0 doi:10.1128/AAC.01152-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Vol. 52, No. 4
MINIREVIEW
A Practical Guide to Measuring Mutation Rates in Antibiotic Resistancev
Cassie F. Pope, Denise M. O’Sullivan, Timothy D. McHugh, and Stephen H. Gillespie*
Centre for Medical Microbiology, Royal Free and University College Medical School,
Rowland Hill Street, London NW 3 2PF, United Kingdom
Bacteria become resistant to antibacterial agents by three 
main mechanisms: acquisition o f complete resistance genes or 
gene complexes via plasmids and other transposable elements 
(12,16, 21, 26, 30), recombination of D N A  from other bacteria 
into the genome by transformation (6), and spontaneous mu­
tational events in the chromosome and accessory D N A  (14). 
Horizontal gene transfer in bacteria has been reviewed by 
Thomas and Nielsen (31). This minireview will concentrate on 
the study of chromosomal mutations that confer resistance. 
Mutational events are assumed to be stochastic, so that the 
rate of beneficial mutation does not occur at a higher fre­
quency than those that are neutral or disadvantageous and that 
mutations are not directed. For bacterial cells, there is a finite 
probability that a mutation conferring the resistant phenotype 
will occur, and unless a revertant mutation occurs, all o f the 
progeny of such a cell will be resistant also. An important 
review by Rosche and Foster which critically analyzes mutation 
rate determination methods lays the foundation o f this mini­
review (29). The terms and abbreviations used here are defined 
in Table 1.
MUTATION RATE OR MUTATION FREQUENCY
A  mutation rate is an estimation o f the probability of a 
mutation occurring per cell division and corresponds to the 
probability of a mutation occurring in the lifetime of a bacterial 
cell. A mutation frequency is simply the proportion of mutant 
bacteria present in a culture. These terms are often used in­
terchangeably, causing confusion. The relationship between 
mutation frequency and the rate at which mutations occur is 
uncertain. If a mutation arises early in the culture period, then 
a large number of mutant progeny occur and this would be 
represented by a high frequency. This phenomenon is known 
as a “jackpot culture” and was first described in 1943 by Luria 
and Delbruck during their seminal set o f experiments investi­
gating the mutation of Escherichia coli from bacteriophage T1 
sensitivity to resistance (19). Understanding of this phenom e­
non was the crucial evidence indicating the role o f mutation in 
phage resistance and underpins all o f the work on mutation 
that followed.
* Corresponding author. Mailing address: Centre for Medical Mi­
crobiology, Royal Free and University College Medical School, Row­
land Hill Street, London NW3 2PF, United Kingdom. Phone: 44
(0)207 794 0500. Fax: 44 (0)207 794 0433. E-mail: s.gillespie@medsch
.ucl.ac.uk.
v Published ahead of print on 4 February 2008.
FLUCTUATION TEST OF LURIA AND DELBRUCK
Luria and Delbruck demonstrated that bacteriophage-resis­
tant mutant colonies arise from a sensitive culture of E. coli if 
bacteriophage T1 is present in excess (19). Resistant colonies 
appeared from sensitive cultures, i.e., in which there was clear­
ing, within 12 to 16 h. These bacteria were resistant to bacte­
riophage T1 but sensitive to other viruses capable of causing 
lysis in that strain o f E. coli. Luria and Delbruck showed that 
reversion to sensitivity was a rare event and that, in a growing 
culture, the proportion of resistant bacteria increased with 
time. They argued that if the presence of the phage was needed 
to trigger the change to resistance, then the distribution of 
mutant colonies should demonstrate a Poisson distribution. 
The high variance in the numbers of mutants in the culture, 
however, led Luria and Delbruck to conclude that resistant 
mutants were present in the culture before bacteriophage ex­
posure and that the bacteriophage resistance mutation arose 
independently. The Luria-Delbriick distribution is different 
from the Poisson distribution in that its variance is greater than 1.
Luria and Delbruck assumed that for a bacterium there was 
a small fixed chance that a resistance-conferring mutation 
could occur per unit o f time if the bacteria are “in an identical 
state.” The number o f mutated cells in a culture depends on 
how early the mutation occurred during the growth of the 
bacterial population. If mutation occurs early in the culture, 
the number o f mutated cells will be higher than if it occurs 
later. M easurement o f the mutation rate, rather than fre­
quency, should be the standard in antibiotic research. A l­
though the protocols and calculation methods are more com­
plex, they are not as inaccessible as it might appear.
DETERMINATION OF MUTATION RATE
Broadly, there are two methods for determination of the 
mutation rate: mutation accumulation and fluctuation analysis. 
Mutant accumulation methods have the advantage that they 
are very accurate, but they are complicated and time-consum­
ing to perform because the culture is sampled at multiple time 
points. The methodology depends on growing bacteria expo­
nentially until probability dictates that a mutant will be 
present. If the assumption is made that the growth rates of 
wild-type and mutant bacteria are the same, then the propor­
tion of mutants will increase linearly with time. Furthermore, if 
the number of mutants and the total number of bacterial cells 
are known at each time point, then the mutation rate (p.) can 
be calculated from the slope of the line describing the rela-
1209
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TABLE 1. Terms and abbreviations used in this minireview
Term Definition
m ................................................No. of mutational events/culture
|x.................................................Mutation rate
r ..................................................Observed no. of mutants
x ..................................................Median no. of mutants
C.................................................No. of cultures
p 0................................................Proportion of cultures without mutants
N0...............................................Initial no. of cells
Nt ...............................................No. of cells at time t
f ..................................................Mutant frequency
n .................................................No. of generations
tionship between the number o f mutants against the genera­
tion number. The mutation rate can be determined by using 
the equation p. =  [(r2/N2) ~  (rJN J] X  In (N 2/N ]) = (/, -  f 2) X 
In (N2/N i), where r, is the observed number of mutants at time 
point 1, r2 is the observed number o f mutants at the next time 
point, and N 1 and N 2 are the numbers o f cells at time points 1 
and 2, respectively, while and f 2 are the mutant frequencies 
at points 1 and 2.
For this method to be accurate, a very large difference in the 
total cell number is required between (the number o f cells 
at the first time point) and N 2 (the number o f cells at the 
second time point) Serial dilutions would make this easier to 
perform, but this introduces sampling errors. If available, con­
tinuous culture would be an alternative but this would allow 
the selection of waves o f bacteria, each better suited than the 
generation before to take over the culture (25). Moreover, 
many studies have shown that the acquisition of a mutation 
providing resistance is associated with a significant fitness def­
icit, which invalidates one o f the basic premises of the mutant 
accumulation method, as less fit mutants will accumulate at a 
different rate than the parent (3). For this reason and for 
greater simplicity, fluctuation methods are more commonly 
used, and this minireview will concentrate on describing vari­
ous- applications o f this approach.
FLUCTUATION ANALYSIS IN ANTIBIOTIC RESEARCH: 
GENERAL PRINCIPLES
Fluctuation analysis involves estimating the mutation rate 
from the distribution of mutants in a number of parallel cul­
tures. This method was pioneered by Luria and Delbruck (19). 
Briefly, an initial inoculum of cells (with a known cell volume) 
from a growing culture is added to a broth and incubated in the 
absence of selective pressure. The bacterial cells are concen­
trated and screened for antibiotic-resistant mutant cells by 
plating the whole cell population onto solid medium contain­
ing a suitable concentration of the test antibiotic, usually at two 
to four times the MIC. It is assumed that this will inhibit the 
growth of susceptible cells, leaving only resistant mutants. A  
plate count is performed on a portion of the culture to deter­
mine the number of viable cells in the cell deposit. The method 
of Miles and Misra can be used to determine viable cell num­
bers. This method involves the spotting o f replicate 20-p.l drops 
of broth onto a plate and counting o f the colonies that grow 
within that spot. This reduces the bacterial cells that are lost by 
spreading (23). Luria and Delbruck suggested two methods for
A n t im ic r o b . A g e n t s  C h e m o t h e r .
estimating the overall mutation rate of the population: the p Q 
method, which is based on the proportion of cultures in which 
there are no mutants observed, and the method of the mean, 
which relies on the determination of the mean number of 
mutants. Both methods assume a Poisson distribution with a 
mean and variance equal to the product of the probability of a 
mutation and the number of bacteria. All of the methods 
described in this minireview use an estimate of the number of 
mutational events (not the number of mutants), m, to deter­
mine the mutation rate and have a Luria-Delbriick distribution 
(19). Parameter m  will be influenced by the amount of growth 
and the mutation rate (p.). The estimated value of m  can be 
divided by the total number of cells to give the mutation rate.
DESIGNING A MUTATION RATE EXPERIMENT
Choice of selective antibiotic. Ideally, mutation rates should 
be calculated by using an antibiotic to which resistance arises 
via a mutation at a single base pair for the reasons noted above. 
This situation rarely arises, and consequently, pragmatic com ­
promises must be made. Manipulating the culture volume 
growth conditions and durations enables these methods to be 
adapted to answer a wide range o f questions in antibiotic 
research.
The choice of the selecting agent depends on the purpose of 
the experiment. Antibiotics which are most suitable for muta­
tion rate methods are those to which resistance arises as a 
result of point mutations in chromosomal genes, including the 
aminoglycosides, quinolones, rifampin, pyrazinamide, and iso- 
niazid (10). If one wants to measure the rate of resistance to a 
particular antibiotic, then the nature of the drug-bacterium 
interaction will dictate how the parameters vary and “ranging” 
experiments may be required. N ot all of the colonies growing 
on the selective plate will contain the same mutation. Thus, a 
mutation rate calculated by including confirmed mutations in a 
single target gene will be lower than a phenotypic mutation 
rate due to the presence o f multiple target genes and nonhe- 
ritable changes. In antibiotic research, it is usual that lethal 
selection for preexisting mutations, as in the case of the exper­
iment o f Luria and Delbruck, is being tested, and this is dif­
ferent from the nonlethal selection used by Cairns et al. in their 
“directed-mutation” experiments with Lac, which allowed mu­
tants arising postplating to grow (5).
Parameters. For each mutation rate experiment, there are 
three main parameters which must be considered, i.e., the 
expected number o f mutational events, the number of cultures 
to be examined, and the size o f the initial inoculum.
If the p 0 method is to be used, m  should be between 0.3 and 
2.3 mutational events per culture. If m  is less than 0.3, then 
none of the mutation rate methods are reliable. When m is 
greater than 2.3, the Luria and Delbruck method of the mean 
can be used to estimate the mutation rate (19). Methods of the 
mean or median described below have constraints on the num­
ber of mutants per culture if the results are to be valid, and 
these ranges are shown in Table 2.
The number o f mutational events present in the culture 
depends on the mutation rate itself and the amount of growth. 
Growth conditions will vary between bacterial species. For 
example, culture aliquots of Streptococcus pneumoniae cannot 
be incubated for extended periods. This is due to the activity of
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TABLE 2. Appropriateness of different methods for 
different values of m
V alue o f m  (no. of
M ethod  m uta tional events/
cu ltu re)
p 0 method................................................................................0.3 < m s 2 . 3
Method of the mean.............................................................Any
Lea and Coulson method of the m edian....................... 1.5 ^  m 15
Drake formula....................................................................... m >  30
the cell wall autolysin, which results in a decrease in the viable 
cell count following extended incubation (15). The value of m 
can be manipulated by inoculating different volumes of broth 
onto solid medium, but this can introduce errors (see below). 
The choice of methods will vary with different values of m, and 
therefore the method chosen will depend on the expected 
value of m.
Number of cultures. The second crucial parameter is the 
number of parallel cultures (C) chosen to represent the bac­
terial population. Irrespective of the method used, the preci­
sion of m  is a function o f l / \ / C  and increases as C increases; 
if more cultures are tested, then precision is increased. Be­
tween 20 and 30 cultures are routinely included (2). For the p 0 
method, a precision level o f 20% is considered necessary to 
provide a suitable estimate of the number of mutational events 
per culture (29). Precision is the coefficient o f variation, u„Jm, 
multiplied by 100% and has been calculated as 0.2 (29) and is 
a measurement o f the reproducibility o f results, as opposed to 
accuracy.
Size of initial inoculum. The final parameter is the size of 
the initial inoculum (N 0). This inoculum should not contain 
any preexisting mutants, and thus it should be small. For ex­
ample, in their E. coli experiments, Luria and Delbruck used 
an initial inoculum of between 50 and 500 bacteria (19). The 
smaller the initial inoculum, the longer the incubation period. 
This is especially important when working with slow-growing 
cultures, e.g., Mycobacterium tuberculosis. We have found that 
between 3,000 and 5,000 cells/ml is sufficient as the initial 
inoculum for S. pneumoniae and M. tuberculosis, respectively. 
There are other complications involved in growing small num­
bers of organisms. For example, many organisms monitor the 
density of cells via quorum sensing and only switch on viru­
lence genes after a quorum o f bacteria is present (24, 28). A  
small inoculum may produce a reduction in viability, resulting 
in greater variation in the final number of cells (N t). In each 
parallel culture, the final cell number ( N{) should be the same 
and the value of N 0 should always be negligible compared to N t 
(a ratio of at least <1:1,000 is desirable). Variations in N t can 
be eliminated by using a large initial inoculum. Rosche and 
Foster (29) found that, in their experiments, a pragmatic com ­
promise between the above factors was to use an initial inoc­
ulum of total cells of m N t /104 (3, 9 ,10 ). To reduce variability, 
the initial inoculum should consist of an even cell suspension. 
This is especially important when working with organisms such 
as M. tuberculosis, which tend to form cellular aggregates. To 
overcome this problem, the initial inoculum should be passed 
through a fine-needle syringe or a filter to form a single-cell 
suspension. Additionally, Middlebrook 7H9 broths contain 
Tween 80 to reduce clumping (3).
Additional relevant considerations, (i) Volume. In order to 
observe a mutation, it is necessary to have a large enough final 
cell number. The size of this final cell number is a function of 
the culture volume and the mutation rate. If the mutation rate 
is high, then a small broth culture can be used, and if the rate 
is low, then larger cultures must be used.
(ii) Cell cycle. Mutation rates may be influenced by the 
growth phase o f the cell. Determinations of mutation rates are 
usually performed by using cells growing in exponential phase 
(3, 10). There are reports, however, that mutation rates in E. 
coli are elevated in stationary phase compared to exponential 
phase (15, 18). The initial inoculum of cells should contain 
cells that are in the same phase of the growth cycle in order to 
compare estimated rates. Therefore, a growth curve should be 
constructed during method optimization. To reduce the degree 
o f variability in these experiments, all of the above parameters 
should be kept constant between experiments.
ASSUM PTIONS OF FLUCTUATION ANALYSIS
Each mutation rate method relies on a set of pragmatic 
assumptions that are made in order to make estimations pos­
sible. (i) The probability of the mutation occurring is constant 
per cell lifetime, (ii) The probability of this mutation occurring 
does not vary between growth phases, (iii) There is no cell 
death, (iv) Revertants occur at a negligible rate, (v) Mutation 
occurs only during cell division and results in only one mutant.
(vi) The growth rates o f  mutants and nonmutants are the same.
(vii) Initial cell numbers are negligible compared to the final 
cell numbers, (viii) A ll mutants are detected, and no mutants 
occur after selection is imposed. However, these assumptions 
may not be true in all situations. Mutation rates of the same 
organism that are obtained by using the same selection tool 
and estimated via different methods can be very different.
DEVIATIONS FROM THE ASSUMPTIONS
Fitness o f mutants. As noted above, mutation rate calcula­
tion methods assume that there is no physiological impairment 
of mutants with respect to their susceptible parents. If mutants 
do not grow as efficiently as their parents, they may not be 
detected and this may affect the calculated mutation rate. 
There are examples in which mutations responsible for resis­
tance occur at no or low cost. For example, the rpsL Lys42Arg 
mutation, which confers resistance to streptomycin in Salmo­
nella enterica serovar Typhimurium, incurs no measurable cost. 
In contrast, the Lys42Thr and Lys42Asn mutations associated 
with resistance incur a heavy fitness burden (4). For example, 
the parC  and gyrA mutations, conferring fluoroquinolone re­
sistance, incur no or low cost in S.pneumoniae (11). The extent 
of a fitness deficit is dependent on the nature of the mutation, 
as demonstrated by M. tuberculosis, where there is a relation­
ship between the rates at which various resistant mutants are 
found in clinical practice and the initial fitness deficit of the 
mutant strain (3, 8, 22).
Completeness of detection. It is possible that not all muta­
tions are detected. For example, mutations that occur late in 
the culture may not give rise to colonies and these mutants will 
not be counted. This phenomenon is known as phenotypic lag. 
Importantly, it is also possible that mutations may occur after
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selection has been imposed; i.e., mutants may arise on antibi­
otic-containing solid medium. In order to overcome these is­
sues, some preliminary ranging experiments could be pre­
formed which would ensure that the correct initial inoculum 
and the correct final plating volum e are used. Colonies should 
be counted as earlier as possible to minimize the number of 
postplating mutants that could occur.
Other factors. There are a number o f other factors that 
complicate the calculation o f mutation rates. For example, 
mutation rates are not constant in a population of cells. They 
can vary depending on the antibiotic concentration (13) and 
the availability o f the carbon source (1).
PLATING A PORTION OF THE CULTURE
It is assumed that all mutants are detected. Plating a portion 
of the culture can introduce an error in the estimation of m. 
Some of the methods used to determine the rate of mutation 
have been derived to take sampling into account. Ma et al. (20) 
and Jones (14) have altered their fluctuation analysis method 
to show that it is possible to plate an aliquot of the culture 
volume when there is a large final inoculum. It is also possible 
to plate a portion of a large culture rather than using multiple 
small cultures, and Crane et al. have proposed a modified 
fluctuation assay for the estimation of mutation rates where 
small increases in the mutation rate are expected (6).
VARATIONS ON THE LURIA-DELBRUCK METHOD FOR 
MUTATION RATE ESTIMATION
No satisfactory solution o f the Luria and Delbruck distribu­
tion has been found that effectively describes the distribution 
numerically. Therefore, extensive attempts have been made to 
improve the accuracy of the estimates (2, 15). The practical 
effect of this is that mutation rates estimated via different 
methods cannot be compared.
CALCULATION METHODS
The p 0 method. The p 0 method is the simplest method to 
calculate and is the one originally described by Luria and 
Delbruck in their seminal paper (19). It is most suitable when 
the number o f mutational events in a culture is low. This 
method has successfully been used to estimate mutation rates 
in M. tuberculosis (3) and S. pneumoniae (10).
The proportion of cultures without mutants {p0) is the zero 
term of the Poisson distribution given by the equation p n =  
e~m. This method should only be used if the proportion of 
cultures without mutants is between 0.1 and 0.7, i.e., the num­
ber of mutational events per culture is between 0.3 and 2.3. 
The formula can be rearranged to give the number of muta­
tional events as follows: m =  — In p Q.
Multiple parallel cultures are performed and scored as pos­
itive if they yield a resistant mutant, i.e., show growth. When 
the proportion o f mutants detected is known, then the actual 
value of m  can be calculated. There is no need to enumerate 
the colonies, and this simplifies the process. It should be noted 
that the precision o f m  varies depending on the value of p 0. 
Compared with other methods, the p 0 method requires more 
cultures for the same level o f precision when m >  1.2. As
cultures are scored as either positive or negative for growth, 
mutations that affect the growth rate of the progeny cells have 
less effect in the p 0 method than on other methods. A clone 
that does not give rise to a colony would add to the proportion 
of cultures without mutants erroneously. Conditions of growth 
and culture volume need to be chosen so that the proportion of 
resistant cultures is in the appropriate range. The p Q estimator 
method is very sensitive to phenotypic lag, postplating muta­
tions, and decreased plating efficiency, as these will increase 
the value of p 0. Some o f the progeny o f each mutant will be lost 
if the plate efficiency is less than 100%. This will be the normal 
situation in most culture systems; thus, cultures with few mu­
tants may be counted as cultures with no mutants.
Methods using the mean. The mean estimator methods use 
the observation that when a population is large enough there 
will be an extra pA t mutants after each generation as each of 
the cells in the final population may undergo mutation. The 
probability of this occurring is determined by the mutation rate 
(p). Therefore, the extra number of mutants will be a product 
of these two terms. The time period after the point when the 
bacterial population of all cultures has reached the required 
size when this may occur is 1/p and is known as the Luria- 
Delbriick period. The mean methods should not be used if 
there is no Luria-Delbriick period, i.e., if TV, <  1/p. Methods 
that use the mean are disproportionally inflated by jackpot 
cultures and are not recommended. They can be made more 
accurate by removing data points caused by jackpot cultures, 
but this makes the approach somewhat arbitrary, with data 
being removed by the investigator. M ethods using the median 
are more accurate and will be discussed in more detail below.
Lea and Coulson method o f the median. Lea and Coulson 
(17) attempted to develop a method with better precision than 
the method of the mean. The function m  is calculated from the 
equation (x/m ) — In m = 1.24.
The method assumes that if the median number of mutants 
is large enough, then most mutations occur early enough to be 
detected. From a practical point o f view, a greater number of 
selective plates (approximately 5 to 10) are needed for this 
method to give an adequate precision level. An additional 
drawback to the increased number of plates required is that 
median methods should not be used if more than half of the 
plates are devoid o f mutants. It is used when all or most of the 
cultures give rise to mutant colonies, and it has been quoted as 
the method of choice (excluding maximum-likelihood meth­
ods) if m is between 1.5 and 15 and if the median number of 
mutational events in a culture is between 2.5 and 60. The main 
drawback o f the m ethod is that it is sensitive to any variation in 
the assumptions, e.g., phenotypic lag and altered growth rate of 
progeny, described previously, which results in reduced preci­
sion.
Drake formula using the median. The Drake formula using 
the median provides an easy option to make an estimate of the 
mutation rate from frequency data, given by the equation p = 
//In (/V, p), where / i s  the final mutation frequency (7). By using 
the median final mutation frequency and not the mean final 
mutation frequency, the impact of jackpot mutations is re­
duced. It can be used when the number of mutational events 
per culture is high, i.e., ^30. This method has been used to 
estimate rates o f mutation of S. pneumoniae to fluoroquin­
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olone resistance and o f Mycobacterium fortuitum  to fluoroquin­
olone, macrolide, and aminoglycoside resistance (9).
Jones median estimator. Jones calculated the hypothetical 
dilutions required so that half o f  the selective plates in a 
putative experiment had mutant colon ies (14). Under these 
circumstances, other median m ethods cannot be used. The 
Jones method has the advantage that it relies on the ob­
served number of mutant co lon ies to estim ate m by an 
explicit equation. Jones (14) verified this method against the 
Lea and Coulson m ethod o f the m edian, by using computer 
simulations, for values o f m  betw een 1.5 and 10 and showed 
that it is more efficient than the Lea and Coulson method of 
the median. Crane et al. m odified the m ethod so that it can 
be used to give more precise m utation rate measurements. 
In this method, a portion o f larger-volum es cultures is 
plated rather than the w hole o f sm aller-volum e cultures (6); 
this allows more mutants to accum ulate. We have used this 
method to estimate the rate o f the rpoB  mutation, which 
confers rifampin resistance (3).
CHOOSING A METHOD
There may be a number o f differences between methods, but 
they all use similar functions. Since the pivotal experiments by 
Luria and Delbruck in the last century, novel methods for the 
calculation of the Luria-Delbriick distribution have made the 
estimation of mutation rates more accurate and easy to per­
form. The most useful methods are the p 0 method (2) and the 
Jones median estimator together with the modification of 
Crane et al. for partial plating (6).
Mutation rate studies have been performed with a number 
of organisms related to antibiotic research, including E. coli, 5. 
pneumoniae (10), Pseudomonas aeruginosa (27), and M. tuber­
culosis (3). Oliver et al. used the modification by Crane et al. of 
the Jones estimator to show that antibiotic-resistant isolates of 
P. aeruginosa were present prior to antibiotic therapy due to 
the existence of hypermutable bacteria (27). As large broths 
were used, aliquots from these broths were taken to reduce 
culture-to-culture variation (27). For example, Billington et al. 
also used this method for experiments with M. tuberculosis for 
similar reasons (3). Mutation rate experiments with S. pneu­
moniae have been used to show that mutations in the gyrA gene 
occur at a lower rate than parC  mutations and that mutations 
in either gene predisposes to further mutation (10). The Drake 
method was used when ciprofloxacin was the selective antibi­
otic as the number o f mutational events per culture was >30. 
However, the p 0 m ethod was used with gemifloxacin as 
the number of mutational events was sm aller (betw een 0.3 
and 2.3).
SUMMARY
Whichever method is chosen, the experimental factors 
should be optimized to improve the precision and accuracy of 
the estimation. It is usually necessary to perform preliminary 
experiments to provide estimates o f the mutation rate, and as 
has been stated previously, it is usually helpful to determine 
growth curves to confirm that the bacteria are in the same 
growth phase when the mutation rate estimation cultures are 
inoculated. The growth conditions o f the experiment can only
be established with the knowledge of the expected mutation 
rate, which requires preliminary experiments to enable the 
researcher to develop the necessary protocol. When mutations 
are likely to be rare, then m  is, by definition, small and thus the 
p 0 method is likely to be the most useful. When m is greater, 
then median methods are most appropriate. The choice of 
calculation method will depend on whether all of the cultures 
were positive, with a median method being chosen for situa­
tions in which all are positive and the p 0 when this is not the 
case.
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Acquisition o f  antibiotic resistance may or may not be associated with a physiological 
cost for the bacterium. Measurement o f planktonic growth rate, by competitive 
growth assays between the resistant mutant and the susceptible parent is a com­
monly used measure o f fitness. However, fitness is a complex characteristic and 
multiple models are required to measure fitness costs, which may be small and 
difficult to quantify. Available in vitro models that can be used to quantify this fitness 
cost when compared to the susceptible parent include quantification o f  biofilm 
growth, survival in water, resistance to drying and alternative methods to determine 
planktonic growth rate. It is an accepted belief that decreased antibiotic use will 
reduce rates o f  resistance. However, some mutations conferring resistance result in a 
small or non existent fitness cost These isolates may out compete the susceptible 
isolate and may remain in the bacterial population to form a pool o f  resistant 
organisms, which can rapidly proliferate i f  the selective antibiotic pressure is reap­
plied.
Introduction
Antibiotic resistance in a bacterial population occurs due to  selection of 
resistant mutants in the presence of antibiotics.The existence of a continuing 
antibiotic selective pressure is responsible for high levels of antibiotic resist­
ance. W hen bacteria are exposed to  antibiotics a m utation conferring resist­
ance to  that antibiotic gives the bacterium an obvious advantage. However it is 
an accepted dogma that a resistant organism pays a physiological price for 
resistance, particularly resistance mediated by chrom osom al m utations 
(Andersson & Levin 1999; Levin et al. 2000). It is an accepted belief tha t with 
rational use of antibiotics, resistant m utants will be ou t-com peted by their 
susceptible coun terparts and will be lost from  the population. Although studies 
have shown th a t acquisition of antibiotic resistance can incur a biological cost 
(Andersson & Levin 1999; Gillespie & McHugh 1997) there  is evidence that 
som e mutations conferring resistance may result in a small o r  none existent 
fitness deficit (Gillespie 2001; Gillespie et al. 2002; Kugelberg et al. 2005). 
Furtherm ore, quantification of fitness costs is im portant when determining the 
stability of antibiotic resistance in a population.
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Fitness and Antibiotic Resistance
Fitness is a com plex characteristic tha t encompasses the ability of a genotype 
to  reproduce within a host, be transm itted and be cleared. It is also a m easure 
of how well bacteria survive in defined environments.The m ajor factors that 
influence the  frequency of antibiotic resistance in a population of bacteria are 
the ex ten t of antibiotic use, the cost of resistance and the ex ten t th a t the 
bacteria can com pensate for this cost.W ithin a population of bacteria different 
genotypes m ust com pete with each o ther to  reproduce.Therefore, incidence 
of resistance can be reduced by the rational use of antibiotics as resistant 
bacteria can be selected against in the absence of antibiotics due to  a fitness 
cost. However, resistance will not disappear from  the population. If m utations 
conferring resistance have a low fitness cost, o r no cost, then these m utants 
may remain a t high levels in the bacterial population if antibiotic use is w ith­
drawn o r may return  to  high frequencies if antibiotic pressure is reintroduced.
Models o f  Fitness
In vitro models of fitness have been used in o rder to  investigate the evolution 
of antibiotic resistance and to  assess the physiological price associated with 
acquisition of resistance.The growth rate of a bacteria in culture medium is a 
commonly used model for evaluating fitness (Bennett et al. 1990; Lenski et al.
1998; Lenski, Simpson, & Nguyen 1994; Nguyen et al. 1989). Relative fitness is 
often determ ined by com petition assay between isogenic antibiotic susceptible 
and antibiotic resistant bacteria in culture o r in animal models.These models 
can be adapted for use in many bacterial species. Models should be chosen that 
reflect growth and environmental survival conditions of the bacterial species of 
interest. For example, a suitable biofilm model should be included fo r bacteria 
which are known to  form  biofilms within the human body e.g. Pseudonomas 
aeruginosa within the cystic fibrosis lung (Govan & Deretic 1996; Singh et al. 
2000). Environmental survival e.g. resistance to  drying o r  survival in w ate r is 
relevant for nosocomial pathogens which can be transm itted via contam inated 
surfaces.
Fitness Costs Incurred by Antibiotic Resistance
The carriage of plasmids has been shown to  reduce the fitness of bacteria (Lee 
& Edlin 1985; Nguyen et al. l989;W arnes & Stephenson 1986). Insertion of a 
plasmid reduced fitness of the strain com pared to  the  plasmid free strain. 
However, this fitness deficit was reduced following passage. Restoration of 
fitness may be due to  loss of plasmid containing bacteria from  th e  population 
as plasmid free bacteria outgrow  them  (Lenski & Bouma 1987).This would 
suggest tha t following rational antibiotic use the frequency of resistant bacteria 
may decline, reducing the  spread of antibiotic resistance. Subsequently, it has 
been dem onstrated  th a t with time chrom osom al changes occur tha t increase 
the fitness of the  bacteria plasmid carrying bacteria (Lenski et al. 1994). O ver 
many generations of association the  effects of fitness can be decreased exten­
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sively (Bouma & Lenski 1988; Modi et al. 1991).
C hrom osom al mutations that confer resistance by altering antibiotic targets 
include D N A  gyrase, RNA polymerase, the cell wall o r  the ribosom e and these 
alterations may cause a reduction in fitness (Andersson & Levin 1999; Gillespie 
& McHugh 1997). Mutations in rpsL confer streptomycin resistance in Salmo­
nella Typhimurium due to  changes in the ribosomal protein SI2.These mutants 
have been shown to  be less fit than the wild type due to  a decrease in peptide 
elongation rate  and resulting decrease in slower protein synthesis and growth 
rate (Bjorkman e£ al. 1998). Chromosomal mutations in RNA polymerase (rpoB) 
th a t confer resistance to  rifampicin are associated with a fitness cost in Staphy­
lococcus aureus and Mycobacterium tuberculosis (Moorman & Mandell 19 8 1; 
W ichelhaus et al. 2002).The extent of this fitness cost depends on the resist­
ance m utation.
In 1953 B arnett and colleagues showed that resistance to  isoniazid in M . 
tuberculosis am eliorated disease a guinea pig model (Barnett, et al. 1953). 
Molecular tools have since shown that point mutations in katG  confer this 
isoniazid resistance. Functional katG, integrated to  the genom e, restored  
virulence to  wild type levels (Wilson et al. 1995). In the mouse model, resistant 
strains of At tuberculosis vary in virulence (Ordway et al. 1995), however, 
increased levels of drug resistance were not associated with a reduction in 
virulence.
Compensation o f  Fitness Costs
A deleterious mutation may be lost from the population, revert to  susceptibility 
o r be com pensated for by another mutation. Bacteria which are less fit may 
acquire com pensatory mutations that restore reproductive potential.These are 
mutations tha t occur in another site which am eliorate the cost incurred by the 
initial resistance mutation w ithout the loss of the  resistance.These mutations 
can accumulate to  resto re  fitness and stabilise the population of resistant 
bacteria.
M ost com pensatory mutations that resto re  fitness are no t revertants to  
susceptibility.This may be because the mutation rate fo r o th e r  m utations is 
higher due to  multiple targets. For example, com pensation of fluoroquinolone 
resistance in S. aureus occurs by decreased expression of topoisom erase IV 
(Inee & H ooper 2003). It has also been dem onstrated  tha t the  fitness cost of 
mutations in rpsL, conferring streptomycin resistance in £. coli can be com pen­
sated to  a resto red  rate of protein synthesis following adaptation (Schrag et al. 
1997). Similarly, adaptation experim ents in M . tuberculosis have dem onstrated 
tha t rifampicin resistant rpoB m utants lose the fitness deficit following serial 
passage (Billington et al. 1999).
Isoniazid resistant M . tuberculosis with mutation in katG, resulting in loss of a
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functional catalase, accumulate com pensatory mutations tha t result in in­
creased expression of the ahpC prom oter.The ahpC gene encodes an alkyl 
hydroperoxidase reductase and it has been proposed that these m utations 
increase the expression of this enzyme which protects M. tuberculosis from  
oxidative stress and com pensates for the loss of catalase (Sherman et al. 1996).
Measuring Fitness
Defining fitness cost can be difficult due to  variations in m easurem ents in 
experim ental procedures. N o one m ethod is likely to  be sufficient in isolation 
and therefo re multiple models are required.The models selected will depend 
on the organism, its natural lifestyle and its mode of growth. Fitness deficits will 
vary depending on the resistance mutation, the organism and the model used 
to  quantify the cost. For example, Sanchez et al. assessed the fitness costs 
associated with overproduction of multidrug efflux pumps in P. aeruginosa using 
survival in water, maintenance on dry surfaces, biofilm formation, nem atode 
killing, production of pyocyanin and pyoverdin and quantification of proteases 
(Sanchez et al. 2002).These mutants have been shown to  have fitness costs in 
term s of resistance to  desiccation, survival in water, loss of quorum  sensing 
response and loss of virulence in the nem atode killing model. However, the 
nalB m utant exhibited g rea ter biofilm formation than the wild type (Sanchez et 
al. 2002). Hence, fitness costs may not be evident in all assays and the models 
chosen should reflect the how the organism causes disease in the host.
Fitness costs are measured in a num ber of ways and a variety of in vitro and 
animal models are available.These include comparison of growth rate  in 
m onocultures (Kugelberg et al. 2005). For example, we have used paired 
com petition assays to  assess fitness costs of fluoroquinolone resistance in 
Streptococcus pneumoniae (Gillespie et al. 2002) and Burkholderia cepacia and 
rifampicin resistance in M . tuberculosis (Billington et al. 1999; Davies et al. 2000). 
Relative fitness is defined by the difference in num ber of generations th a t have 
occurred between the susceptible parent and the resistant mutant. W e have 
adapted the m ethod of Youmans and Youmans (1949) to  determ ine generation 
times in a semi autom ated liquid culture system for B. cepacia and M. tuberculo­
sis, using the  difference in time to  positivity of diluted inoculums.These m eth­
ods may minimise observed variation and allow fitness costs to  be calculated in 
term s of generations.
Most studies investigating fitness costs use in vitro models while few have used 
in vivo models.These in vivo studies commonly use competitive colonisation to  
measure fitness (Johnson et al. 2005). For example, fitness of fluoroquinolone 
resistant Campylobacter jejuni, was assessed via colonisation and persistence in 
chickens in the absence of antibiotic selective pressure (Luo et al. 2005). Few 
studies have used human colonization o r  infection to  measure fitness cost. 
Andersson et al. have assessed the fitness costs conferred by parC  and fusR
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mutations, conferring resistance to  fluoroquinolones and fusidic acid respec­
tively, in Staphylococcus epidermidis using a human com petition mode 
(Gustafsson et al. 2003). Susceptible and resistant bacteria w ere inoculated 
on to  human skin and relative numbers monitored. N o loss of fitness associated 
with parC  m utation was found. However fusA mutations resulted in a consider­
able loss of fitness as compared to  the susceptible isogenic strain during 
com petition. It is unrealistic to  assume that in vitro assays, using biological rich 
media, will accurately reflect the fitness costs experienced by the pathogen 
during infection. Fitness deficits may be affected by growth conditions (D urso  
et al. 2004; Remold & Lenski 2001) and so use of a minimal medium may be 
m ore appropriate if in vivo models are not possible.
Biofilm Fitness Models
Biofilms have a role in many infectious diseases. For bacteria tha t grow  as 
biofilms during infection a biofilm quantification assay should be included as a 
fitness assay.This is because the propensity to  form biofilms is likely to  affect 
fitness.There are numerous systems that have been developed and used to 
model the growth of bacterial biofilms. However, no single model is ideal for all 
experim ental scenarios as each as been designed for a specific purpose. For 
use as a fitness assay the model of biofilm growth should be simple and 
reproducible with sufficient replicate biofilms to allow statistical analysis.
G row th within a biofilm can be measured by sacrificing cells from  the biofilm 
by sonication and/or vortexing the biofilm before determ ining viable cell 
num bers estim ated by plate counting, although using this m ethod biofilm 
specific characteristics may be lost. Biofilm growth can also be visualised in situ 
with fluorescent probes and rep o rte r genes (Geesey 2001) as well as using 
imaging software to  estimate biofilm coverage of the surface. Bioluminescence 
is particurarly useful in vitro and in vivo as it allows biofilms to  be m onitored in 
real time (Kadurugamuwa et al. 2003a,b). Models of quantifying biofilm form a­
tion, in selected m odels,are shown in Table I.
The crystal violet m icrotitre plate assay is a simple and rapid m ethod that 
quantifies adherence of bacteria to  the wells of a m icrotitre plate. It is especially 
useful as a fitness assay as replicate biofilms can be grown in large numbers.
The use of a ro b o t can increase reproducibility and partly autom ate the 
procedure. Bacteria are grown in wells of a m icrotitre plate containing a 
suitable medium.Wells are washed to  remove planktonic cells and incubated 
with crystal violet. Unbound crystal violet is rem oved by repeated  washing with 
water. Ethanol is added to  release bound crystal violet and biofilm formation is 
quantified by determ ination of the absorbance of the solution a t 590 nm.This 
assay has been used to study biofilm formation in a num ber of bacteria includ­
ing Escherichia coli (Pratt & Kolter 1998), 8. cepacia complex (BCC) bacteria 
(Conway et al. 2002), Pseudomonas fluorescens (O ’Toole & Kolter 1998b), P. 
aeruginosa (O ’Toole & Kolter 1998a), Vibrio cholerae (W atnick & Kolter 1999)
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and Streptococcus gordonii (Loo et al. 2000) and has been used as a fitness assay 
to  quantify the physiological cost of antibiotic resistance in P. aeruginosa 
(Kugelberg et al. 2005) and B. cepacia.
T able I M odels th a t have been  used to  quantify bacterial biofilm grow th
Model O rganism s Flow Substratum M ethod o f
quantifying
biofilm
Reference
Constant Depth B. cepacia. Continuous Variable Vortex plug, (Hengtrakool, Pearson, &
Film fermenter P.aeruginosa, oral viable count. W ilson 2006; Hope &
(CDFF) bacteria Can be 
observed 
directly by  
SEM and 
CLSM
W ilson 2006; Peters & 
W impenny 1987)
CDC Biofilm Gram  negative Continuous Plastic Sonicate, (Murga el al. 2001)
Reactor bacteria connectors vortex, 
homogenise, 
viable count
M odified Robbins B. pseudomallei. Batch Variable Viable count (Honraet & Nelis 2006;
device P. aeruginosa M ikuniya et al. 
2005;Vorachit et at. 1993)
Calgary biofilm P. aeruginosa, Batch Plastic pegs Sonicate peg, (Ceri et al. 1999)
device S. aureus, 
E. coli
viable count
Sorborads Filter S. aureus,
P. aeruginosa
Continuous Filter paper Vortex, viable 
count
(Hodgson el al. 1995)
Use o f Fitness Models to assess Fitness Costs Associated with Fluoroquinolone 
Resistance Mutations
Fluoroquinolones (FQs) inhibit two homologous enzymes, DNA gyrase and 
topoisom erase IV which consist of two subunits, gyrase is encoded by gyrA and 
gyrB and topoisom erase IV by parC  and pare, respectively. Target alteration, 
together with efflux and reduced permeability are the primary mechanisms 
that confer resistance to  FQs in Gram-negative bacteria (Ince & H ooper 
2003).. Resistance develops via the stepwise accumulation of m utations in the 
Q uinolone Resistance Determining Regions (QRDR) of topoisom erase genes, 
increasing the  level of resistance with each successive mutation (Everett et al. 
l996).The cost of mutations conferring fluoroquinolone m utations has been 
investigated in a num ber of organisms including E. coli (Bagel et al. 1999), S. 
pneumoniae (Gillespie et al. 2002), S. typhimurium (Giraud et al. 2003) and P. 
aeruginosa (Kugelberg et al. 2005).The fitness cost varies in these organisms 
and depends on the resistance mutations. Multiple mutations associated with 
high levels of resistance exhibit reduced fitness.
Conclusion
In a culture, a non fatal deleterious mutation is m ore frequent than the occur­
rence of favourable m utations leading to  an increase in fitness.Therefore an 
accumulation of deleterious mutations will occur, a decline in fitness will be 
observed and the  fittest individuals can eventually be lost from  the  population. 
This has been referred to  a s ‘Muller’s ratchet’(Muller 1964). Andersson and 
Hughes showed tha t Muller’s ratchet also operates in Salmonella typhimurium
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(Andersson & Hughes 1996).
A num ber of fitness models are available that can be used as tools to  assess the 
cost of acquiring antibiotic resistance. The context of a fitness model is impor­
tan t and models should be chosen to  rep resen t how the organism survives in 
the environm ent and causes disease and therefore multiple models may be 
required.
Few studies have investigated the effect of reduction in antibiotic use and 
subsequent levels of resistance in bacterial populations.Austin et al. (1999) 
attem pted  to  quantify the relationship between antibiotic use and frequency of 
resistance.Their findings suggested that significant reduction in antibiotic use is 
required to  cause a significant decline in resistance.This decline in resistance is 
likely to  occur a t a lower rate than the initial emergence of the resistance 
(Austin e ta l. 1999). Reduction in macrolide use within outpatients in Finland 
during the  1990s resulted in a decline in erythromycin resistance in G roup A 
streptococci isolated from  th roat swabs and pus samples (Seppala et al. 1997). 
Isolates containing no cost mutations may not be outcom peted by their suscep­
tible counterparts and may remain in the population to  form  a pool of resistant 
organism s.Therefore rational use of antibiotics, in isolation, may no t be ad­
equate to  reverse the continuing rise in antibiotic resistance.
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Rapid methods to determine fitness in bacteria using automated culture 
systems 
Cassie Pope, Timothy McHugh and Stephen Gillespie 
Abstract
Determination of growth rate and generation time is often used to measure fitness costs 
associated with antibiotic resistance. However the use of growth curve techniques to 
determine generation time is laborious, time consuming and can introduce sampling 
error. We have described the use of a semi automated liquid culture system to estimate 
generation time in Burkholderia cepacia complex bacteria. We have also used the 
BacT/ALERT system to determine generation time and enumerate bacterial numbers in 
Mycobacterium tuberculosis. These methods, therefore, can be adapted for use with 
other organisms. This chapter outlines a method to use the Bactec 9000 series of 
instruments to measure generation time.
Introduction
It is an accepted dogma that a resistant organism pays a physiological price for resistance, 
particularly resistance mediated by chromosomal mutations (1,2). Although studies have 
shown that acquisition of antibiotic resistance can incur a biological cost (1,3) there is 
evidence that some mutations conferring resistance may result in a low or no existent 
fitness deficit (4-6). In vitro models of fitness have been used in order to investigate the 
evolution of antibiotic resistance and to assess the physiological price associated with 
acquisition of resistance. The growth rate of bacteria in culture medium is a commonly 
used model for evaluating fitness as a measure of reproductive potential (7-10). However 
fitness is a complex characteristic that encompasses the ability of a genotype to reproduce
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within a host, be transmitted and be cleared. Multiple models should therefore be chosen 
carefully that represent the mode of life of the organism in question. We have used 
competitive pair wise cultures, growth rate, biofilm formation and environmental survival 
models to assess the fitness cost of acquisition of fluoroquinolone resistance in 
Burkholderia cepacia (11). Relative fitness is often determined by competition assay 
between isogenic antibiotic susceptible and antibiotic resistant bacteria in culture or in 
animal models. These models can be adapted for use in many bacterial species.
Viable cell count estimation is subjective and dependent on enumeration of colonies that 
grow under growth conditions provided, introducing sampling error. By using an 
automated system which is less time consuming and not user dependent, it is possible to 
determine growth rate for large numbers of strains. Youmans and Youmans used the 
difference in time to positivity, measured as time to a certain turbidity, of small inoculums 
of M. tuberculosis to determine generation time (12). We have adapted this method to 
determine generation times in a semi automated liquid culture system for B. cepacia and M. 
tuberculosis, using the difference in time to positivity of diluted inoculums. These methods 
may minimise observed variation and allow fitness costs to be calculated in terms of 
generations. Laurent et al have also used an automated liquid culture system (MS2 
Research System, Abbott Laboratories, Dallas, Tx, USA) and paired competitive cultures 
to determine growth rate, as a measure of fitness in MRSA (13). This chapter describes use 
of a semi automated liquid culture system for measurement of generation time in 
Burkholderia cepacia.
We have used the Bactec 9240 continuous, blood culture system with standard aerobic 
medium was used to determine growth rate in B. cepacia. The Bactec 9000
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(9240/9120/9050) series of automated blood culture systems are used to rapidly detect 
viable microorganisms in clinical specimens and is used in most clinical laboratories with 
in the UK. Bactec Plus Aerobic vials, contain 25 mL of enriched soybean-caesin digest 
broth, 0.05% sodium polyanetholesulfonate (SPS), resins, CO2, O2 and a sensor. This 
sensor, within each vial, responds to changes in oxygen and carbon dioxide levels as a 
result of bacterial metabolism. These changes are measured by an increase in the 
fluorescence of the sensor which is monitored every ten minutes. A positive fluorescence 
reading indicates an increase in CO2 or decrease in oxygen and the presence of 
microorganisms in that vial.
Materials
1. Test organisms
2. Incubator
3. Muller Hinton Broth
4. Orbital incubator
5. Phosphate buffer saline (PBS)
6. Spectrophotometer
7. 0.5 mL syringe
8. 0.5 mm guage needle
9. Bactec automated blood culture system (Bactec 9000 series)
10. Steret alcohol wipes
11. Aerobic Bactec bottles
12. Blood agar plates
13. Microscope
14. Gram stain reagents
15. Glass slides
Methods
1. Grow B. cepacia on Columbia blood agar plates at 37°C for 18 hours
2. Using a sterile loop inoculate one colony of B. cepacia in Muller Hinton broth 
(5mL) and incubate using an orbital incubator (200rpm) for 4 hours to obtain 
an exponentially growing culture. Dilute culture to standard optical density 
using PBS.
3. Dilute culture via serial dilution (10"1 -1 O'6) in PB S.
4. Aseptically inoculate triplicate Bactec bottles with 0.5 mL of the 10'2 and 10'4 
dilutions using steret alcohol wipe, needle and syringe.
5. Invert bottles to mix.
6. Load into system.
7. Incubate until bottles flag as positive.
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8. Print growth curve and time to positivity.
9. Remove bottles and discard.
10. Confirm absence of contaminants by Gram stain and spreading of one drop of 
bottle content onto Columbia blood agar.
The growth rate constant and generation time can be determined by the following 
equations
K  = log a -  log b 
t
G = log 2 
K
Where K  is the growth rate constant, a is the largest inoculum (1:10), b is the smallest 
inoculum (1:1000), t is the difference in time (h) taken for each of the sets of bottles 
to signal positive and G is the generation time.
Notes
1. The Bactec 9000 series of instruments are used by most clinical microbiology 
laboratories and are therefore available for translational research following 
discussion with the service manager and chief Biomedical Scientists.
2. Bactec bottles should be allowed to equilibrate at room temperature before 
inoculation.
3. Bottles should be left in the system until time to positivity data can be printed, 
as the system only stores data temporarily. If with discussion, the Biomedical 
Scientist wishes to remove bottles immediately after flagging as positive then 
they should print the growth plot at the same time.
4. Bottles may flag as positive overnight therefore ensure that the on call 
Biomedical Scientist is aware of the experiment and understands the 
importance of printing the growth plot or leaving bottles in the system.
5. Print out of growth curve can be integrated into clinical service if required.
6. Bottles must to be booked into the laboratory computer system because 
otherwise sample data will not be recorded.
7. Bottle bar code stickers must be retained in order to identify bottles.
8. Any bottles that do not become positive must be removed from the system.
9. Cells must be added to bottles while in exponential phase to limit the effect of 
lag time differences on time to positivity. An initial growth curve experiment 
should be performed to determine incubation conditions required for bacterial 
cells to be in exponential phase
10. This method can be adapted for other fast growing bacteria. We have also used 
the BacT/ALERT system to determine generation time in M. tuberculosis.
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